

CITATION REPORT

List of articles citing

Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients

DOI: 10.1002/1097-0142(19850815)56:43.0.co;2-e
Cancer, 1985, 56, 918-28.

Source: <https://exaly.com/paper-pdf/17684523/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1767	Regional intra-arterial infusion of cisplatin in primary hepatocellular carcinoma. A phase II study. <i>Cancer</i> , 1986 , 58, 2386-8	6.4	67
1766	Primary hepatocellular carcinoma. 1986 , 14, 281-7		1
1765	Primary liver cancer. Quadrennial review lecture. 1986 , 31, 133S-146S		66
1764	Effects of habitual alcohol intake and cigarette smoking on the development of hepatocellular carcinoma. 1987 , 11, 45-8		10
1763	Portal venous hemodynamics in hepatocellular carcinoma. Effects of hepatic artery embolization. 1987 , 93, 591-6		11
1762	Hepatic resection for hepatocellular carcinoma. Clinical features and long-term prognosis. 1987 , 205, 33-40		233
1761	Chemotherapy and radiotherapy of malignant hepatic tumours. 1987 , 1, 151-69		6
1760	Response to cyproterone acetate treatment in primary hepatocellular carcinoma is related to fall in free 5 alpha-dihydrotestosterone. 1987 , 23, 1659-64		43
1759	The clinical features and natural history of malignant liver tumours. 1987 , 1, 17-34		5
1758	A Clinico-Pathologic Study of Clear-Cell Hepatocellular Carcinoma. 1987 , 73, 389-395		10
1757	A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. <i>Cancer</i> , 1987 , 60, 1194-203	6.4	225
1756	Prognosis of hepatocellular carcinoma smaller than 5 cm in relation to treatment: study of 100 patients. 1987 , 7, 1285-90		83
1755	Combined peripheral and central chemoembolization of liver tumors. Experience with lipiodol-doxorubicin and gelatin sponge (L-TAE). <i>Cancer</i> , 1988 , 61, 238-42	6.4	64
1754	Hepatocellular carcinoma. A retrospective analysis of treatments to manage disease confined to the liver. <i>Cancer</i> , 1988 , 61, 1884-8	6.4	43
1753	Intrahepatic chemotherapy for unresectable hepatocellular carcinoma. <i>Cancer</i> , 1988 , 61, 1983-7	6.4	73
1752	The surgical management of hepatoma: a review of 29 hepatic resections. 1988 , 32, 227-9		1
1751	Factors affecting the prognosis of primary liver carcinoma. 1988 , 6, 321-8		47

1750	The biodistribution and effect on hepatic parenchyme with intraarterial injected I-131 Lipiodol into hepatic artery. 1989 , 25, 548		
1749	Effects of nucleosides and a nucleotide on DNA and RNA syntheses by the salvage and de novo pathway in primary monolayer cultures of hepatocytes and hepatoma cells. 1989 , 13, 51-8		31
1748	Screening for Hepatocellular Carcinoma in High-Risk Individuals. 1989 , 149, 1741		22
1747	Flow cytometric analysis of the nuclear DNA content of hepatocellular carcinoma. 1989 , 19, 662-73		35
1746	Regional treatment of hepatic metastases and hepatocellular carcinoma. 1989 , 13, 197-283		25
1745	Morphological and histological features of resected hepatocellular carcinoma in cirrhotic patients in the West. 1989 , 9, 253-7		43
1744	A 5-year experience of lipiodolization: selective regional chemotherapy for 200 patients with hepatocellular carcinoma. 1989 , 10, 98-102		181
1743	Effect of D-tryptophan-6-luteinizing hormone-releasing hormone on the tumoral growth and plasma sex steroid levels in cirrhotic patients with hepatocellular carcinoma. 1989 , 10, 346-8		17
1742	Prevalence of hepatocellular carcinoma and relation to cirrhosis: comparison of two different cities of the world--Trieste, Italy, and Chiba, Japan. 1989 , 10, 998-1002		74
1741	Evaluation of the prognosis for small hepatocellular carcinoma based on tumor volume doubling time. A preliminary report. <i>Cancer</i> , 1989 , 63, 2207-10	6.4	103
1740	Hepatic arterial injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma. <i>Cancer</i> , 1989 , 64, 1586-94	6.4	125
1739	Intraarterial infusion of 5-fluoro-2-deoxyuridine-C8 dissolved in a lymphographic agent in malignant liver tumors. A preliminary report. <i>Cancer</i> , 1989 , 64, 2437-44	6.4	28
1738	Hepatic artery embolization for inoperable hepatocellular carcinoma; prognosis and risk factors. 1989 , 23 Suppl, S123-5		44
1737	Laparoscopy compared with ultrasonography in the diagnosis of hepatocellular carcinoma. 1989 , 35, 508-11		9
1736	Hepatocellular carcinoma in cirrhotic liver in Trieste. 1989 , 4, 521-7		2
1735	[Chemoembolization of hepatocellular carcinoma--computed tomographic follow-up observation]. 1989 , 151, 15-22		7
1734	Asymptomatic hepatocellular carcinoma in Child's A cirrhosis. A comparison of natural history and surgical treatment. 1989 , 96, 1566-71		103
1733	Ultrasonic Doppler studies of hepatocellular carcinoma and comparison with other hepatic focal lesions. 1989 , 97, 1489-97		42

1732	Interventional Angiography for Primary and Secondary Hepatic Malignancies: A Review. 1990,		
1731	A novel model of solitary hepatic tumor in rats using ascites hepatoma AH13: suitability for chemotherapeutic studies. 1990, 81, 1045-51		
1730	Resection of hepatocellular carcinomas. 1990, 98, 733-738		276
1729	Resolution of inferior vena cava syndrome after embolization of a hepatic adenoma. 1990, 99, 1502-6		6
1728	Geographic heterogeneity of hepatocellular carcinoma. 1990, 25, 787-92		5
1727	The influence of partial hepatectomy on the pharmacokinetics of preoperatively injected 4'-epidoxorubicin in rats. 1990, 26, 444-8		4
1726	Hepatic artery infusion and chemoembolization in the management of liver metastases. 1990, 13, 153-60		54
1725	Encapsulated hepatocellular carcinoma: radiologic findings and pathologic correlation. 1990, 15, 233-7		38
1724	Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. 1990, 12, 680-7		352
1723	Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients. 1990, 12, 753-60		202
1722	Long survival and prognostic factors in hepatocellular carcinoma. 1990, 45, 257-60		10
1721	Spontaneous regression of hepatocellular carcinoma. <i>Cancer</i> , 1990, 65, 2779-83	6.4	43
1720	Hepatic arterial embolization with microencapsulated mitomycin C for unresectable hepatocellular carcinoma in cirrhosis. <i>Cancer</i> , 1990, 66, 228-36	6.4	23
1719	Treatment of Hepatocellular Carcinoma by Segmental Hepatic Artery Injection of Adriamycin-In-Oil Emulsion with Overflow to Segmental Portal Veins. 1990, 31, 347-349		41
1718	A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. 1990, 11, 181-4		351
1717	Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen. 1990, 11, 297-301		89
1716	Natural history of hepatocellular carcinoma in Spain. Five year's experience in 249 cases. 1990, 10, 311-7		111
1715	Diagnostic and prognostic value of the determination of the aminopropeptide of type III procollagen in patients with primary liver cancer. 1990, 5, 633-8		1

1714	Hormonal therapy for hepatocellular carcinoma. 1991 , 36, 162-5		8
1713	Selective regional chemotherapy of unresectable hepatic tumours using lipiodol. 1991 , 4, 223-34; discussion 234-6		14
1712	Hepatocellular carcinoma in the Amsterdam area. A retrospective analysis in 61 patients. 1991 , 188, 108-17		3
1711	Prognostic factors in unresectable hepatocellular cancer: Radiation Therapy Oncology Group Study 83-01. 1991 , 20, 65-71		33
1710	Hepatocellular carcinoma. A worldwide problem and the major risk factors. 1991 , 36, 962-72		315
1709	Lipiodol-Cisplatin embolisation in hepatocellular carcinoma. Radiological technique and evaluation. 1991 , 1, 131-138		2
1708	Differences in glycolytic capacity and hypoxia tolerance between hepatoma cells and hepatocytes. 1991 , 13, 297-303		47
1707	Transcatheter oily chemoembolization in the management of advanced hepatocellular carcinoma in cirrhosis: Results of a western comparative study in 60 patients. 1991 , 13, 427-433		131
1706	Hepatocellular carcinoma presenting with pyrexia and leukocytosis: Report of five cases. 1991 , 13, 695-700		27
1705	Prognosis of unresectable hepatocellular carcinoma: An evaluation based on multivariate analysis of 90 cases. 1991 , 14, 262-268		78
1704	Prognostic factors in the treatment of hepatocellular carcinoma with transcatheter arterial embolization and arterial infusion. <i>Cancer</i> , 1991 , 67, 385-91	6.4	110
1703	Multimodality cisplatin treatment in nonresectable alpha-fetoprotein-positive hepatoma. <i>Cancer</i> , 1991 , 67, 896-900	6.4	27
1702	A new approach to chemoembolization for unresectable hepatocellular carcinoma using aclarubicin microspheres in combination with cisplatin suspended in iodized oil. <i>Cancer</i> , 1991 , 68, 2555-60	6.4	44
1701	Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. 1991 , 15, 270-85		675
1700	Advances in neoplastic disease of the liver and biliary tract. 1991 , Suppl, S104-10		1
1699	Small hepatocellular carcinoma treated with percutaneous ethanol injection: MR imaging findings. 1991 , 180, 333-6		44
1698	Things are seldom what they seem. 1992 , 327, 1663-6		2
1697	Detection of malignant tumors in end-stage cirrhotic livers: efficacy of sonography as a screening technique. 1992 , 159, 727-33		114

1696	Analysis of cost-effectiveness of different strategies for hepatocellular carcinoma screening in hepatitis B virus carriers. 1992 , 7, 463-8	30
1695	Hypercholesterolaemia in patients with hepatocellular carcinoma. 1992 , 7, 491-6	19
1694	Hepatocellular carcinoma. 1992 , 15, 225-36	198
1693	Surgical resection and survival in Western patients with hepatocellular carcinoma. 1992 , 15, 350-5	24
1692	Management of hepatocellular carcinoma. 1992 , 15, 281-3	4
1691	Hepatocellular carcinoma. Prognostic factors and survival analysis in 135 Italian patients. 1992 , 16, 66-72	21
1690	Primary treatment of hepatocellular carcinoma by arterial chemoembolization. 1992 , 163, 387-94	241
1689	Evaluation of oil-soluble FUDR ester for transcatheter arterial treatment of hepatomas. 1992 , 3, 367-70	5
1688	Radiotherapy for Bone Metastases of Hepatocellular Carcinoma. 1992 ,	
1687	Clinical evaluation of intermittent arterial infusion chemotherapy with an implanted reservoir for hepatocellular carcinoma. 1992 , 31 Suppl, S93-8	9
1686	Liver transplantation for hepatocellular carcinoma: clinical results and future aspects. 1992 , 31 Suppl, S157-61	33
1685	Transcatheter arterial embolization of hepatic neoplasms. 1992 , 13, 93-105	9
1684	Die chirurgische Therapie des hepatozellulären Karzinoms. 1992 , 24, 348-352	2
1683	Treatment of hepatocellular carcinoma associated with advanced cirrhosis by transcatheter arterial chemoembolization using autologous blood clot: a preliminary report. 1992 , 15, 252-7	20
1682	Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. 1992 , 16, 112-7	81
1681	Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. 1992 , 16, 132-7	342
1680	Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. 1992 , 16, 353-7	233
1679	Comparison of hepatectomy and transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma: necessity for prospective randomized trial. 1992 , 16, 702-6	38

1678	Postresection recurrence of hepatocellular carcinoma treated by arterial embolization: analysis of prognostic factors. 1992 , 16, 906-11		52
1677	Internal radiation therapy for hepatocellular carcinoma. Results of a French multicenter phase II trial of transarterial injection of iodine 131-labeled Lipiodol. <i>Cancer</i> , 1992 , 69, 346-52	6.4	63
1676	Treatment of unresectable primary liver cancer with intrahepatic fluorodeoxyuridine and mitomycin C through an implantable pump. <i>Cancer</i> , 1992 , 69, 920-4	6.4	59
1675	Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b. <i>Cancer</i> , 1993 , 72, 2574-82	6.4	61
1674	Effects of preoperative transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma. The relationship between postoperative course and tumor necrosis. <i>Cancer</i> , 1993 , 72, 3593-8	6.4	103
1673	Orthotopic liver transplantation in primary liver tumors. 1993 , 3, 74-7		10
1672	Effect of treatment on clinical trials: chemoembolization. 1993 , 3, 87-90		2
1671	Preoperative chemoembolization for hepatocellular carcinoma. 1993 , 3, 91-3		20
1670	Efficacy of chemoembolization for hepatocellular carcinomas: experience from the Gustave Roussy Institute and the Bicêtre Hospital. 1993 , 3, 94-6		16
1669	Intratumor ethanol injection. 1993 , 3, 97-9		25
1668	Non-surgical treatment of hepatocarcinoma. 1993 , 3, 104-11		24
1667	Effects of treatments in clinical trials: surgery. 1993 , 3, 186-8		1
1666	Clinical results of fractionated proton therapy. 1993 , 25, 49-60		79
1665	Evaluation of preoperative transcatheter arterial embolization in the treatment of resectable primary liver cancer. 1993 , 9, 327-31		10
1664	Ultrasound-guided percutaneous laser ablation of liver tissue in a rabbit model. 1993 , 3, 26		24
1663	Die konservative Therapie des hepatozellulären Karzinoms (HCC). 1993 , 25, 106-109		
1662	Operative results in 143 patients with hepatocellular carcinoma. 1993 , 17, 663-7; discussion 668		27
1661	Postoperative recurrence of hepatocellular carcinoma: results of transcatheter arterial chemoembolization. 1993 , 16, 21-4		34

1660	Analysis of mononuclear cells infiltrating tumor in solitary hepatoma model. 1993 , 1, 21-30	1
1659	Efficacy of Prophylactic Endoscopic Variceal Sclerotherapy in Patients with Hepatocellular Carcinoma. 1993 , 5, 350-358	1
1658	Palliative Treatment of Hepatocellular Carcinoma with Transcatheter Arterial Embolization. 1993 , 34, 26-29	4
1657	Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. 1993 , 34, 1598-600	110
1656	Percutaneous ethanol injection therapy for hepatocellular-carcinoma (review). 1993 , 2, 669-75	1
1655	PROGNOSTIC VALUE OF PERIODIC ACID-SCHIFF (PAS) STAINING OF FINE-NEEDLE ASPIRATES FROM PATIENTS WITH PRIMARY HEPATOCELLULAR-CARCINOMA. 1993 , 3, 245	
1654	Percutaneous Ethanol Injection Therapy for Liver Neoplasms. 1993 , 10, 57-68	22
1653	Interstitial laser photocoagulation therapy for liver tumors: clinical results. 1993 ,	3
1652	Hepatocellular carcinoma in cirrhotics. 1993 , 13, 374-83	27
1651	Small hepatocellular carcinoma: MR follow-up of treatment with percutaneous ethanol injection. 1993 , 187, 119-23	36
1650	Case report: spinal cord compression due to metastatic hepatocellular carcinoma. 1993 , 306, 233-5	16
1649	Hepatocellular carcinoma. 1993 , 94, 71-74	4
1648	Improved survival for hepatocellular cancer with combination surgery and multimodality treatment. 1993 , 217, 149-54	70
1647	Hepatocellular carcinoma in liver cirrhosis. A prospective study. 1993 , 28, 540-4	33
1646	Hepatocellular Carcinoma with Portal Tumor Thrombus: Analysis of Factors Determining Prognosis. 1993 ,	
1645	Symptom relief and survival after chemo-embolization with adriamycin, lipiodol and gelfoam for hepatocellular carcinoma. 1993 , 37, 173-6	5
1644	CT findings of exophytic hepatocellular carcinoma. 1993 , 29, 1214	
1643	Prognostic factors in patients affected by hepatocellular carcinoma treated with systemic chemotherapy: the experience of the National Cancer Institute of Milan. 1993 , 4, 489-93	9

1642	Selective radionuclide localisation in primary liver tumours (pilot study). 1994 , 7, 185-99; discussion 200		4
1641	Medical Treatment of Hepatocellular Carcinoma: Any Progress?. 1994 , 80, 315-326		12
1640	Chemotherapy v symptomatic treatment for hepatoma. 1994 , 35, 865		
1639	Liver disease. 1994 , 70, 162-84		3
1638	Iron deficiency anaemia. 1994 , 35, 864-5		3
1637	Transcatheter Hepatic Subsegmental Arterial Chemoembolization Therapy Using Iodized Oil for Small Hepatocellular Carcinomas: Correlation between Lipiodol Accumulation Pattern and Local Recurrence. 1994 , 35, 576-580		25
1636	Measurement of androgen receptor expression in adult liver, fetal liver, and Hep-G2 cells by the polymerase chain reaction. 1994 , 35, 683-6		7
1635	Reply. 1994 , 35, 865-865		
1634	Reply. 1994 , 35, 865-865		
1633	Importance of cytotoxic T lymphocytes in the rejection of transplanted hepatocellular carcinoma. 1994 , 29, 282-8		2
1632	Transcatheter arterial embolization followed by percutaneous ethanol injection in the treatment of hepatocellular carcinoma. 1994 , 17, 70-5		32
1631	Determination of the optimum dose level of lipiodol in transcatheter arterial embolization of primary hepatocellular carcinoma based on retrospective multivariate analysis. 1994 , 17, 76-80		17
1630	Lipiodolization for unresectable hepatocellular carcinoma: an analysis of 205 patients using univariate and multivariate analysis. 1994 , 56, 54-8		20
1629	Interleukin-6 in transcatheter arterial embolization for patients with hepatocellular carcinoma. Effects of serine protease inhibitor. <i>Cancer</i> , 1994 , 73, 53-7	6.4	31
1628	Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year study of 127 French patients. <i>Cancer</i> , 1994 , 74, 16-24	6.4	162
1627	Prospective flow cytometric DNA analysis of hepatocellular carcinoma specimens collected by ultrasound-guided fine needle aspiration. <i>Cancer</i> , 1994 , 74, 599-605	6.4	23
1626	Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. <i>Cancer</i> , 1994 , 74, 817-25	6.4	515
1625	Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study. <i>Cancer</i> , 1994 , 74, 2449-53	6.4	135

1624	Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. The Liver Cancer Study Group of Japan. <i>Cancer</i> , 1994 , 74, 2772-80	6.4	327
1623	Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: A multivariate analysis of prognostic factors. 1994 , 19, 1115-1123		155
1622	Phase II study of transarterial embolization in european patients with hepatocellular carcinoma: Need for controlled trials. 1994 , 20, 643-650		77
1621	Transcatheter arterial embolisation versus no treatment in cirrhotic patients with hepatocellular carcinoma: a retrospective comparative study. 1994 , 4, 155		4
1620	Computed tomography after Lipiodol chemoembolization in hepatocellular carcinoma. 1994 , 4, 238-242		10
1619	Study of trace elements in blood of cancer patients by proton-induced X-ray emission (PIXE) analysis. 1994 , 43-45, 351-5		6
1618	Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. 1994 , 70, 994-9		194
1617	Clostridial bacteremia and death following chemoembolization for hepatocellular carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 1994 , 5, 167-70	2.4	12
1616	Intra-arterial alcoholization of advanced hepatocellular carcinoma. 1994 , 33 Suppl, S42-7		14
1615	Five-year survival after transcatheter chemoembolization for hepatocellular carcinoma. 1994 , 33 Suppl, S89-92		40
1614	Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. 1994 , 20, 702-6		105
1613	Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. 1994 , 20, 65-71		249
1612	Detection of hepatitis C virus replication in ovarian metastases of a patient with hepatocellular carcinoma. 1994 , 21, 47-51		4
1611	Mass screening for hepatocellular carcinoma: experience in Hokkaido, Japan. 1994 , 9, 361-5		36
1610	Analyses of proliferating cell nuclear antigen-positive cells in hepatocellular carcinoma: comparisons with clinical findings. 1994 , 9, 425-32		5
1609	Liver transplantation for hepatocellular carcinoma--is it worth it?. 1994 , 69, 599-600		1
1608	Management options for primary hepatocellular carcinoma. An overview. 1994 , 33, 895-900		11
1607	Predictive factors for postoperative recurrence of hepatocellular carcinoma. 1994 , 106, 1618-24		236

1606	A new, effective, and safe therapeutic option using proton irradiation for hepatocellular carcinoma. 1994 , 106, 1032-41		83
1605	Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. 1994 , 106, 720-7		346
1604	Case report: hepatocellular carcinoma diagnosed radiologically, treated by transcatheter arterial embolization and limited-field radiotherapy. 1994 , 67, 591-5		7
1603	Clinical features of hepatocellular carcinoma in the elderly: a study of 91 patients older than 70 years. 1994 , 70, 690-3		44
1602	Comparison of tumor pathology with duration of survival of North American patients with hepatocellular carcinoma. <i>Cancer</i> , 1995 , 76, 579-88	6.4	69
1601	Epirubicin-Lipiodol chemotherapy versus 131iodine-Lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma. <i>Cancer</i> , 1995 , 76, 2202-10	6.4	60
1600	Prognostic significance of pathologic features of hepatocellular carcinoma. A multivariate analysis of 278 patients. <i>Cancer</i> , 1995 , 76, 2443-8	6.4	132
1599	Hepatic artery chemoembolization or embolization for primary and metastatic liver tumors: post-treatment management and complications. 1995 , 60, 116-21		65
1598	Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: Incidence and prevalence of hepatocellular carcinoma in a North American urban population. 1995 , 22, 432-438		255
1597	Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan. 1995 , 22, 1027-1033		326
1596	Study of repeated arterial infusion chemotherapy with a subcutaneously implanted reservoir for advanced hepatocellular carcinoma. 1995 , 30, 356-66		34
1595	Impaired liver function and long-term prognosis after hepatectomy for hepatocellular carcinoma. 1995 , 19, 439-43		31
1594	Transcatheter arterial chemoembolization (TACE) in the treatment of unresectable liver cancer. 1995 , 19, 795-800		48
1593	Therapeutic modalities and prognostic factors for primary and secondary liver tumors. 1995 , 19, 252-63		54
1592	Antitumoral efficacy and pharmacokinetic properties of pirarubicin upon hepatic intra-arterial injection in the rabbit V x 2 tumour model. 1995 , 71, 518-24		20
1591	5-Fluorouracil and d,l-leucovorin calcium are active to treat unresectable hepatocellular carcinoma patients: preliminary results of a phase II study. 1995 , 52, 487-91		46
1590	Treatment of unresectable hepatocellular carcinoma. 1995 , 333, 877; author reply 878		6
1589	Therapy for hepatocellular-carcinoma (review). 1995 , 6, 1113-22		1

1588	A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. 1995 , 332, 1256-61	740
1587	Prognostic Factors in Cancer. 1995 ,	30
1586	Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. 1995 , 109, 917-22	160
1585	Pulmonary metastasis of hepatocellular carcinoma associated with transarterial chemoembolization. 1995 , 23, 563-8	70
1584	Transarterial embolization for hepatocellular carcinoma. Antibiotic prophylaxis and clinical meaning of postembolization fever. 1995 , 22, 410-5	80
1583	Effect of androgens and their manipulation on cell growth and androgen receptor (AR) levels in AR-positive and -negative human hepatocellular carcinomas. 1995 , 22, 295-302	18
1582	No synergistic activity of epirubicin and interferon-alpha 2b in the treatment of hepatocellular carcinoma. 1995 , 35, 334-8	15
1581	Clinical pilot study on high-dose intraarterial chemotherapy with direct hemoperfusion under hepatic venous isolation in patients with advanced hepatocellular carcinoma. 1995 , 117, 510-9	30
1580	Levels of amino acids in human hepatocellular carcinoma and adjacent liver tissue. 1995 , 23, 85-90	9
1579	Intraarterial infusion of dibutyl cyclic adenosine monophosphate plus mitomycin C for unresectable hepatocellular carcinoma: long-term survival and response to tumor growth inhibition. 1995 , 2, 286-92	4
1578	Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: Incidence and prevalence of hepatocellular carcinoma in a North American urban population*1. 1995 , 22, 432-438	20
1577	Announcement. 1996 , 3, 224	
1576	Etiology, screening, and treatment of hepatocellular carcinoma. 1996 , 80, 1121-45	17
1575	Comparison of resection, liver transplantation and transcatheter oily chemoembolization in the treatment of hepatocellular carcinoma. 1996 , 24, 293-300	88
1574	Comparison of clinico-pathological features in hepatitis B virus-associated hepatocellular carcinoma with or without hepatitis D virus superinfection. 1996 , 25, 439-44	21
1573	The loop electrode: in vitro evaluation of a device for ultrasound-guided interstitial tissue ablation using radiofrequency electrosurgery. 1996 , 3, 219-24	6
1572	Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. 1996 , 334, 693-9	5394
1571	Regional Transcatheter Therapy of Hepatic Neoplasms. 1996 , 3, 407-413	1

1570	Unresectable hepatocellular carcinoma in cirrhosis: survival, prognostic factors, and unexpected side effects after transcatheter arterial chemoembolization. 1996 , 41, 2332-9		61
1569	Pharmacokinetics of intravenous adriamycin for anhepatic chemotherapy during liver transplantation. 1996 , 9, S105-S108		4
1568	Phase II study of flutamide in the treatment of hepatocellular carcinoma. <i>Cancer</i> , 1996 , 77, 635-639	6.4	46
1567	Needle biopsy of hepatocellular carcinoma: Assessment of prognostic contribution of histologic parameters including proliferating cell nuclear antigen labeling and correlations with clinical outcomes. 1996 , 77, 864-871		14
1566	Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. <i>Cancer</i> , 1996 , 77, 2217-22	6.4	278
1565	Clinical and pathologic features of hepatocellular carcinoma in young and older Italian patients. <i>Cancer</i> , 1996 , 77, 2223-32	6.4	44
1564	Flow cytometric DNA analysis of cirrhotic liver cells in patients with hepatocellular carcinoma can provide a new prognostic factor. <i>Cancer</i> , 1996 , 78, 1195-202	6.4	28
1563	Radiolabelling of Lipiodol with generator-produced ¹⁸⁸ Re for hepatic tumor therapy. 1996 , 47, 267-71		27
1562	A phase II study of weekly oral methotrexate and zidovudine (AZT) in advanced adenocarcinoma of the pancreas and hepatocellular carcinoma. 1996 , 14, 207-12		6
1561	A prospective randomized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma. 1996 , 87, 206-11		145
1560	Human liver cancer cells and endothelial cells incorporate iodised oil. 1996 , 73, 877-81		49
1559	Influence of partial hepatectomy on theophylline pharmacokinetics in rats. 1996 , 85, 1133-5		4
1558	Low-molecular-weight heparin--an opportunity for home treatment of venous thrombosis. 1996 , 334, 724-5		42
1557	Liver (clinical). 1996 , 38, A5-A8		
1556	Cellular distribution of androgen receptors in the liver. 1996 , 49, 418-20		12
1555	Orthotopic liver transplantation for hepatocellular carcinoma. Factors affecting long-term patient survival. 1996 , 131, 935-9; discussion 939-41		23
1554	Short-term effects of transcatheter arterial chemoembolisation on metabolic activity of the liver of cirrhotic patients with hepatocellular carcinoma. 1996 , 39, 325-9		8
1553	Mergers and acquisitions--who benefits? Who loses?. 1996 , 334, 722-3		17

1552	Allergies to transgenic foods--questions of policy. 1996 , 334, 726-8	42
1551	Treating small hepatocellular carcinomas. 1996 , 334, 728-9	11
1550	Improving the outcomes of care for patients with human immunodeficiency virus infection. 1996 , 334, 729-31	23
1549	Therapeutic results of resection, transcatheter arterial embolization and percutaneous transhepatic ethanol injection in 3225 patients with hepatocellular carcinoma: a retrospective multicenter study. 1997 , 27, 251-7	109
1548	Treatment for advanced hepatocellular carcinoma by transarterial chemotherapy using reservoirs or one-shot arterial chemotherapy. 1997 , 9, 347-51	4
1547	[Volumetric and morphological CT parameters for assessing prognosis and treatment control in hepatocellular carcinoma undergoing arterial chemoembolization]. 1997 , 167, 219-26	3
1546	Embolization of Primary and Secondary Hepatic Malignancies. <i>Journal of Vascular and Interventional Radiology</i> , 1997 , 8, 74-80	2.4
1545	Nonresectional therapies for hepatocellular carcinoma. 1997 , 173, 358-65	118
1544	Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: a phase II study. 1997 , 33, 1784-8	55
1543	Proposal of invasiveness score to predict recurrence and survival after curative hepatic resection for hepatocellular carcinoma. 1997 , 122, 571-7	56
1542	Prognostic significance of serum anti-p53 antibody in patients with hepatocellular carcinoma. 1997 , 27, 661-8	34
1541	Treatment of hepatocellular carcinoma in patients with cirrhosis. 1997 , 27, 756-65	58
1540	Spontaneous regression of hepatocellular carcinoma. 1997 , 27, 211-5	31
1539	Liver resection or transplantation for hepatocellular carcinoma? Retrospective analysis of 215 patients with cirrhosis. 1997 , 26, 1274-80	140
1538	Gastrointestinal bleeding in cirrhotic patients with hepatocellular carcinoma undergoing intrahepatic artery chemotherapy. 1997 , 46, 430-4	7
1537	Regional Chemotherapy of Gastro-Intestinal Cancer. 1997 , 14, 9-22	3
1536	Hepatocellular carcinoma in the caudate lobe: early diagnosis and active treatment may result in long-term survival. 1997 , 12, 144-8	17
1535	Phase II study of megestrol acetate in the treatment of hepatocellular carcinoma. 1997 , 12, 277-81	19

1534	Partial hepatic resection for hepatocellular carcinoma. 1997 , 12, S329-34		27
1533	Treatment of hepatocellular carcinoma. 1997 , 4 Suppl 1, 125-30		14
1532	Cellular DNA content and histopathological analysis in hepatocellular carcinoma with multiple nodules. 1997 , 27, 483-90		4
1531	Treatment of hepatocellular carcinoma: a single-center experience. 1997 , 20, 23-8		7
1530	Influence of prognostic groupings and treatment results in the management of unresectable hepatoma: experience with Cisplatinium-based chemoradiotherapy in 76 patients. 1997 , 39, 1077-85		11
1529	A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. <i>Cancer</i> , 1997 , 79, 1890-6	6.4	98
1528	The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. <i>Cancer</i> , 1997 , 79, 2087-2094	6.4	191
1527	Spontaneous regression of a recurrent hepatocellular carcinoma. 1998 , 43, 323-8		13
1526	4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) inhibits the intrahepatic spread of hepatocellular carcinoma and prolongs the life-span of tumor-bearing animals. 1998 , 16, 633-43		15
1525	Case report: A hepatocellular carcinoma metastasis in the distal pancreas. 1998 , 13, 467-70		12
1524	Enhanced in vivo adenovirus-mediated gene transfer to rat hepatocarcinomas by selective administration into the hepatic artery. 1998 , 5, 896-904		43
1523	Stable lipiodolized emulsions for hepatoma targeting and treatment by transcatheter arterial chemoembolization. 1998 , 50, 135-43		31
1522	Screening for hepatocellular carcinoma. 1998 , 27, 273-8		312
1521	Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. 1998 , 27, 1572-7		302
1520	Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. 1998 , 27, 1578-83		403
1519	A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. 1998 , 28, 751-5		1116
1518	The long term efficacy of combined transcatheter arterial embolization and percutaneous ethanol injection in the treatment of patients with large hepatocellular carcinoma and cirrhosis. <i>Cancer</i> , 1998 , 82, 78-85	6.4	69
1517	Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection--a single-center analysis including 132 patients. 1998 , 79, 601-5		90

1516	Undetected hepatocellular carcinoma: clinical features and outcome after liver transplantation. 1998 , 4, 477-82		42
1515	Spontaneous regression of hepatocellular carcinoma confirmed by surgical specimen: report of two cases and review of the literature. 1998 , 383, 447-52		25
1514	Improved long-term survival for unresectable hepatocellular carcinoma (HCC) with a combination of surgery and intrahepatic arterial infusion of 131I-anti-HCC mAb. Phase I/II clinical trials. <i>Journal of Cancer Research and Clinical Oncology</i> , 1998 , 124, 275-80	4.9	24
1513	The natural history of untreated hepatocellular carcinoma. 1998 , 3, 299-303		5
1512	Arterial hepatic embolization of unresectable hepatocellular carcinoma using a cyanoacrylate/lipiodol mixture. 1998 , 21, 214-8		13
1511	Pattern and management of recurrent hepatocellular carcinoma after liver transplantation. 1998 , 5, 29-34		116
1510	Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. 1998 , 40, 583-92		306
1509	Prognosis of hepatocellular carcinoma in relation to treatment: A multivariate analysis of 178 patients from a single European institution. 1998 , 124, 575-583		51
1508	Ultrasound screening for hepatocellular carcinoma (HCC) in cirrhosis: the evidence for an established clinical practice. 1998 , 53, 713-6		20
1507	Treatment options in Western hepatocellular carcinoma: a prospective study of 224 patients. 1998 , 29, 650-9		42
1506	Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. 1998 , 29, 129-34		331
1505	Particle embolization for hepatocellular carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 1998 , 9, 822-8	2.4	88
1504	Practical considerations in the treatment of hepatocellular carcinoma. 1998 , 55, 367-82		18
1503	Hepatectomy: preoperative analysis of hepatic function and postoperative liver failure. 1998 , 15, 1-11		32
1502	Surgical therapy of hepatocellular carcinoma. 1998 , 59 Suppl 2, 78-9		10
1501	Radiotherapy for osseous metastases from hepatocellular carcinoma: a retrospective study of 57 patients. 1998 , 93, 2167-71		69
1500	TNP-470 inhibits collateralization to complement the anti-tumour effect of hepatic artery ligation. 1998 , 77, 638-42		8
1499	Preoperative chemoembolization of hepatocellular carcinoma: a comparative study. 1998 , 133, 767-72		66

1498	Systemic chemotherapy for inoperable hepatocellular carcinoma. 1998,	
1497	Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma. 1998, 55, 39-47	82
1496	Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. 1999, 17, 324-31	181
1495	Neoadjuvant and adjuvant therapy for operable hepatocellular carcinoma. 2000, CD001199	17
1494	Hepatic intraarterial ¹³¹ I iodized oil for treatment of hepatocellular carcinoma in patients with impeded portal venous flow. 1999, 212, 665-8	29
1493	Small hepatocellular carcinoma treated with percutaneous RF ablation: MR imaging follow-up. 1999, 173, 1225-9	102
1492	Chemoembolization of hepatic neoplasms: safety, complications, and when to worry. 1999, 19, 399-414	105
1491	Standards for selecting percutaneous ethanol injection therapy or percutaneous microwave coagulation therapy for solitary small hepatocellular carcinoma: consideration of local recurrence. 1999, 94, 1914-7	32
1490	Hepatocellular carcinoma in the elderly: results of surgical and nonsurgical management. 1999, 94, 2460-6	97
1489	An active liver transplant programme for hepatocellular carcinoma in cirrhotic patients: is it justified?. 1999, 13, 531-5	13
1488	Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma. 1999, 43, 393-7	140
1487	Liver transplantation for hepatocellular carcinoma in cirrhotic patients. 1999, 69, 798-801	7
1486	Colonic wall thickening in cirrhotic patients: CT features and its clinical significance. 1999, 24, 125-8	8
1485	Hepatocyte growth factor promotes migration of human hepatocellular carcinoma via phosphatidylinositol 3-kinase. 1999, 17, 507-14	56
1484	Surgical treatment of malignant liver tumours. 1999, 13, 557-74	21
1483	Locoregional treatments for hepatocellular carcinoma. 1999, 13, 611-22	13
1482	Major compared with limited hepatic resection for hepatocellular carcinoma without underlying cirrhosis: a retrospective analysis. 1999, 165, 638-46	17
1481	Use of FDP and F1P aldolase to detect tumorous and nontumorous tissue damage by ethanol injection of hepatocellular carcinoma. 1999, 44, 1610-8	2

1480	Hepatocellular carcinoma with spontaneous regression of multiple lung metastases. 1999 , 49, 893-7		15
1479	Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. 1999 , 29, 62-7		864
1478	Small hyperechoic nodules in chronic liver diseases include hepatocellular carcinomas with low cyclin D1 and Ki-67 expression. 1999 , 29, 1722-9		31
1477	Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. 1999 , 30, 1434-40		1594
1476	Long-term follow-up arterial chemoembolization combined with transportal ethanol injection used to treat hepatocellular carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 1999 , 10, 641-7	2.4	24
1475	Hepatobiliary malignancies. Primary hepatic malignant neoplasms. 1999 , 79, 43-57, viii		39
1474	The changing role of radiology in imaging liver tumors: an overview. 1999 , 32, 36-51		8
1473	Primary and metastatic liver cancer. 1999 , 15, 48-57		6
1472	Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. 1999 , 353, 797-801		373
1471	Hepatocellular carcinoma. 1999 , 353, 1253-7		467
1470	Preoperative assessment of mortality risk in hepatic resection by clinical variables: a multivariate analysis. 1999 , 5, 227-37		21
1469	A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. 1999 , 31, 133-41		371
1468	Clinical efficacy of portal vein stent placement in patients with hepatocellular carcinoma invading the main portal vein. 1999 , 30, 660-8		53
1467	Effect of transcatheter arterial chemoembolization on kidney hemodynamics and function in patients with cirrhosis and hepatocellular carcinoma. 1999 , 31, 340-6		3
1466	Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, ethiodol, and polyvinyl alcohol: prospective evaluation of response and survival in a U.S. population. <i>Journal of Vascular and Interventional Radiology</i> , 1999 , 10, 793-8	2.4	92
1465	Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. 2000 , 133, 665-75		105
1464	Estimating future hepatitis C morbidity, mortality, and costs in the United States. 2000 , 90, 1562-9		433
1463	Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. 2000 , 31, 302-8		227

1462	Phase I clinical trial of oral furtulon and combined hepatic arterial chemoembolization and radiotherapy in unresectable primary liver cancers, including clinicopathologic study. 2000 , 23, 449-54		6
1461	Complete remission of unresectable hepatocellular carcinoma on healthy liver by the combination of aggressive surgery and high-dose-intensity chemotherapy by CPT-11. 2000 , 11, 649-52		8
1460	A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. <i>Cancer</i> , 2000 , 88, 50-7	6.4	139
1459	Percutaneous microwave coagulation therapy for patients with primary and metastatic hepatic tumors during interruption of hepatic blood flow. <i>Cancer</i> , 2000 , 88, 302-311	6.4	54
1458	The National Cancer Data Base Report on treatment patterns for hepatocellular carcinomas: improved survival of surgically resected patients, 1985-1996. <i>Cancer</i> , 2000 , 88, 912-20	6.4	80
1457	Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma. 2000 , 88, 1574-1581		41
1456	Prediction of recurrence and extratumor spread of hepatocellular carcinoma following resection. 2000 , 75, 241-5		15
1455	Carriage of HFE mutations and outcome of surgical resection for hepatocellular carcinoma in cirrhotic patients. <i>Cancer</i> , 2000 , 89, 297-302	6.4	28
1454	How should patients with hepatocellular carcinoma be staged?. <i>Cancer</i> , 2000 , 89, 2266-2273	6.4	144
1453	Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. 2000 , 31, 54-8		192
1452	Hepatocellular carcinoma with lymphoid stroma: a tumour with good prognosis after liver transplantation. 2000 , 37, 523-9		46
1451	Spontaneous regression of hepatocellular carcinoma and review of literature. 2000 , 15, 1079-86		38
1450	Outcomes of primary hepatocellular carcinoma treatment: an 8-year experience with 368 patients in Thailand. 2000 , 15, 860-4		29
1449	Spontaneous regression of hepatocellular carcinoma. 2000 , 15, 965-6		5
1448	Treatment of hepatocellular carcinoma. 2000 , 15, 822-4		1
1447	Local radiotherapy for unresectable hepatocellular carcinoma patients who failed with transcatheter arterial chemoembolization. 2000 , 47, 1331-5		107
1446	Gene transfer to hepatocellular carcinoma: transduction efficacy and transgene expression kinetics by using retroviral and lentiviral vectors. 2000 , 7, 1286-92		43
1445	Surgical results for hepatocellular carcinoma with macroscopic portal vein tumor thrombosis. 2000 , 191, 657-60		76

1444	Proposed abdominal sonographic staging to predict severity of liver diseases: analysis with peritoneoscopy and histology. 2000 , 45, 554-64	17
1443	Liver transplantation for hepatitis C virus related cirrhosis. 2000 , 14, 307-25	3
1442	Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. 2000 , 31, 840-5	481
1441	A la carte interferon for hepatitis C?. 2000 , 32, 678-9	6
1440	Prospective validation of the Cancer of the Liver Italian Program (CLIP) score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. 2000 , 32, 679-80	107
1439	High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. 2000 , 32, 43-8	115
1438	Role of transarterial chemoembolization before liver resection for hepatocarcinoma. 2000 , 6, 619-26	56
1437	[Curative therapy of hepatocellular carcinoma (HCC). Resection or transplantation?]. 2000 , 41, 191-7	1
1436	Radiotherapy for hepatocellular carcinoma. 2000 , 176, 406-10	12
1435	Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. 2000 , 7, 490-5	95
1434	Recurrent hepatocellular carcinoma after spontaneous regression. 2000 , 35, 552-6	20
1433	Canadian consensus conference on the management of viral hepatitis. Canadian Association for the Study of the Liver. 2000 , 14 Suppl B, 5B-20B	28
1432	[Hepatocellular carcinoma. Part 2. Treatment]. 2000 , 37, 133-43	1
1431	Oral doxifluridine in advanced hepatocellular carcinoma: A phase II study. 2000 , 59, 204-9	6
1430	Validation of the Modified Tnm-Izumi Classification for Hepatocellular Carcinoma. 2000 , 86, 8-11	10
1429	Hepatocellular Carcinoma. 2000 ,	
1428	Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study. 2000 , 95, 218-22	87
1427	Mitotic index is the best predictive factor for survival of patients with resected hepatocellular carcinoma. 2000 , 17, 42-8	17

1426	Extrahepatic metastases of hepatocellular carcinoma. 2000 , 216, 698-703	530
1425	Prognostic significance of arterial phase CT for prediction of response to transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: a retrospective analysis. 2000 , 175, 1665-72	48
1424	Hepatocellular carcinoma : the clinical problem. 2000 , 45, 3-20	
1423	Power Doppler sonography: evaluation of hepatocellular carcinoma after treatment with transarterial embolization or percutaneous ethanol injection therapy. 2000 , 174, 337-41	20
1422	Transarterial chemoembolization for hepatocellular carcinoma: volumetric and morphologic CT criteria for assessment of prognosis and therapeutic success-results from a liver transplantation center. 2000 , 214, 349-57	137
1421	Novel effective tumor vaccines for hepatocellular carcinoma. 2000 , 45, 237-46	
1420	Evaluation of combined therapy with chemoembolization and irradiation for large hepatocellular carcinoma. 2000 , 73, 1091-7	53
1419	Liver transplantation for hepatic and biliary malignancy. 2000 , 20, 425-36	22
1418	Phyllanthus amarus extract administration increases the life span of rats with hepatocellular carcinoma. 2000 , 73, 215-9	66
1417	Tumors of the liver, bile duct, and pancreas. 2000 , 29, 71-107	
1416	Factors affecting survival and long-term outcome in the cirrhotic patient undergoing hepatic resection for hepatocellular carcinoma. 2000 , 26, 387-92	26
1415	Cancer and liver transplantation. 2000 , 14, 183-198	5
1414	Pediatric intervention: an update--part II. <i>Journal of Vascular and Interventional Radiology</i> , 2000 , 11, 807-24	30
1413	Therapeutic radiopharmaceuticals. 2000 , 6, 1085-121	51
1412	Tumores hepáticos. 2000 , 8, 567-572	
1411	The current status of liver transplantation for primary hepatic malignancy. 2000 , 4, 591-605	21
1410	Mouse alpha-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice. 2000 , 119, 1104-12	92
1409	Radiofrequency ablation in the treatment of hepatocellular carcinoma - a clinical viewpoint. 2000 , 33, 667-672	21

1408	A randomized clinical trial comparing autologous blood clot and gelfoam in transarterial chemoembolization for inoperable hepatocellular carcinoma. 2000 , 32, 955-64	30
1407	Hepatocellular carcinoma and the art of prognostication. 2000 , 33, 1006-8	16
1406	Prevalence and prognostic value of hepatocellular carcinoma in cirrhotic patients presenting with spontaneous bacterial peritonitis. 2000 , 33, 423-9	19
1405	Feasibility and potential benefit of maintenance endoscopic variceal ligation in patients with unresectable hepatocellular carcinoma and acute esophageal variceal hemorrhage: a controlled trial. 2001 , 54, 18-23	26
1404	Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis. 2001 , 96, 1160-1163	
1403	Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. 2001 , 35, 421-30	355 ⁸
1402	Prognostic features and survival of hepatocellular carcinoma in Italy: impact of stage of disease. 2001 , 37, 239-45	54
1401	Lipiodol solution of a lipophilic agent, (188)Re-TDD, for the treatment of liver cancer. 2001 , 28, 197-204	75
1400	Liver cancer. 2001 , 5, 479-507	28
1399	Nonsurgical treatment of hepatocellular carcinoma. 2001 , 5, 175-89	8
1398	Cost-effectiveness of percutaneous radiofrequency ablation for malignant hepatic neoplasms. <i>Journal of Vascular and Interventional Radiology</i> , 2001 , 12, 823-33	2.4 37
1397	[Spontaneous regression of hepatocellular carcinoma in a cirrhotic patient]. 2001 , 24, 503-5	3
1396	[Radiofrequency in the treatment of hepatocellular carcinoma]. 2001 , 24, 303-11	3
1395	Hepatocellular carcinoma in Central Europe: prognostic features and survival. 2001 , 48, 103-9	156
1394	Systemic chemotherapy with epirubicin for treatment of advanced or multifocal hepatocellular carcinoma. 2001 , 47, 359-65	37
1393	Clinicopathologic correlation of serum tissue polypeptide specific antigen in hepatocellular carcinoma. 2001 , 61, 64-70	4
1392	Liver transplantation for hepatocellular carcinoma. 2001 , 233, 652-9	242
1391	Value of lipiodol computed tomography and digital subtraction angiography in the era of helical biphasic computed tomography as preoperative assessment of hepatocellular carcinoma. 2001 , 234, 56-62	29

1390	Randomized control trials on chemoembolization for hepatocellular carcinoma: is there room for new studies?. 2001 , 32, 383-9	97
1389	Does the choice of treatment influence survival of patients with small hepatocellular carcinoma in compensated cirrhosis?. 2001 , 13, 1217-24	10
1388	Close correlation of p53 mutation to microvascular invasion in hepatocellular carcinoma. 2001 , 33, 397-401	36
1387	Influence of hepatic regeneration after partial hepatectomy on theophylline pharmacokinetics in rats. 2001 , 26, 53-8	3
1386	[Transarterial chemoembolization in hepatocellular carcinomas: technique, indications, results]. 2001 , 41, 906-14	10
1385	Hepatitis C and hepatocellular carcinoma. 2001 , 2, 473-83	26
1384	Hepatocellular cancer in liver transplantation. 2001 , 8, 427-34	13
1383	Current status of surgery and transplantation in the management of hepatocellular carcinoma: an overview. 2001 , 8, 323-36	8
1382	Effectiveness of endoscopic biliary drainage for unresectable hepatocellular carcinoma associated with obstructive jaundice. 2001 , 36, 173-80	22
1381	Le carcinome h�pato-cellulaire, pr�vention et diagnostic pr�coce: o��en sommes-nous?. 2001 , 31, 515-520	1
1380	Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stage IV-A hepatocellular carcinoma. 2001 , 16, 452-9	50
1379	Percutaneous ethanol injection therapy for liver tumors. 2001 , 13, 95-106	28
1378	Selective internal radiation therapy by yttrium-90 microspheres for hepatocellular carcinoma after renal transplantation. 2001 , 15, 284-8	1
1377	A prospective, randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices. 2001 , 33, 1060-4	344
1376	Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. 2001 , 33, 1124-9	595
1375	Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. 2001 , 34, 529-34	227
1374	Repeated hepatic dearterialization for unresectable carcinomas of the liver: report of a 10-year experience. 2001 , 31, 984-90	2
1373	Treatment of hepatocellular carcinoma. 2001 , 52, 209-15	3

1372	Combining transcatheter arterial chemoembolization with percutaneous ethanol injection therapy for small size hepatocellular carcinoma. 2001 , 19, 909-12	2
1371	Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. 2001 , 48, 251-9	477
1370	Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. 2001 , 96, 1877-80	114
1369	Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis. 2001 , 96, 1160-3	84
1368	Impact of Histological Grade of Hepatocellular Carcinoma on the Outcome of Liver Transplantation. 2001 , 136, 25	188
1367	The anti-tumoral activity of neoadjuvant intra-arterial 131I-lipiodol treatment for hepatocellular carcinoma: a pilot study. 2001 , 16, 333-8	16
1366	Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). 2002 , 97, 734-44	255
1365	UGT1A1 polymorphisms and colorectal cancer susceptibility. 2002 , 50, 748-9	4
1364	Easy as 1, 2, 3? Histamine receptors and gastric acid. 2002 , 50, 747-8	2
1363	[Hepatocellular carcinoma: rising incidence of hepatitis C virus-associated cases at a university clinic in Germany]. 2002 , 127, 2665-8	6
1362	[Indications for liver transplantation in chronic liver diseases]. 2002 , 40, 891-902	4
1361	Prognostic factors in patients with hepatocellular carcinoma treated by transcatheter arterial embolization. 2002 , 32, 455-60	21
1360	HCC: what's the score. 2002 , 50, 749-50	4
1359	Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study. 2002 , 20, 4459-65	97
1358	. 2002 , 10, 237-241	3
1357	Simplified staging for hepatocellular carcinoma. 2002 , 20, 1527-36	551
1356	Treatment of hepatocellular carcinoma. 2002 , 161-172	1
1355	Radiotherapy after transcatheter arterial chemoembolization for patients with hepatocellular carcinoma and portal vein tumor thrombus. 2002 , 25, 189-93	99

1354	C-erb B2 (Her2/neu) is neither overexpressed nor amplified in hepatic neoplasms. 2002 , 10, 237-41	11
1353	Interventional nuclear medicine in hepatocellular carcinoma and other tumours. 2002 , 23, 837-41	9
1352	Synopsis for the Yale Workshop on Hepatocellular Carcinoma. 2002 , 35, S152-3	
1351	Combination of topotecan and oxaliplatin in inoperable hepatocellular cancer patients. 2002 , 25, 198-203	21
1350	Surgery and ablative therapy for hepatocellular carcinoma. 2002 , 35, S130-7	56
1349	Interferon for hepatocellular carcinoma. 2002 ,	1
1348	Comparison of transarterial chemoembolization in patients with unresectable, diffuse vs focal hepatocellular carcinoma. 2002 , 137, 653-7; discussion 657-8	53
1347	Prognostic assessment and evaluation of the benefits of treatment. 2002 , 35, S138-42	26
1346	Hepatocellular carcinoma: diagnosis and treatment. 2002 , 122, 1609-19	436
1345	Spontaneous necrosis of hepatocellular carcinoma: a case report. 2002 , 19, 413-8	34
1344	Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. 2002 , 50, 881-5	185
1343	Risk of hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma: predictive value of the monoethylglycinexylidide test. 2002 , 97, 1223-7	61
1342	Arterial embolization of unresectable hepatocellular carcinoma with use of cyanoacrylate and lipiodol. <i>Journal of Vascular and Interventional Radiology</i> , 2002 , 13, 61-9	2.4 19
1341	La resección es un buen tratamiento del hepatocarcinoma sobre el hígado cirrótico en pacientes seleccionados. 2002 , 71, 28-33	4
1340	Survival benefit of cirrhotic patients with hepatocellular carcinoma treated by percutaneous ethanol injection as a salvage therapy. 2002 , 37, 350-5	26
1339	Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. 2002 , 359, 1734-9	2679
1338	Patellar metastasis. 2002 , 359, 1739	6
1337	Chemoembolization of hepatocellular carcinoma--what to tell the skeptics: review and meta-analysis. 2002 , 5, 122-6	19

1336	Treatment of hepatocellular carcinoma with sub-selective transcatheter arterial oily chemoinfusion. 2002 , 5, 127-31		12
1335	Variant estrogen receptors and their role in liver disease. 2002 , 193, 65-9		40
1334	Chemoembolization for hepatocellular carcinoma: where does the truth lie?. <i>Journal of Vascular and Interventional Radiology</i> , 2002 , 13, 991-4	2.4	64
1333	Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. <i>Journal of Vascular and Interventional Radiology</i> , 2002 , 13, S223-9	2.4	203
1332	Imaging evaluation of hepatocellular carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2002 , 13, S173-84	2.4	22
1331	Chemoembolization of hepatocellular carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2002 , 13, S211-21	2.4	179
1330	Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis. 2002 , 62 Suppl 1, 69-73		36
1329	Hepatocellular carcinoma: therapeutic experience with percutaneous ethanol injection under real-time contrast-enhanced color Doppler sonography with the contrast agent Levovist. 2002 , 21, 1015-22		3
1328	New interventions for liver tumors. 2002 , 37, 303-11		4
1327	Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: A systematic review. 2002 , 36, S84-S92		62
1326	Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. <i>Cancer</i> , 2002 , 94, 421-7	6.4	97
1325	Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. <i>Cancer</i> , 2002 , 94, 1760-9	6.4	455
1324	Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. <i>Cancer</i> , 2002 , 94, 2040-6	6.4	256
1323	A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. <i>Cancer</i> , 2002 , 94, 1747-52	6.4	188
1322	Serum tissue polypeptide specific antigen as a noninvasive prognostic indicator for early recurrence of hepatocellular carcinoma after curative resection. <i>Cancer</i> , 2002 , 95, 112-8	6.4	8
1321	Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. <i>Cancer</i> , 2002 , 95, 588-95	6.4	281
1320	Hepatocellular carcinoma in elderly patients: beneficial therapeutic efficacy using percutaneous ethanol injection therapy. <i>Cancer</i> , 2002 , 95, 816-23	6.4	44
1319	[Shoulder metastasis as the initial manifestation of hepatocellular carcinoma (HCC)]. 2002 , 97, 361-4		2

1318	Prognosis of a large cohort of patients with hepatocellular carcinoma in a single European centre. 2002 , 22, 23-8		32
1317	Novel arterial infusion chemotherapy using cisplatin, 5-fluorouracil, and leucovorin for patients with advanced hepatocellular carcinoma. 2002 , 23, 7-17		24
1316	Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. 2002 , 6, 224-32; discussion 232		193
1315	Hepatocellular carcinoma: a prime indication for living donor liver transplantation. 2002 , 6, 102-7		70
1314	Diagnostic des h�patopathies et de leur s�vfit. 2002 , 23, 41-48		2
1313	¹³¹ I lipiodol therapy for unresectable hepatocellular carcinoma. 2002 , 72, 210-4		11
1312	Clinical features, etiology, and survival of hepatocellular carcinoma among different countries. 2002 , 17 Suppl, S40-9		7
1311	Natural history of hepatocellular carcinoma including fibrolamellar and hepato-cholangiocarcinoma variants. 2002 , 17, 401-5		83
1310	Prognostic factors in patients with small hepatocellular carcinoma treated by percutaneous ethanol injection. 2002 , 17, 1205-10		13
1309	CT-guided intratumoural administration of cisplatin/epinephrine gel for treatment of malignant liver tumours. 2002 , 86, 524-9		38
1308	Thyroid uptake and radiation dose after (¹³¹ I)-lipiodol treatment: is thyroid blocking by potassium iodide necessary?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002 , 29, 1311-6	8.8	11
1307	How to detect hepatocellular carcinoma in cirrhosis. 2002 , 12, 2258-72		49
1306	Clinical predictors of large esophagogastric varices in patients with hepatocellular carcinoma. 2002 , 47, 723-9		7
1305	Prognostic prediction and treatment strategy in hepatocellular carcinoma. 2002 , 35, 519-24		843
1304	Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. 2002 , 35, 1164-71		1934
1303	Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. 2002 , 36, S84-92		72
1302	High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. 2002 , 36, 1221-6		153
1301	Liver transplantation in association with hepatocellular carcinoma: an update of the International Tumor Registry. 2002 , 8, 736-48		101

1300	Hepatocellular carcinoma: Can it be considered a controversial indication for liver transplantation in centers with high rates of hepatitis C?. 2002 , 8, 1020-7	42
1299	Cellular retinol-binding protein-1 in hepatocellular carcinoma correlates with beta-catenin, Ki-67 index, and patient survival. 2003 , 38, 470-80	46
1298	Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma. 2003 , 38, 1237-41	78
1297	AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: rationale and overview of the conference. 2003 , 5, 238-42	13
1296	AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: consensus statement. 2003 , 5, 243-50	92
1295	Extrahepatic spread of hepatocellular carcinoma: a pictorial review. 2003 , 13, 874-82	40
1294	IHPBA concordant classification of primary liver cancer: working group report. 2003 , 10, 26-30	59
1293	Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). 2003 , 38, 207-15	531
1292	Predictors and patterns of recurrence after resection of hepatocellular carcinoma. 2003 , 197, 753-8	219
1291	Multimodality management of hepatocellular carcinoma larger than 10 cm. 2003 , 197, 730-8	62
1290	Elicitation of prior distributions for a phase III randomized controlled trial of adjuvant therapy with surgery for hepatocellular carcinoma. 2003 , 24, 110-21	36
1289	Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. 2003 , 90, 325-31	101
1288	Transcatheter arterial procedures in the treatment of patients with hepatocellular carcinoma: a review of literature. 2003 , 46, 285-95	6
1287	Hepatocellular carcinoma: surgical indications and results. 2003 , 47, 13-27	59
1286	1,25-Dihydroxyvitamin D(3) induced cell cycle arrest in the human primary liver cancer cell line HepG2. 2003 , 26, 34-39	14
1285	Arterial infusion chemotherapy using cisplatin, 5-fluorouracil, and isovorin for patients with advanced hepatocellular carcinoma, pilot study: Is a high dose of the biochemical modulator effective?. 2003 , 27, 36-44	10
1284	Randomized controlled trial to compare the dose of adjuvant chemotherapy after curative resection of hepatocellular carcinoma. 2003 , 18, 450-5	20
1283	Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. 2003 , 3, 19	208

1282	Review article: natural history and prognostic prediction of patients with hepatocellular carcinoma. 2003 , 17 Suppl 2, 98-102		19
1281	Review article: intra-arterial treatments in patients with hepatocellular carcinoma. 2003 , 17 Suppl 2, 111-8		10
1280	Ruptured hepatocellular carcinoma as a complication of transarterial oily chemoembolization. 1998 , 85, 512-4		35
1279	Hepatocellular carcinoma. 1998 , 85, 1319-31		120
1278	Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma. 2003 , 89, 1865-9		50
1277	Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B results of a comparative study in 96 Chinese patients. 2003 , 98, 1181-1185		3
1276	Modified CLIP using PIVKA-II for evaluating prognosis after hepatectomy for hepatocellular carcinoma. 2003 , 29, 735-42		20
1275	Prognostic factors after resection of hepatocellular carcinoma: are there landmarks in the wild forest?. 2003 , 38, 237-9		10
1274	Hepatocellular carcinoma: present status and future prospects. 2003 , 38 Suppl 1, S136-49		176
1273	Hepatocellular carcinoma. 2003 , 362, 1907-17		3580
1272	MR-guided laser thermal ablation of primary and secondary liver tumours. 2003 , 58, 112-20		47
1271	[Consensus document on indications for liver transplantation. 2002]. 2003 , 26, 355-75		12
1270	Guidelines for 131I-ethiodised oil (Lipiodol) therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003 , 30, BP20-2	8.8	4
1269	Critical issues in the design and implementation of clinical trials in hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2003 , 3, 421-3	3.5	4
1268	Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for hepatocellular carcinoma in cirrhotic patients: a prospective study. 2003 , 38, 770-8		70
1267	Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. 2003 , 98, 679-90		199
1266	Etiology of hepatocellular carcinoma influences clinical and pathologic features but not patient survival. 2003 , 98, 907-14		27
1265	Imaging in the diagnosis, staging, treatment, and surveillance of hepatocellular carcinoma. 2003 , 180, 441-54		57

1264 Liver Cancer: An Overview. **2003**, 01, 297-311

1263 Current Status of Surgery in the Management of Hepatocellular Carcinoma. **2003**, 01, 211-226

1262 Controversies in the Staging of Hepatocellular Carcinoma. **2003**, 01, 179-189

4

1261 Sequential transarterial chemoembolization and percutaneous acetic acid injection therapy versus repeated percutaneous acetic acid injection for unresectable hepatocellular carcinoma: a prospective study. **2003**, 14, 1648-53

24

1260 Increasing sensitivity of morphological diagnosis in hepatocellular carcinoma (HCC) by combination of cytological and fine-needle histological examination after ultrasound guided fine needle biopsy. **2003**, 41, 559-64

10

1259 Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B: results of a comparative study in 96 Chinese patients. **2003**, 98, 1181-5

36

1258 Chemoembolization of hepatocellular carcinoma: results of a metaanalysis. **2003**, 26, 344-9

63

1257 An independent evaluation of modern prognostic scores in a central European cohort of 120 patients with hepatocellular carcinoma. **2003**, 15, 1305-15

17

1256 . **2003**, 26, 344-349

63

1255 Pilot study of transcatheter arterial chemoembolization with degradable starch microspheres in patients with hepatocellular carcinoma. **2003**, 26, 159-64

32

1254 Living-donor liver transplantation for hepatocellular carcinoma. **2003**, 75, S37-40

136

1253 Comparison of clinicopathologic characteristics and outcomes after resection in patients with hepatocellular carcinoma treated in the United States, France, and Japan. **2003**, 238, 711-9

65

1252 Hepatic Resection for Bilobar Hepatocellular Carcinoma. **2003**, 138, 100

29

1251 Epidemiologie und Klinik des hepatozellulären Karzinoms. **2003**, 19, 214-217

1250 Mechanisms of human hepatocarcinogenesis. **2003**, 3, 573-88

203

1249 Pilot Study of Transcatheter Arterial Chemoembolization with Degradable Starch Microspheres in Patients With Hepatocellular Carcinoma. **2003**, 26, 159-164

26

1248 Hepatocellular carcinoma - issues in imaging. **2004**, 4, 174-80

2

1247 [Hepatocellular carcinoma with cardiovascular invasion. Report of five cases]. **2004**, 132, 1517-22

1

1246	Diagnosis, staging and treatment of hepatocellular carcinoma. 2004 , 37, 1689-705	60
1245	[Prognosis of hepatocellular carcinoma according to new staging classifications]. 2004 , 129, 1725-30	7
1244	Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. 2004 , 15, 1661-6	132
1243	Three-dimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoembolization. 2004 , 34, 532-9	81
1242	Induction of VX2 carcinoma in rabbit liver: comparison of two inoculation methods. 2004 , 38, 79-84	51
1241	The effect of megestrol acetate on growth of HepG2 cells in vitro and in vivo. 2004 , 10, 5226-32	21
1240	Interventional Radiology in Cancer. 2004 ,	1
1239	Transcatheter arterial chemotherapy with and without embolization in patients with hepatocellular carcinoma. 2004 , 66, 24-31	73
1238	Extracellular signal-regulated kinase induces cyclin D1 and Cdk-2 expression and phosphorylation of retinoblastoma in hepatocellular carcinoma. 2004 , 25, 1839-47	10
1237	Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. 2004 , 22, 1815-22	207
1236	Overexpression of tumour suppressor retinoblastoma 2 protein (pRb2/p130) in hepatocellular carcinoma. 2004 , 25, 1485-94	22
1235	Differential mechanism and prognostic impact of diabetes mellitus on patients with hepatocellular carcinoma undergoing surgical and nonsurgical treatment. 2004 , 99, 1479-87	50
1234	Regression of hepatocellular carcinoma spontaneous or herbal medicine related?. 2004 , 32, 579-85	12
1233	Surgical management of hepatic malignancy. 2004 , 22, 283-303	16
1232	Induction of complete tumor necrosis may reduce intrahepatic metastasis and prolong survival in patients with hepatocellular carcinoma undergoing locoregional therapy: a prospective study. 2004 , 15, 775-80	20
1231	Preliminary analysis of a newly proposed prognostic scoring system (SLiDe score) for hepatocellular carcinoma. 2004 , 19, 805-11	35
1230	Many staging systems for hepatocellular carcinoma: evolution from Child-Pugh, Okuda to SLiDe. 2004 , 19, 1227-32	11
1229	Management of inoperable hepatocellular carcinoma. 2004 , 19, S272-S278	4

1228	Long-term oral branched chain amino acids in patients undergoing chemoembolization for hepatocellular carcinoma: a randomized trial. 2004 , 19, 779-88	88
1227	Acute renal failure after transarterial chemoembolization for hepatocellular carcinoma: a retrospective study of the incidence, risk factors, clinical course and long-term outcome. 2004 , 19, 999-1007	40
1226	Comparison of transarterial chemoembolization and percutaneous acetic acid injection as the primary loco-regional therapy for unresectable hepatocellular carcinoma: a prospective survey. 2004 , 19, 1301-8	15
1225	Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection. 2004 , 11, 366-74	42
1224	Selective use of diagnostic laparoscopy prior to planned hepatectomy for patients with hepatocellular carcinoma. 2004 , 135, 273-81	29
1223	Neoplasms of the liver and the bile ducts. 2004 , 39, 412-27	7
1222	[Staging systems in hepatocellular carcinoma]. 2004 , 28, 359-66	6
1221	[Best supportive care of hepatocellular carcinoma]. 2004 , 45, 777-85	2
1220	The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. 2004 , 53, 296-304	24
1219	Key research issues in the management of hepatocellular carcinoma. 2004 , 54 Suppl 1, S87-90	3
1218	Preliminary results of transarterial rhenium-188 HDD lipiodol in the treatment of inoperable primary hepatocellular carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004 , 31, 250-7	8.8 45
1217	Staging for hepatocellular carcinoma. 2004 , 3, 61-66	1
1216	Prognosis of hepatocellular carcinoma in anti-HCV positive cirrhotic patients: a single-centre comparison amongst four different staging systems. 2004 , 255, 399-408	23
1215	Critical evaluation of the different staging systems for hepatocellular carcinoma. 2004 , 91, 400-8	56
1214	Prognostic prediction in HCC: Did anybody expect it to be easy?. 2004 , 39, 551-552	13
1213	A common staging system for hepatocellular carcinoma. 2004 , 39, 550-551	35
1212	The strategic role of staging in the treatment of HCC. 2004 , 39, 552-553	10
1211	Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. 2004 , 40, 667-76	697

1210	Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. 2004 , 40, 1396-405		306
1209	Liver transplantation in patients with hepatocellular carcinoma. 2004 , 10, S81-5		32
1208	Surgical treatment of hepatocellular carcinoma: similar long-term results despite geographic variations. 2004 , 10, S74-80		34
1207	High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. 2004 , 10, 1294-300		229
1206	Spontaneous regression of hepatocellular carcinoma: two case reports and a literature review. 2004 , 29, 180-190		25
1205	Patterns of methylation profiles as diagnostic markers for multiple hepatocellular carcinomas. 2004 , 39, 246-51		7
1204	[Treatment modalities in patients with hepatocellular carcinoma: a retrospective series in a single institution in Mexico]. 2004 , 27, 11-7		8
1203	Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. <i>Journal of Vascular and Interventional Radiology</i> , 2004 , 15, 335-45	2.4	181
1202	Hepatoma--resection or transplantation. 2004 , 84, 495-511, x		17
1201	Current role of portal vein embolization/hepatic artery chemoembolization. 2004 , 84, 643-57		46
1200	Hepatic arterial infusion chemotherapy with use of an implanted port system in patients with advanced hepatocellular carcinoma: prognostic factors. <i>Journal of Vascular and Interventional Radiology</i> , 2004 , 15, 835-41	2.4	19
1199	Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. 2004 , 127, S51-5		143
1198	Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: Ethanol injection therapy and radiofrequency ablation. 2004 , 127, S159-66		169
1197	Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. 2004 , 127, S194-205		269
1196	Hepatocellular carcinoma: current management and future trends. 2004 , 127, S218-24		196
1195	Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma. 2004 , 90, 65-9		49
1194	Hepatocellular Carcinoma. 2004 , 3, 349-368		
1193	Hepatocellular carcinoma. 2004 , 50, 556-73		24

1192	The Japanese integrated staging score using liver damage grade for hepatocellular carcinoma in patients after hepatectomy. 2004 , 30, 765-70	35
1191	Preparation and biodistribution of rhenium-188 ECD/Lipiodol in rats following hepatic arterial injection. 2004 , 31, 671-7	21
1190	Experiences in liver transplantation for hepatocellular carcinoma. 2004 , 36, 195-8	8
1189	The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available?. 2004 , 40, 124-31	138
1188	Transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma invading the portal veins: therapeutic effects and prognostic factors. 2004 , 51, 12-8	21
1187	Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. 2004 , 5, 409-18	136
1186	Therapy for unresectable hepatocellular carcinoma: time for XRT?. 2004 , 10, 291-3	
1185	Transcatheter arterial embolisation and chemoembolisation for hepatocellular carcinoma. 2004 ,	
1184	Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. 2004 , 239, 142-9	161
1183	CLIP score as a prognostic indicator for hepatocellular carcinoma: experience with patients in the Middle East. 2004 , 16, 675-80	9
1182	Percutaneous injection therapy for hepatocellular carcinoma in patients with chronic renal insufficiency. 2004 , 16, 325-31	4
1181	The role of the immune system in the control of hepatocellular carcinoma. 2004 , 16, 1257-60	26
1180	Does screening or surveillance for primary hepatocellular carcinoma with ultrasonography improve the prognosis of patients?. 2004 , 10, 317-25	35
1179	Advances in the surgical management of liver malignancies. 2004 , 10, 74-87	19
1178	Recent advances in imaging hepatocellular carcinoma: diagnosis, staging and response assessment: functional imaging. 2004 , 10, 121-7	13
1177	Liver transplantation for hepatocellular carcinoma in cirrhosis: is clinical tumor classification before transplantation realistic?. 2005 , 79, 483-7	86
1176	Octreotide therapy for advanced hepatocellular carcinoma. 2005 , 39, 333-8	29
1175	Time-varying predictors for clinical surveillance of small hepatocellular carcinoma. 2005 , 11, 226-33	3

1174	Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. 2005 , 28, 496-504	153
1173	Selective portal vein clamping for radiofrequency ablation of hepatocellular carcinoma with portal vein invasion. 2005 , 9, 489-93	1
1172	Survival benefits of intra-arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. 2005 , 32, 127-33	25
1171	A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus. 2005 , 61, 432-43	154
1170	General management. 2005 , 19, 161-74	7
1169	Molecular mechanisms in hepatocellular carcinoma development. 2005 , 19, 25-37	76
1168	Prognostic evaluation of the new American Joint Committee on Cancer/International Union Against Cancer staging system for hepatocellular carcinoma: analysis of 112 cirrhotic patients resected for hepatocellular carcinoma. 2005 , 12, 289-97	37
1167	Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. 2005 , 12, 364-73	203
1166	Staging systems in hepatocellular carcinoma. 2005 , 7, 35-41	183
1165	Coordinated expression of cyclin D1 and LEF-1/TCF transcription factor is restricted to a subset of hepatocellular carcinoma. 2005 , 25, 839-47	23
1164	Comparison of recurrence after hepatic resection in patients with hepatitis B vs. hepatitis C-related small hepatocellular carcinoma in hepatitis B virus endemic area. 2005 , 25, 236-41	58
1163	Evaluation of predictive value of CLIP, Okuda, TNM and JIS staging systems for hepatocellular carcinoma patients undergoing surgery. 2005 , 20, 765-71	49
1162	Tumour staging, morphology and p53 overexpression concur in predicting survival in hepatocellular carcinoma. 2005 , 257, 367-73	6
1161	The role of transcatheter arterial embolization for patients with unresectable hepatocellular carcinoma: a nationwide, multicentre study evaluated by cancer stage. 2005 , 21, 687-94	31
1160	alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma. 2005 , 22, 217-26	40
1159	SarCNU-induced G2/M arrest in hepatoma cells is mediated by a p53-independent phosphorylation of cdc-2 at Tyr15. 2005 , 204, 785-91	2
1158	Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. 2005 , 41, 707-16	498
1157	Management of hepatocellular carcinoma. 2005 , 42, 1208-36	477 ⁸

1156	Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. <i>Cancer</i> , 2005 , 103, 749-55	6.4	95
1155	Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus. <i>Cancer</i> , 2005 , 104, 794-801	6.4	89
1154	Resectability rate of hepatocellular carcinoma in rural southern Africans. 1988 , 75, 335-8		23
1153	Adverse effects of preoperative hepatic artery chemoembolization for resectable hepatocellular carcinoma: A retrospective comparison of 138 liver resections. 2005 , 76, 871-876		2
1152	Limited hepatic resection for selected cirrhotic patients with hepatocellular or cholangiocellular carcinoma: a prospective study. 1991 , 78, 459-62		53
1151	Therapeutic aspects of radio-isotopes in hepatobiliary malignancy. 1991 , 78, 901-6		13
1150	Resection for extrahepatic recurrence of hepatocellular carcinoma. 1994 , 81, 1019-21		47
1149	Iodized oil in the treatment of hepatocellular carcinoma. 1994 , 81, 1563-71		61
1148	Resection of hepatocellular carcinoma in patients with cirrhosis. 1996 , 83, 758-61		72
1147	Selection of patients with hepatocellular carcinoma for liver transplantation. 2006 , 93, 11-8		33
1146	Arterial embolization of unresectable hepatocellular carcinoma with use of microspheres, lipiodol, and cyanoacrylate. 2005 , 28, 313-8		47
1145	Treatment of hepatocellular carcinoma. 2005 , 19, 129-45		33
1144	Assessment of hepatic reserve prior to hepatic resection. 2005 , 12, 10-5		20
1143	Adjuvant arterial infusion chemotherapy after resection of hepatocellular carcinoma with portal thrombosis: a pilot study. 2005 , 12, 249-53		21
1142	Step classification is useful for the determination of indications for systematized hepatectomy in hepatocellular carcinoma. 2005 , 12, 371-7		2
1141	Controversies in staging of hepatocellular carcinoma. 2005 , 12, 456-62		6
1140	Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. 2005 , 40, 70-8		54
1139	Updated treatment approach to hepatocellular carcinoma. 2005 , 40, 225-35		420

1138	Early liver cancer: concepts, diagnosis, and management. 2005 , 10, 384-90	5
1137	Hepatocellular carcinoma: therapy and prevention. <i>World Journal of Gastroenterology</i> , 2005 , 11, 7391-409.6	186
1136	Computed Tomography. 2005 ,	
1135	Complete tumor response following intratumoral ³² P BioSilicon on human hepatocellular and pancreatic carcinoma xenografts in nude mice. 2005 , 11, 7532-7	71
1134	Novel presentation of coeliac disease after following the Atkins' low carbohydrate diet. 2005 , 54, 1342	4
1133	The Inflammatory Bowel Disease Yearbook 2004. 2005 , 54, 1350-1350	78
1132	Is there an ideal prognostic model for hepatocellular carcinoma?. 2005 , 54, 1348	5
1131	Comparison of the usefulness of three staging systems for hepatocellular carcinoma (CLIP, BCLC, and JIS) in Japan. 2005 , 100, 1764-71	76
1130	Calprotectin and IBD. 2005 , 54, 1349-50; author reply 1350	4
1129	Wireless capsule endoscopy and Crohn's disease. 2005 , 54, 323-6	56
1128	Staging classifications for hepatocellular carcinoma. 2005 , 5, 377-83	10
1127	Cap polyposis: an inflammatory disorder or a spectrum of mucosal prolapse syndrome?. 2005 , 54, 1342-3	14
1126	Chronic intestinal pseudo-obstruction due to lymphocytic leiomyositis: is there a place for immunomodulatory therapy?. 2005 , 54, 1343-4	23
1125	Colitis evolving into ulcerative colitis. 2005 , 54, 1347-8	3
1124	Response to steroid therapy of sclerosing cholangitis after duodenopancreatectomy due to autoimmune pancreatitis. 2005 , 54, 1348-9	9
1123	Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers?. 2005 , 54, 321-2	33
1122	Surgical Pathology of the GI Tract, Liver, Biliary Tract and Pancreas. 2005 , 54, 1350-1350	78
1121	Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. 2005 , 11, 3799-805	199

1120	Inflammatory biomarkers predict relapse in IBD. 2005 , 54, 1346-7	10
1119	Prognostic prediction in patients with hepatocellular carcinoma. 2005 , 25, 171-80	71
1118	Advanced hepatocellular carcinoma: treatment with high-intensity focused ultrasound ablation combined with transcatheter arterial embolization. 2005 , 235, 659-67	196
1117	RANK ligand and osteoprotegerin: emerging roles in mucosal inflammation. 2005 , 54, 1345-6	
1116	Genetic profiling of human hepatocellular carcinoma. 2005 , 25, 125-32	46
1115	Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. 2005 , 92, 1862-8	139
1114	Snail accelerates cancer invasion by upregulating MMP expression and is associated with poor prognosis of hepatocellular carcinoma. 2005 , 92, 252-8	175
1113	Natural history of untreated nonsurgical hepatocellular carcinoma. 2005 , 100, 1995-2004	111
1112	Deranged smooth muscle alpha-actin expression as a biomarker of intestinal pseudo-obstruction. 2005 , 54, 1346	1
1111	Predicting survival in early hepatocellular carcinoma. 2005 , 54, 328-9	7
1110	Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. 2005 , 54, 419-25	195
1109	Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. 2005 , 23, 4338-46	107
1108	Postprandial abdominal pain, megaloblastic anaemia, and severe weight loss in an 80 year old man. 2005 , 54, 418, 436	
1107	Pancreaticobiliary biofilm: is cholesterol the answer?. 2005 , 54, 326-8	2
1106	Synbiotic therapy for ulcerative colitis. 2005 , 54, 1346	2
1105	UK guidelines for management of acute pancreatitis: is it time to change?. 2005 , 54, 1344-5	30
1104	Analysis of CD4+ T-Cell responses to a novel alpha-fetoprotein-derived epitope in hepatocellular carcinoma patients. 2005 , 11, 6686-94	41
1103	The progression of hepatitis B- and C-infections to chronic liver disease and hepatocellular carcinoma: presentation, diagnosis, screening, prevention, and treatment of hepatocellular carcinoma. 2005 , 89, 345-69	9

1102	Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. <i>Journal of Vascular and Interventional Radiology</i> , 2005 , 16, 1627-39 ^{2.4}	2.4	346
1101	Chemoembolization and bland embolization: a critical appraisal. 2005 , 9, 287-300, vii		9
1100	Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. <i>Journal of Vascular and Interventional Radiology</i> , 2005 , 16, 205-13 ^{2.4}	2.4	152
1099	Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2005 , 16, 195-203	2.4	105
1098	Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. 2005 , 54, 411-8		189
1097	Down-regulation of dehydroepiandrosterone sulfotransferase gene in human hepatocellular carcinoma. 2005 , 231, 87-94		16
1096	Tamoxifen does not improve overall survival in people with advanced-stage hepatocellular carcinoma. 2005 , 31, 491-5		2
1095	Comparison between the fifth and sixth editions of the AJCC/UICC TNM staging systems for hepatocellular carcinoma: multicentric study on 393 cirrhotic resected patients. 2005 , 31, 760-7		61
1094	Comparative study of survival of patients with hepatocellular carcinoma predicted by different staging systems using multivariate analysis. 2005 , 31, 882-90		21
1093	Case records of the Massachusetts General Hospital. Case 23-2005. A 57-year-old man with a mass in the liver. 2005 , 353, 401-10		2
1092	Staging for liver cancer. 2005 , 9, 213-23, vi		8
1091	Selective internal radiation therapy with SIR-Spheres in patients with nonresectable liver tumors. 2005 , 20, 200-8		80
1090	Hepatitis B: the pathway to recovery through treatment. 2006 , 35, 425-61, x		9
1089	Portal hypertension and hepatocellular carcinoma: prognosis and beyond. 2006 , 4, 1318-9		18
1088	Hepatitis B: the pathway to recovery through treatment. 2006 , 35, 895-931		17
1087	The progression of hepatitis B- and C-infections to chronic liver disease and hepatocellular carcinoma: presentation, diagnosis, screening, prevention, and treatment of hepatocellular carcinoma. 2006 , 20, 1-25		6
1086	The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2006 , 17, 505-12	2.4	175
1085	Multidisciplinary treatment of patients with hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2006 , 6, 1377-84	3.5	8

1084	Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. <i>Journal of Vascular and Interventional Radiology</i> , 2006 , 17, 1251-78	2.4	551
1083	Carcinome h�pato-cellulaire. 2006 , 195-217		
1082	Hepatocellular carcinoma. 2006 , 10, 339-51, ix		26
1081	[Hepatocellular carcinoma revealed by prurigo]. 2006 , 133, 243-5		4
1080	Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. 2006 , 131, 461-9		629
1079	Genomic decoding of hepatocellular carcinoma. 2006 , 131, 1344-6		12
1078	Liver resection in the treatment of hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2006 , 6, 567-79	3.5	10
1077	Unresectable hepatocellular carcinoma: survival and prognostic factors after lipiodol chemoembolisation in 89 patients. 2006 , 38, 125-33		19
1076	Prospective validation of the Barcelona Clinic Liver Cancer staging system. 2006 , 44, 723-31		323
1075	Molecular prognostication of liver cancer: end of the beginning. 2006 , 44, 798-805		59
1074	Staging systems for hepatocellular carcinoma: should we all use the BCLC system?. 2006 , 44, 630-2		24
1073	Differentially expressed genes between early and advanced hepatocellular carcinoma (HCC) as a potential tool for selecting liver transplant recipients. 2006 , 12, 97-104		23
1072	Who decides? Living donor liver transplantation for advanced hepatocellular carcinoma. 2006 , 82, 1136-9		15
1071	Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo. 2006 , 21, 129-37		11
1070	Circulating IL-6 and sIL-6R in patients with hepatocellular carcinoma. 2002 , 963, 46-52		44
1069	Treatment and prognostic factors in patients with hepatocellular carcinoma. 2006 , 26, 680-7		42
1068	Surveillance of hepatocellular carcinoma in patients with hepatitis C virus infection may improve patient survival. 2006 , 26, 543-51		37
1067	Comparison of staging systems to predict survival in hepatocellular carcinoma. 2006 , 26, 673-9		21

1066	Do young hepatocellular carcinoma patients have worse prognosis? The paradox of age as a prognostic factor in the survival of hepatocellular carcinoma patients. 2006 , 26, 766-73	53
1065	Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong. 2006 , 24, 573-83	60
1064	Preserved reticulin network in a case of hepatocellular carcinoma. 2006 , 48, 876-8	7
1063	Comparative and integrative functional genomics of HCC. 2006 , 25, 3801-9	96
1062	Complexes with the fac- $\{M(CO)_3\}^+$ (M=99mTc, Re) moiety and long alkyl chain ligands as Lipiodol surrogates. 2006 , 359, 4087-4094	24
1061	Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). 2006 , 16, 661-9	189
1060	Postoperative changes in protein-induced vitamin K absence or antagonist II levels after hepatectomy in patients with hepatocellular carcinoma: relationship to prognosis. 2006 , 8, 137-41	10
1059	Management of hepatocellular carcinoma in Japan. 2006 , 41, 100-6	35
1058	A modified Japan Integrated Stage score for prognostic assessment in patients with hepatocellular carcinoma. 2006 , 41, 884-92	72
1057	Primary hepatoma [guidelines for interdisciplinary treatment. 2006 , 38, 94-99	2
1056	(188)Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006 , 33, 344-52	8.8 23
1055	Diagnosis of benign and malignant portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma: color Doppler US, contrast-enhanced US, and fine-needle biopsy. 2006 , 31, 537-44	131
1054	Percutaneous treatment of hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts. 2006 , 29, 778-84	23
1053	Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma. 2006 , 57, 436-42	17
1052	Management of hepatocellular carcinoma. 2006 , 10, 761-80	65
1051	Transarterial chemoembolization for hepatocellular carcinoma. 2006 , 202, 155-68	71
1050	Hepatocellular carcinoma: molecular biology and therapy. 2006 , 33, S79-83	35
1049	Radiation therapy for hepatocellular carcinoma: from palliation to cure. <i>Cancer</i> , 2006 , 106, 1653-63	6.4 196

1048	Particle embolization of recurrent hepatocellular carcinoma after hepatectomy. <i>Cancer</i> , 2006 , 106, 2181-84	50
1047	Endoscopic injection sclerotherapy for esophageal varices associated with concomitant portal venous thrombus of hepatocellular carcinoma. 1995 , 59, 125-30	7
1046	Radiofrequency ablation of hepatocellular carcinoma in patients with decompensated cirrhosis: evaluation of therapeutic efficacy and safety. 2006 , 186, S261-8	15
1045	Therapie des hepatozellulären Karzinoms. 2006 , 27, 171-177	
1044	[Treatment of hepatocellular carcinoma]. 2006 , 44, 43-9	8
1043	Technology insight: Image-guided therapies for hepatocellular carcinoma--intra-arterial and ablative techniques. 2006 , 3, 315-24	48
1042	Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. 2006 , 17, 1083-9	85
1041	Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma. 2006 , 36, 93-9	19
1040	Imaging characteristics of hepatocellular carcinoma using the hepatobiliary contrast agent Gd-EOB-DTPA. 2006 , 47, 15-23	65
1039	Hepatocellular carcinoma in patients with chronic liver disease: comparison of SPIO-enhanced MR imaging and 16-detector row CT. 2006 , 238, 531-41	94
1038	Treatment of portal vein tumor thrombosis of hepatoma patients with either stereotactic radiotherapy or three-dimensional conformal radiotherapy. 2006 , 36, 212-7	73
1037	Multivariate and univariate analysis of prognostic factors following resection in HCC: the Birmingham experience. 2006 , 23, 103-9	19
1036	Les cancers digestifs. 2006 ,	
1035	Fractionated stereotactic radiotherapy in patients with primary hepatocellular carcinoma. 2006 , 36, 154-8	68
1034	Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. 2007 , 72 Suppl 1, 2-15	149
1033	Radioembolization with Yttrium-90 microspheres: review of an emerging treatment for liver tumors. 2007 , 3, 73-81	25
1032	Survival impact of delayed treatment in patients with hepatocellular carcinoma undergoing locoregional therapy: is there a lead-time bias?. 2007 , 42, 485-92	20
1031	Prognostic models in hepatocellular carcinoma (HCC) and statistical methodologies behind them. 2007 , 13, 1527-32	7

1030	Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma by placing a temporary catheter via the subclavian route. 2007 , 48, 734-40	7
1029	Evaluating patients with cirrhosis for hepatocellular carcinoma: value of clinical symptomatology, imaging and alpha-fetoprotein. 2007 , 72 Suppl 1, 117-23	49
1028	Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. 2007 , 188, 768-75	97
1027	Radiographically identified necrosis after 90Y microsphere brachytherapy: a new standard for oncologic response assessment?. 2007 , 188, 765-7	7
1026	Hepatic arterial infusion chemotherapy with epirubicin in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis. 2007 , 72, 188-93	11
1025	Aktuelle Diagnostik und Therapie des hepatozellulären Karzinoms. 2007 , 3, 115-132	
1024	Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. 2007 , 6, 138-46	127
1023	Emerging approaches in hepatocellular carcinoma. 2007 , 41, 839-54	15
1022	Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. 2007 , 245, 909-22	249
1021	Elevation of endoglin (CD105) concentrations in serum of patients with liver cirrhosis and carcinoma. 2007 , 19, 755-61	33
1020	Hepatocellular carcinoma presenting as musculoskeletal metastases: A report of two cases. 2007 , 62, 25-29	3
1019	Primary hepatocellular cancer in the explanted liver: outcome of transplantation and risk factors for HCC recurrence. 2007 , 33, 868-73	23
1018	Comparison of clinical staging systems in predicting survival of hepatocellular carcinoma patients receiving major or minor hepatectomy. 2007 , 33, 480-7	30
1017	Predicting survival in patients with hepatocellular carcinoma: a UK perspective. 2007 , 33, 188-94	9
1016	Factors predicting survival in advanced T-staged hepatocellular carcinoma patients treated with reduction hepatectomy followed by transcatheter arterial chemoembolization. 2007 , 33, 1019-24	4
1015	Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. 2007 , 47, 527-37	189
1014	Intra-arterial injection of iodine-131-labeled lipiodol for treatment of hepatocellular carcinoma. 2007 , 82, 76-82	36
1013	Protocolo y guía para el diagnóstico histopatológico de carcinoma hepatocelular: Subprotocolo de Anatomía Patológica para un protocolo general hospitalario de hepatocarcinoma. 2007 , 40, 147-160	

1012	Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2007 , 18, 49-56	2.4	111
1011	A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. 2007 , 5, 1100-8		234
1010	[Updated guide for diagnosis, staging and treatment of hepatocellular carcinoma]. 2007 , 128, 741-8		3
1009	Epidemiology and outcome of hepatocellular carcinoma in Lombardy. 2007 , 39, 1011-7		10
1008	FDG-PET for evaluating the antitumor effect of intraarterial 3-bromopyruvate administration in a rabbit VX2 liver tumor model. 2007 , 8, 216-24		18
1007	[Hepatocellular carcinoma: impact of waiting list and pre-operative treatment strategies on survival of cadaveric liver transplantation in pre-MELD era in one center in Brazil]. 2007 , 44, 189-94		8
1006	Kentucky hepatoma: epidemiologic variant or same problem in a different region?. 2007 , 142, 431-6; discussion 436-7		6
1005	Therapy of hepatocellular carcinoma with 131I-lipiodol: patient dosimetry. 2007 , 46, 192-7		1
1004	Liver Resection for Hepatocellular Carcinoma: a Multivariate Analysis of Factors Associated with Improved Prognosis. the Role of Clinical, Pathological and Surgical Related Factors. 2007 , 93, 264-268		10
1003	Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: analysis of 5,613 cases from a medical center in southern Taiwan. 2007 , 120, 2650-5		88
1002	Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy. 2007 , 45, 1382-9		55
1001	Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. 2008 , 47, 71-81		448
1000	Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. <i>Cancer</i> , 2007 , 110, 129-37	6.4	85
999	CD117 (c-kit) expression in human hepatocellular carcinoma. 2007 , 19, 204-8		30
998	Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy. 2007 , 67, 225-31		108
997	A novel approach to brachytherapy in hepatocellular carcinoma using a phosphorous32 (32P) brachytherapy delivery device--a first-in-man study. 2007 , 67, 786-92		76
996	Evaluation of the prognostic value of Okuda, Cancer of the Liver Italian Program, and Japan Integrated Staging systems for hepatocellular carcinoma patients undergoing radiotherapy. 2007 , 67, 1037-42		27
995	The role of 5' untranslated region in translational suppression of OKL38 mRNA in hepatocellular carcinoma. 2007 , 26, 1155-65		14

994	Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study. 2007 , 97, 582-8	34
993	Orthotopic hepatocellular carcinoma model with a controlled and reproducible tumorigenicity. 2007 , 22, 423-8	4
992	Comparison of surgical outcomes for small hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a Chinese experience. 2007 , 22, 1936-41	43
991	Long-term survival of patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoinfusion. 2007 , 26, 839-46	14
990	Outcome of patients with hepatocellular carcinoma referred to a tertiary centre with availability of multiple treatment options including cadaveric liver transplantation. 2007 , 27, 1240-8	17
989	A simple prognostic scoring system for patients with unresectable hepatocellular carcinoma treated by chemo-embolization. 2007 , 31, 154-60	18
988	Consensus and controversy in the management of hepatocellular carcinoma. 2007 , 205, 108-23	21
987	Cancer of the Liver Italian Program (CLIP) score for staging hepatocellular carcinoma. 2007 , 37 Suppl 2, S206-9	18
986	Review of current staging systems for hepatocellular carcinoma. 2007 , 37 Suppl 2, S210-5	7
985	Palliation of hepatic tumors. 2007 , 16, 277-91	37
984	Epidemiology of hepatocellular carcinoma in Bas-Rhin: analysis of all incident cases from 1990 to 1999. 2007 , 31, 838-43	3
983	Outcomes of hepatic resection for a single large hepatocellular carcinoma. 2007 , 31, 795-801	39
982	Prognostic index for survival in patients after treatment for primary hepatocellular carcinoma. 2007 , 52, 2444-51	6
981	Cyclooxygenase-2 expression in hepatocellular carcinoma, cirrhosis and chronic hepatitis in the United States. 2007 , 52, 220-7	12
980	Causes of death in patients with unresectable hepatocellular carcinoma. 2007 , 52, 3285-9	45
979	Hepatocellular carcinoma with portal vein tumor thrombosis: clinical characteristics, prognosis, and patient survival analysis. 2007 , 52, 3290-5	111
978	Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma. 2006 , 41, 1214-9	44
977	Complete remission of hepatocellular carcinoma with portal vein tumor thrombus and lymph node metastases by arterial infusion of 5-fluorouracil and interferon-alpha combination therapy following hepatic resection. 2007 , 42, 501-6	9

976	Referrals for surgical therapy in patients with hepatocellular carcinoma: a community experience. 2007 , 11, 76-81		5
975	Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials. 2008 , 17, 831-43		48
974	Edmondson-Steiner grading increases the predictive efficiency of TNM staging for long-term survival of patients with hepatocellular carcinoma after curative resection. 2008 , 32, 1748-56		70
973	Hepatic resection is justified for elderly patients with hepatocellular carcinoma. 2008 , 32, 2223-9		62
972	Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with inferior vena cava and right atrial tumors. 2008 , 31, 735-44		42
971	Changes of cytokines in cirrhosis patients with advanced hepatocellular carcinoma treated by intra-arterial chemotherapy. 2008 , 62, 271-6		2
970	Th1/Th2 balance: an important indicator of efficacy for intra-arterial chemotherapy. 2008 , 62, 959-63		17
969	[HCC screening]. 2008 , 48, 33-8		1
968	Angiographic evaluation of hepatic arterial damage after transarterial chemoembolization for hepatocellular carcinoma. 2008 , 26, 206-12		37
967	Standards und neue Aspekte der Diagnostik und Therapie des hepatozellulären Karzinoms. 2008 , 1, 109-119		
966	The impact of new data in the treatment of advanced hepatocellular carcinoma. 2008 , 10, 199-205		23
965	Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival. 2008 , 43, 159-70		52
964	Changing management and outcome of hepatocellular carcinoma: evaluation of 501 patients treated at a single comprehensive center. 2008 , 98, 81-8		12
963	Treatment and prognosis of hepatocellular carcinoma: a population based study in France. 2008 , 98, 505-9		59
962	Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. <i>Cancer</i> , 2008 , 113, 995-1003	6.4	128
961	A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy: implication for patient selection in systemic therapy trials. <i>Cancer</i> , 2008 , 113, 2742-51	6.4	53
960	Identification of metastasis-related microRNAs in hepatocellular carcinoma. 2008 , 47, 897-907		573
959	Value of serum anti-p53 antibodies as a prognostic factor in Egyptian patients with hepatocellular carcinoma. 2008 , 41, 1131-9		22

958	Implementation of a multidisciplinary treatment team for hepatocellular cancer at a Veterans Affairs Medical Center improves survival. 2008 , 10, 405-11		61
957	Diaphragmatic and subcutaneous seeding of hepatocellular carcinoma following fine-needle aspiration biopsy. 1998 , 18, 251-4		35
956	An enormous hepatitis B virus-related liver disease burden projected in Vietnam by 2025. 2008 , 28, 525-31		55
955	Extrahepatic metastasis of hepatocellular carcinoma: incidence and risk factors. 2008 , 28, 1256-63		100
954	Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score. 2008 , 23, 445-52		40
953	Efficacy and safety of epirubicin and etoposide combination chemotherapy in advanced hepatocellular carcinoma: a retrospective analysis. 2008 , 23, 811-6		6
952	Evaluation of the prognostic powers of various tumor status grading scales in patients with hepatocellular carcinoma. 2008 , 23, 1267-75		10
951	Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a case cohort study. 2008 , 23, 1259-66		29
950	Comparison of four current staging systems for Chinese patients with hepatocellular carcinoma undergoing curative resection: Okuda, CLIP, TNM and CUPI. 2008 , 23, 1874-8		56
949	Radiofrequency ablation of hepatic tumors: lessons learned from 3000 procedures. 2008 , 23, 1492-500		36
948	Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. <i>BMC Cancer</i> , 2008 , 8, 349	4.8	73
947	Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis. <i>BMC Cancer</i> , 2008 , 8, 351	4.8	109
946	Thymostimulin in advanced hepatocellular carcinoma: a phase II trial. <i>BMC Cancer</i> , 2008 , 8, 72	4.8	6
945	A novel prognostic nomogram is more accurate than conventional staging systems for predicting survival after resection of hepatocellular carcinoma. 2008 , 206, 281-91		98
944	MicroRNA involvement in hepatocellular carcinoma. 2008 , 12, 2189-204		212
943	Liver Tumors in Children. 2008 , 227-260		2
942	Radioiodine gene therapy of hepatocellular carcinoma targeted human alpha fetoprotein. 2008 , 23, 551-60		7
941	Hepatocellular carcinoma: epidemiology and clinical aspects. 2008 , 29, 130-43		78

940	Liver transplantation in patients with hepatocellular carcinoma: one center's experience. 2008 , 40, 213-8	4
939	Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma. 2008 , 122, 299-306	76
938	Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402). 2008 , 44, 528-38	78
937	The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients. 2008 , 44, 1000-6	163
936	Liver transplantation for hepatocellular carcinoma: Are the Milan criteria still valid?. 2008 , 34, 256-62	46
935	Carcinoma hepatocelular. 2008 , 10, 770-776	
934	Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. 2008 , 38, 37-51	250
933	Chemoembolization of the liver after portal vein embolization: report of three cases. <i>Journal of Vascular and Interventional Radiology</i> , 2008 , 19, 1513-7	2.4 6
932	Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. 2008 , 103, 914-21	333
931	Molecular Targeting in Hepatocellular Carcinoma. 2008 , 165-210	1
930	Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. 2008 , 299, 1669-77	148
929	Predictive factors of outcome and tumor response to systemic chemotherapy in patients with metastatic hepatocellular carcinoma. 2008 , 38, 675-82	15
928	Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. 2008 , 19, 1117-26	64
927	Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. 2008 , 14, 2056-64	131
926	Advances in prevention and diagnosis of hepatocellular carcinoma. 2008 , 2, 425-33	8
925	Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. 2008 , 103, 597-604	94
924	Treatment of hepatocellular carcinoma using arterial chemoembolization with degradable starch microspheres and continuous arterial infusion of 5-fluorouracil. 2008 , 38, 596-603	12
923	Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. 2008 , 75 Suppl 1, 1-12	95

922	Embolotherapy in the management of hepatocellular carcinoma. 2008 , 25, 234-41	3
921	Adjuvant intraarterial injection of 131I-labeled lipiodol after resection of hepatocellular carcinoma: progress report of a case-control study with a 5-year minimal follow-up. 2008 , 49, 362-6	22
920	Recent advances in transarterial therapy of primary and secondary liver malignancies. 2008 , 28, 101-17	47
919	Selective or targeted gene/drug delivery for liver tumors: advantages and current status of local delivery. 2008 , 2, 791-802	5
918	Therapeutic strategy of advanced hepatocellular carcinoma by using combined intra-arterial chemotherapy. 2008 , 3, 220-6	15
917	A new chemoimmunotherapy regimen (OXAFI) for advanced hepatocellular carcinoma. 2008 , 1, 159-65	3
916	Staging Systems for Hepatocellular Carcinoma. 107-114	
915	Assessment of Tumor Response on Magnetic Resonance Imaging after Locoregional Therapy. 86-98	
914	The role of surgery in the treatment of hepatocellular carcinoma and hepatic metastases. 127-147	
913	Complete pathological response of hepatocellular carcinoma with systemic combination chemotherapy. 2008 , 19, 837-40	5
912	Spontaneous regression of hepatocellular carcinoma is possible and might have implications for future therapies. 2008 , 20, 804-9	18
911	Surgical resection of hepatocellular carcinoma. 2008 , 14, 100-10	44
910	Evolving therapies in the treatment of hepatocellular carcinoma. 2008 , 2, 453-62	13
909	[Evaluation of liver function before living donor liver transplantation and liver resection]. 2008 , 149, 779-86	2
908	Staging of hepatocellular carcinoma. 51-56	
907	Cost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil. 2009 , 13, 191-9	11
906	Optimal treatment for hepatocellular carcinoma in the cirrhotic liver. 2009 , 91, 545-50	1
905	[Local therapy for hepatocellular carcinoma as a bridge to liver transplantation]. 2009 , 36, 487-92	

904	Hepatocellular carcinoma in Keio affiliated hospitals--diagnosis, treatment, and prognosis of this disease. 2009 , 58, 161-75		6
903	Image-guided interstitial high-dose-rate brachytherapy in hepatocellular carcinoma. 2009 , 27, 170-4		14
902	Clinical staging of hepatocellular carcinoma. 2009 , 27, 131-41		14
901	[Hepatic resection for hepatocellular carcinoma--results and analysis of the current literature]. 2009 , 134, 127-35		16
900	[Selective internal radiotherapy (radioembolization) and radiation therapy for HCC--current status and perspectives]. 2009 , 47, 37-54		20
899	Hepatocellular Carcinoma. 2009 ,		
898	Diffusion-weighted imaging of surgically resected hepatocellular carcinoma: imaging characteristics and relationship among signal intensity, apparent diffusion coefficient, and histopathologic grade. 2009 , 193, 438-44		160
897	Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. 2009 , 20, 1402-7		42
896	Surgical resection of resectable thoracic metastatic hepatocellular carcinoma after liver transplantation. 2009 , 138, 240-1		5
895	Radio-guided surgery for ventricular remodeling in patients with ischemic dilated cardiomyopathy: a new tool to discriminate in vivo viable myocardium and scar. 2009 , 138, 241-3		1
894	Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study. <i>BMC Cancer</i> , 2009 , 9, 33	4.8	68
893	Is selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis?. 2009 , 208, 375-82		59
892	Comparison Between the CLIP and Okuda Staging Systems for Prediction of Survival Time of Patients with Hepatocellular Carcinoma in Eastern Taiwan. 2009 , 21, 34-39		1
891	Selective targeting by preS1 domain of hepatitis B surface antigen conjugated with phosphorylcholine-based amphiphilic block copolymer micelles as a biocompatible, drug delivery carrier for treatment of human hepatocellular carcinoma with paclitaxel. 2009 , 124, 2460-7		25
890	Hepatocellular carcinoma with main portal vein tumor thrombus: treatment with 3-dimensional conformal radiotherapy after portal vein stenting and transarterial chemoembolization. <i>Cancer</i> , 2009 , 115, 1245-52	6.4	62
889	A comparison of outcomes from treating hepatocellular carcinoma by hepatic artery embolization in patients younger or older than 70 years. <i>Cancer</i> , 2009 , 115, 5000-6	6.4	17
888	An atypical extrahepatic metastasis of the distal phalanx from hepatocellular carcinoma. 2009 , 14, 159-62		8
887	Combined pancreatoduodenectomy and orthotopic liver transplantation for hepatocellular carcinoma with portal vein tumor thrombus: A case report. 2009 , 8, 734-736		

886	Lebertransplantation bei Patienten mit hepatozellulärem Karzinom. 2009 , 15, 575-588	
885	Usefulness of the CLIP scoring system for prediction of postoperative prognosis of patients with large hepatocellular carcinoma. 2009 , 16, 538-45	4
884	Treatment strategy for hepatocellular carcinoma: expanding the indications for radiofrequency ablation. 2009 , 44 Suppl 19, 142-6	16
883	A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. 2009 , 3, 480-9	18
882	Role of stereotactic body radiotherapy in the management of primary hepatocellular carcinoma. Rationale, technique and results. 2009 , 11, 276-83	14
881	Das hepatozelluläre Karzinom aus der Sicht des Internisten und des Chirurgen. 2009 , 4, 301-311	
880	Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. 2009 , 185, 782-8	92
879	Influence of the etiology of liver cirrhosis on the response to combined intra-arterial chemotherapy in patients with advanced hepatocellular carcinoma. 2009 , 64, 109-14	8
878	Changes of host immunity in relation to efficacy in liver cirrhosis patients with advanced hepatocellular carcinoma treated by intra-arterial chemotherapy. 2009 , 64, 271-7	8
877	Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. 2009 , 16, 453-63	214
876	Predictors and survival in hepatitis B-related hepatocellular carcinoma in New South Wales, Australia. 2009 , 24, 436-42	8
875	Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma. 2009 , 24, 1437-44	24
874	Comparative performances of staging systems for early hepatocellular carcinoma. 2009 , 11, 382-90	22
873	Is the Cancer of the Liver Italian Program system an adequate weighting for survival of hepatocellular carcinoma? Evaluation of intrascore prognostic value among 36 subgroups. 2009 , 29, 74-81	30
872	Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. 2009 , 29, 502-10	234
871	Telomerase activity, telomere length and human telomerase reverse transcriptase expression in hepatocellular carcinoma is independent of hepatitis virus status. 2009 , 29, 1162-70	43
870	Time-dependent analysis of predisposing factors for the recurrence of hepatocellular carcinoma. 2010 , 30, 1027-32	15
869	A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. 2009 , 74, 831-6	159

868	Both fibrous capsule formation and extracapsular penetration are powerful predictors of poor survival in human hepatocellular carcinoma: a histological assessment of 365 patients in Japan. 2009 , 16, 2539-46	42
867	Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer. 2009 , 10, 333-43	147
866	Targeted therapy for hepatocellular carcinoma. 2009 , 6, 423-32	95
865	Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method--analysis of 2010 Taiwanese patients. 2009 , 45, 1630-9	62
864	Validation of the BCLC prognostic system in surgical hepatocellular cancer patients. 2009 , 41, 1260-3	35
863	[Diagnosis and treatment of hepatocellular carcinoma]. 2009 , 132, 272-87	37
862	[Prognostic prediction in patients with hepatocellular carcinoma not amenable to locoregional treatment]. 2009 , 133, 581-5	1
861	Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer. 2009 , 50, 323-33	110
860	Prognostication of the outcome of hepatocellular carcinoma: how to rely on science instead of on the art of Nostradamus. 2009 , 41, 382-4	4
859	Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma. 2009 , 7, 110	64
858	Octreotide treatment of patients with hepatocellular carcinoma--a retrospective single centre controlled study. 2009 , 28, 142	4
857	Value of the model for end-stage liver disease for predicting survival in hepatocellular carcinoma patients treated with transarterial chemoembolization. 2009 , 44, 346-57	6
856	Both the 5th and 6th editions of TNM staging system fail to independently predict long-term prognosis after radical hepatectomy in hepatocellular carcinoma sized > or = 5 cm. 2009 , 24, 220-6	2
855	Hepatocarcinoma en un paciente de 23 a�s de origen subsahariano portador del virus de la hepatitis B. 2009 , 35, 532-535	
854	Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: Is the addition of subcutaneous interferon-alpha-2b beneficial?. 2009 , 39, 223-30	17
853	Current management of hepatocellular carcinoma. 2009 , 93, 885-900, viii	45
852	Perioperative mortality for management of hepatic neoplasm: a simple risk score. 2009 , 250, 929-34	35
851	Fluorine-18-fluorodeoxyglucose-PET/computed tomography has a role in predicting the outcome of hepatocellular carcinoma. 2009 , 21, 771-775	

850	NCCN clinical practice guidelines in oncology: hepatobiliary cancers. 2009 , 7, 350-91		390
849	Is female sex a significant favorable prognostic factor in hepatocellular carcinoma?. 2009 , 21, 1212-8		37
848	Spontaneous regression of advanced hepatocellular carcinoma: a case report. 2009 , 2, 6251		9
847	Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. 2009 , CD001199		79
846	Sorafenib in hepatocellular carcinoma. 2010 , 71, 451-6		13
845	Nonsurgical options for hepatocellular carcinoma: evolving role of external beam radiotherapy. 2010 , 17, 100-10		19
844	Comparing hepatic resection and transarterial chemoembolization for Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma: change for treatment of choice?. 2010 , 34, 2155-61		71
843	Hepatotoxicity of intra-arterial combination chemotherapy in patients with liver cirrhosis and advanced hepatocellular carcinoma. 2010 , 66, 1123-9		6
842	A new staging system is more discriminant than conventional staging systems for unresectable hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010 , 136, 821-7	4-9	11
841	Evaluation of hepatocellular carcinoma with portal vein tumor thrombosis by CEUS before and after hepatic arterial infusion chemotherapy. 2010 , 37, 137-41		
840	Advancement in HCC imaging: diagnosis, staging and treatment efficacy assessments: imaging diagnosis and staging of hepatocellular carcinoma. 2010 , 17, 369-73		45
839	Staging systems: is there a surgical staging and a medical one?: hepatologist's perspective. 2010 , 17, 440-2		6
838	Transcatheter arterial infusion chemotherapy with cisplatin-lipiodol suspension in patients with hepatocellular carcinoma. 2010 , 45, 60-7		22
837	Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study. 2009 , 4, 396-405		31
836	Effect of surveillance for hepatocellular carcinoma on tumor staging and treatment decisions in Egyptian patients. 2010 , 4, 500-6		22
835	HCC in older patients. 2010 , 55, 3584-90		8
834	Network-based analysis of survival for unresectable hepatocellular carcinoma. 2010 , 37, 170-81		13
833	Hepatocellular carcinoma: current management. 2010 , 47, 10-67		59

832	Molecularly targeted therapy in hepatocellular carcinoma. 2010 , 80, 550-60		98
831	In-hospital mortality from liver resection for hepatocellular carcinoma: a simple risk score. <i>Cancer</i> , 2010 , 116, 1733-8	6.4	42
830	Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival. 2010 , 78, 172-9		84
829	Absence of symptom and intact liver function are positive prognosticators for patients undergoing radiotherapy for lymph node metastasis from hepatocellular carcinoma. 2010 , 78, 729-34		15
828	Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication. 2010 , 78, 1073-80		114
827	Comparison of coplanar and noncoplanar intensity-modulated radiation therapy and helical tomotherapy for hepatocellular carcinoma. <i>Radiation Oncology</i> , 2010 , 5, 40	4.2	29
826	Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study. 2010 , 12, 174-80		39
825	Locoregional therapies for hepatocellular carcinoma: which patients are most likely to gain a survival advantage?. 2010 , 25, 1299-305		4
824	Low alpha-fetoprotein hepatocellular carcinoma. 2010 , 25, 1543-9		26
823	Interobserver and intraobserver variability in evaluating vascular invasion in hepatocellular carcinoma. 2010 , 25, 1556-61		25
822	Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. <i>Annals of Hepatology</i> , 2010 , 9, 63-69	3.1	35
821	Refusal of cancer-directed surgery strongly impairs survival of patients with localized hepatocellular carcinoma. 2010 , 2010, 381795		11
820	Comparison of survival rates between patients treated with transcatheter arterial chemoembolization and hepatic resection for solitary hepatocellular carcinoma. 2010 , 1, 905-911		3
819	Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. 2010 , 28, 3994-4005		306
818	The challenge of prognosis and staging for hepatocellular carcinoma. 2010 , 15 Suppl 4, 23-33		106
817	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. 2010 , 56, e1-48		160
816	Advanced hepatocellular carcinoma: which staging systems best predict prognosis?. 2010 , 28, 2889-95		242
815	Current strategy for staging and treatment: the BCLC update and future prospects. 2010 , 30, 61-74		770

814	Hepatocellular carcinoma associated with membranous obstruction of the inferior vena cava: incidence, characteristics, and risk factors and clinical efficacy of TACE. 2010 , 254, 617-26	42
813	Tyrosine kinase inhibitors to treat liver cancer. 2010 , 15, 13-26	19
812	Fundamentals of Vascular Interventions. 2010 , 47-78	
811	The changing pattern of epidemiology in hepatocellular carcinoma. 2010 , 42 Suppl 3, S206-14	409
810	The intermediate hepatocellular carcinoma stage: Should treatment be expanded?. 2010 , 42 Suppl 3, S258-63	46
809	Clinical Development and Future Direction for the Treatment of Hepatocellular Carcinoma. 2010 , 2, 93-103	18
808	Characterization of urinary biomarkers of hepatocellular carcinoma using magnetic resonance spectroscopy in a Nigerian population. 2010 , 9, 1096-103	66
807	Hepatocellular carcinoma: A global view. 2010 , 7, 448-58	992
806	The fusion protein of HSP65 with tandem repeats of beta-hCG acting as a potent tumor vaccine in suppressing hepatocarcinoma. 2010 , 10, 230-8	11
805	LCSGJ-T classification, 6th or 5th edition TNM staging did not independently predict the long-term prognosis of HBV-related hepatocellular carcinoma after radical hepatectomy. 2010 , 159, 538-44	17
804	A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. 2010 , 53, 108-17	131
803	Is there an ideal prognostic classification for hepatocellular carcinoma? The quest for the Holy Grail. 2010 , 53, 23-4	6
802	Ultrasonography-guided percutaneous radiofrequency ablation of hepatocellular carcinomas: a feasibility scoring system for planning sonography. 2010 , 75, 253-8	30
801	Prognosis evaluation in alpha-fetoprotein negative hepatocellular carcinoma after hepatectomy: comparison of five staging systems. 2010 , 36, 718-24	28
800	Glass and Medicine. 2010 , 1, 104-117	114
799	Effect of a late evening snack using branched-chain amino acid-enriched nutrients in patients undergoing hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. 2010 , 40, 574-84	28
798	Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). 2010 , 40, 667-85	144
797	Pain at presentation and survival in hepatocellular carcinoma. 2010 , 11, 988-93	13

796	Radioembolisation using yttrium 90 (Y-90) in patients affected by unresectable hepatic metastases. 2010 , 115, 619-33	33
795	Compensatory enlargement of the liver after treatment of hepatocellular carcinoma with carbon ion radiotherapy - relation to prognosis and liver function. 2010 , 96, 236-42	26
794	Circulating Lamin B1 (LMNB1) biomarker detects early stages of liver cancer in patients. 2010 , 9, 70-8	91
793	Learning Vascular and Interventional Radiology. 2010 ,	
792	Outcome of supraselective transarterial chemoembolization in patients with hepatocellular carcinoma. 2011 , 46, 201-10	4
791	Urinary metabolic biomarkers of hepatocellular carcinoma in an Egyptian population: a validation study. 2011 , 10, 1828-36	81
790	Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. 2011 , 9, 64-70	170
789	Novel intraarterial therapy for liver cancer using ethylbromopyruvate dissolved in an iodized oil. 2011 , 18, 471-8	9
788	Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. 2011 , 141, 526-35, 535.e1-2	133
787	Preserved liver function, portal thrombosis and absence of oesophageal varices are risk factors for metastasis of hepatocellular carcinoma. 2011 , 43, 319-24	19
786	Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. 2011 , 29, 339-64	627
785	Hepatocellular Carcinoma:. 2011 ,	3
784	Venous Embolization of the Liver. 2011 ,	1
783	Gastrointestinal Oncology. 2011 ,	
782	Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. 2011 , 37, 212-20	407
781	Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options. 2011 , 37, 169-77	47
780	A new approach to percutaneous coronary revascularization in patients requiring undeferrable non-cardiac surgery. 2011 , 146, 399-403	12
779	Predicting the prognosis of hepatocellular carcinoma using gene expression. 2011 , 171, 524-31	6

778	Internal radiotherapy of painful bone metastases. 2011 , 55, 258-70		21
777	Glass and Glass-Ceramic Technologies to Transform the World. 2011 , 2, 162-176		22
776	Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting. 2011 , 54, 108-14		25
775	Advanced hepatocellular carcinoma. Review of targeted molecular drugs. <i>Annals of Hepatology</i> , 2011 , 10, 21-27	3.1	86
774	The Analysis of the Causes of Prolonged Hospitalization after Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma. 2011 , 64, 33		2
773	Prognostic index for portal vein tumor thrombosis in patients with hepatocellular carcinoma treated with radiation therapy. 2011 , 26, 1014-22		48
772	Hepatocellular carcinoma: current management and perspectives for the future. 2011 , 253, 453-69		333
771	Clinical management and case reports for the treatment of hepatocellular carcinoma with sorafenib. 2011 , 45, 733-7		3
770	Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. 2011 , 254, 108-13		281
769	Glass Microspheres for Cancer Treatment. 2011 , 57-64		
768	Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. 2011 , 26, 340-7		64
767	Tumor size as a prognostic factor in resected small hepatocellular carcinoma: a controversy revisited. 2011 , 26, 851-7		23
766	Chemoembolization for hepatocellular carcinoma. 2011 , 46, 105-14		4
765	Yttrium-90 (90Y) in the principal radionuclide therapies: an efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999-2009). 2011 , 80, 393-410		30
764	Clinical presentation of hepatocellular carcinoma (HCC) in Asian-Americans versus non-Asian-Americans. 2011 , 13, 842-8		20
763	A new classification for hepatocellular carcinoma with portal vein tumor thrombus. 2011 , 18, 74-80		102
762	A new staging system for resectable hepatocellular carcinoma: comparison with six existing staging systems in a large Chinese cohort. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011 , 137, 739-50	4.9	40
761	EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011 , 38, 1393-406	8.8	161

760	Multimodal therapy for liver cirrhosis patients with advanced hepatocellular carcinoma. 2011 , 68, 139-45		2
759	Comparison of cancer care for hepatocellular carcinoma at two tertiary-care referral centers from high and low endemic regions for viral hepatitis. 2011 , 42, 228-35		5
758	Are surgical indications of Barcelona Clinic Liver Cancer staging classification justified?. 2011 , 31, 637		7
757	Ex vivo hepatic venography for hepatocellular carcinoma in livers explanted for liver transplantation. 2011 , 9, 111		1
756	Evaluation of the new AJCC staging system for resectable hepatocellular carcinoma. 2011 , 9, 114		40
755	What is the best staging system for hepatocellular carcinoma in the setting of liver transplantation?. 2011 , 17 Suppl 2, S26-33		15
754	Usefulness of a modified inflammation-based prognostic system for predicting postoperative mortality of patients undergoing surgery for primary hepatocellular carcinoma. 2011 , 103, 801-6		34
753	MRI findings of recurrent hepatocellular carcinoma after liver transplantation: preliminary results. 2011 , 33, 1399-405		14
752	V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials. <i>Cancer</i> , 2011 , 117, 2478-88	6.4	34
751	Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. <i>Cancer</i> , 2011 , 117, 4475-83	6.4	275
750	microRNA involvement in hepatocellular carcinoma. 2011 , 11, 500-21		78
749	Arterially directed therapies for hepatocellular carcinoma. 2011 , 197, W590-602		16
748	[Increasing number and improved survival of patients with hepatocellular carcinoma from 1988 to 2007: data of a German university clinic]. 2011 , 49, 720-7		6
747	Influence of MTHFR 1298A->C polymorphism on response to transarterial chemoembolization in primary hepatocellular carcinoma: A pilot study. 2011 ,		
746	Treatment of Advanced Hepatocellular Carcinoma: Sorafenib and Beyond. 2011 , 3, 39-47		
745	Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. 2011 , 29, 3892-9		98
744	Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models. 2011 , 80, 167-74		40
743	Comparison of staging systems of hepatocellular carcinoma. 2011 , 2011, 818217		18

- 742 Zunahme und verbessertes Überleben des hepatozellulären Karzinoms im Zeitraum von 1988-2007: Daten einer deutschen Universitätsklinik. **2012**, 33, 34-41
- 741 Tumours and tumour-like lesions of the liver. **2012**, 761-851 19
- 740 Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems. **2012**, 107, 1672-7 18
- 739 Prognostic factors and outcomes of patients with hepatocellular carcinoma in non-cirrhotic liver. **2012**, 47, 718-28 30
- 738 Factors impacting prognosis prediction in BCLC stage C and Child-Pugh class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy. **2012**, 17, 970-7 9
- 737 Hepatocellular carcinoma in hepatitis D: does it differ from hepatitis B mono-infection?. **2012**, 18, 18-22 18
- 736 Circulating tumor cells measurements in hepatocellular carcinoma. **2012**, 2012, 684802 36
- 735 Small hepatocellular carcinomas and thrombocytopenia. **2012**, 83, 331-8 19
- 734 Thrombocytopenia in relation to tumor size in patients with hepatocellular carcinoma. **2012**, 83, 339-45 30
- 733 Application of Radiotherapeutic Strategies in the BCLC-Defined Stages of Hepatocellular Carcinoma. **2012**, 1, 216-25 26
- 732 Primary Liver Cancer. **2012**, 163-182 1
- 731 What is the role of radiation therapy in treating liver tumors?. **2012**, 9, 683-699
- 730 Chemoembolization of unresectable hepatocellular carcinoma: Decreased toxicity with slow-release doxorubicin-eluting beads compared with lipiodol. **2012**, 27, 1377-83 32
- 729 Toxicity and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma (Review). **2012**, 3, 259-263 22
- 728 Caffeine increases the antitumor effect of Cisplatin in human hepatocellular carcinoma cells. **2012**, 35, 400-7 19
- 727 Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. **2012**, 13, e11-22 701
- 726 Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma. **2012**, 47, 1152-9 9
- 725 Salvage treatment with hypofractionated radiotherapy in patients with recurrent small hepatocellular carcinoma. **2012**, 82, e603-7 30

724	Presentation, treatment, and clinical outcomes of patients with hepatocellular carcinoma, with and without human immunodeficiency virus infection. 2012 , 10, 1284-90		12
723	Retrospective study on the use of different protocols for repeated transarterial chemoembolization in the treatment of patients with hepatocellular carcinoma. 2012 , 19, 434-9		7
722	Hepatocellular Carcinoma. 2012 , 1005-1031		1
721	Impact of an inflammation-based prognostic system on patients undergoing surgery for hepatocellular carcinoma: a retrospective study of 398 Japanese patients. 2012 , 203, 101-6		77
720	EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. 2012 , 56, 908-43		4465
719	Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. 2012 , 56, 1080-1088		88
718	EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. 2012 , 48, 599-641		356
717	Superselective transarterial chemoembolization vs hepatic resection for resectable early-stage hepatocellular carcinoma in patients with Child-Pugh class a liver function. 2012 , 81, 466-71		45
716	Selective and sequential transarterial chemoembolization: survival in patients with hepatocellular carcinoma. 2012 , 81, 2290-7		11
715	Primary Hepatic Cancer. 2012 , 161-181		
714	Rhenium-188 Generator-Based Radiopharmaceuticals for Therapy. 2012 , 51-81		3
713	Prognosis predictability of hepatocellular carcinoma according to staging systems in hepatitis B virus-endemic area. 2012 , 36, 357-64		1
712	Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy. 2012 , 83, 216-24		37
711	Abstracts of CIRSE (Cardiovascular and Interventional Radiological Society of Europe) 2012. September 15-19, 2012. Lisbon, Portugal. 2012 , 35 Suppl 1, S2-301		1
710	Primary Liver Cancer. 2012 ,		1
709	Are metastases from metastases clinical relevant? Computer modelling of cancer spread in a case of hepatocellular carcinoma. <i>PLoS ONE</i> , 2012 , 7, e35689	3-7	11
708	Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort. <i>PLoS ONE</i> , 2012 , 7, e45066	3-7	47
707	The value of the Barcelona Clinic Liver Cancer and alpha-fetoprotein in the prognosis of hepatocellular carcinoma. 2012 , 104, 298-304		29

706	Hepatocellular carcinoma in developing countries: Prevention, diagnosis and treatment. 2012 , 4, 99-104		55
705	Hepatocellular Carcinoma: Methods of Circulating Tumor Cells (CTC) Measurements. 2012 ,		1
704	Hepatozelluläres Karzinom: Bridging-Verfahren vor der Lebertransplantation. 2012 , 28, 317-323		1
703	Epidemiology and Molecular Mechanisms of Hepatocarcinogenesis. 2012 , 142-156		1
702	Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. 2012 , 55, 1443-52		88
701	Model to estimate survival in ambulatory patients with hepatocellular carcinoma. 2012 , 56, 614-21		67
700	Runt-related transcription factor 3 reverses epithelial-mesenchymal transition in hepatocellular carcinoma. 2012 , 131, 2537-46		40
699	Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon β for advanced hepatocellular carcinoma with portal venous invasion. <i>Cancer</i> , 2012 , 118, 3302-10	6.4	20
698	Hepatocellular carcinoma. 2012 , 1283-1289.e2		6
697	Hepatic artery embolization and chemoembolization of liver tumors. 2012 , 1344-1361.e3		
696	Recurrence rates and factors for recurrence after radiofrequency ablation combined with transarterial chemoembolization for hepatocellular carcinoma: a retrospective cohort study. 2012 , 6, 505-10		8
695	Hepatocellular carcinoma: MR staging and therapeutic decisions. 2012 , 37, 231-8		1
694	Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinoma. 2012 , 32, 271-8		14
693	The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma. 2012 , 8, 164-71		23
692	Survival after diagnosis of hepatocellular carcinoma and potential impact of treatment in a hepatitis B or C infected cohort. 2012 , 42, 1175-86		5
691	Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma. 2012 , 15, 59-70		45
690	Determination of the R_1 ratio for the normal liver on the basis of radiation-induced hepatic toxicities in patients with hepatocellular carcinoma. <i>Radiation Oncology</i> , 2013 , 8, 61	4.2	18
689	Dosimetric parameter predicting the deterioration of hepatic function after helical tomotherapy in patients with unresectable locally advanced hepatocellular carcinoma. <i>Radiation Oncology</i> , 2013 , 8, 11	4.2	16

688	Defining prognostic factors of survival after external beam radiotherapy treatment of hepatocellular carcinoma with lymph node metastases. 2013 , 15, 732-40	14
687	Surgical treatment of hepatocellular carcinoma with inferior vena cava tumor thrombus: a new classification for surgical guidance. 2013 , 12, 263-9	32
686	Clinical characteristics and survival of European patients with resectable large hepatocellular carcinomas. 2013 , 44, 329-35	4
685	Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolization. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013 , 139, 635-43	4.9 26
684	Adjuvant hepatic arterial infusion chemotherapy after hepatic resection of hepatocellular carcinoma with macroscopic vascular invasion. 2013 , 37, 1034-42	29
683	Hepatocellular carcinoma: epidemiology, biology, diagnosis, and therapies. 2013 , 59, 514-24	65
682	Comparison of current staging systems for advanced hepatocellular carcinoma not amendable to locoregional therapy as inclusion criteria for clinical trials. 2013 , 9, 86-92	13
681	External validation of a simplified BCLC staging system for early hepatocellular carcinoma. 2013 , 39, 850-7	20
680	Management of hepatocellular carcinoma. 2013 , 93, 1423-50	27
679	A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. 2013 , 108, 1252-9	99
678	Liver Cancer and Metastases. 2013 , 151-166	
677	Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature. 2013 , 58, 3389-96	57
676	A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. 2013 , 24, 2565-2570	200
675	Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside. 2013 , 35, 111-20	25
674	Hepatocellular carcinoma: epidemiology, biology, diagnosis, and therapies. 2013 , 59, 514-524	1
673	The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma. 2013 , 58, 509-21	52
672	Percutaneous comprehensive cryoablation for metastatic hepatocellular cancer. 2013 , 66, 76-80	19
671	The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib. 2013 , 45, 408-13	28

670	Medical therapies for hepatocellular carcinoma: a critical view of the evidence. 2013 , 10, 34-42		243
669	Evaluation of seven different staging systems for alpha-fetoprotein expression in hepatocellular carcinoma after hepatectomy. 2013 , 34, 1061-70		6
668	Health care costs associated with hepatocellular carcinoma: a population-based study. 2013 , 58, 1375-84		52
667	Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma. 2013 , 18, 207-13		64
666	Low fat intake is associated with pathological manifestations and poor recovery in patients with hepatocellular carcinoma. 2013 , 12, 79		3
665	A modified TNM-7 staging system to better predict the survival in patients with hepatocellular carcinoma after hepatectomy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013 , 139, 1709-19	4.9	18
664	Validation of the 7th edition TNM staging system for hepatocellular carcinoma: an analysis of 8,828 patients in a single medical center. 2013 , 58, 2721-8		41
663	Hepatocellular carcinoma: high hepatitis B viral load and mortality in patients treated with transarterial chemoembolization. 2013 , 267, 638-47		24
662	[Diagnosis of and therapy for hepatocellular carcinoma]. 2013 , 51, 1269-326		67
661	Multidisciplinary management of hepatocellular carcinoma: where are we today?. 2013 , 33 Suppl 1, S3-10		28
660	Clinical features and prognostic factors of hepatocellular carcinoma patients; single center experience. 2013 , 28, 143-149		
659	Surgical Management of HCC. 2013 ,		1
658	Surgical therapy for hepatocellular carcinoma: formulating a rational approach. 2013 , 47 Suppl, S30-6		7
657	Lymphatic vessel endothelial hyaluronan receptor-1 is a novel prognostic indicator for human hepatocellular carcinoma. 2013 , 1, 1039-1048		6
656	Modified cisplatin/interferon β /doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. <i>Cancer</i> , 2013 , 119, 3334-42	6.4	22
655	Survival and health-related quality of life in patients with spinal metastases originated from primary hepatocellular carcinoma. 2013 , 6, 81-9		7
654	ADAM10 is overexpressed in human hepatocellular carcinoma and contributes to the proliferation, invasion and migration of HepG2 cells. 2013 , 30, 1715-22		19
653	Anterior approach versus conventional liver resection for hepatocellular carcinoma. 2013 ,		1

652	Hepatocellular carcinoma size: platelets, α -glutamyl transpeptidase, and alkaline phosphatase. 2013 , 85, 153-9		29
651	Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective. 2013 , 25, 639-51		27
650	Postoperative adjuvant transarterial (chemo)embolisation after liver resection for hepatocellular carcinoma. 2013 ,		
649	Yttrium-90 Microspheres for Other Liver Metastases. 2013 , 157-165		
648	Treatment Options of Metastatic Brain Tumors from Hepatocellular Carcinoma: Surgical Resection vs. Gamma Knife Radiosurgery vs. Whole Brain Radiation Therapy. 2013 , 1, 78-84		9
647	Protein profiling in hepatocellular carcinoma by label-free quantitative proteomics in two west African populations. <i>PLoS ONE</i> , 2013 , 8, e68381	3.7	13
646	The cooperative effect of p53 and Rb in local nanotherapy in a rabbit VX2 model of hepatocellular carcinoma. 2013 , 8, 3757-68		5
645	Prognostic implication of serum vascular endothelial growth factor in advanced hepatocellular carcinoma staging. <i>Annals of Hepatology</i> , 2013 , 12, 915-925	3.1	4
644	Surgical Management of Primary Hepatocellular Carcinoma. 2013 ,		
643	Surgical Treatment Strategies and Prognosis of Hepatocellular Carcinoma. 2013 ,		1
642	The Role of Surgery in the Treatment of Hepatocellular Carcinoma. 2013 ,		
641	Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt. <i>PLoS ONE</i> , 2014 , 9, e90929	3.7	51
640	Expert perspectives on evidence-based treatment planning for patients with hepatocellular carcinoma. 2014 , 21, 5-16		1
639	Role of stereotactic body radiation therapy for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014 , 20, 3100-11	5.6	53
638	Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer. 2014 , 9, 81-7		16
637	Transcatheter arterial chemoembolization therapy for patients with unresectable hepatocellular carcinoma. 2014 , 14, e25792		6
636	Role of surgical resection for hepatocellular carcinoma based on Japanese clinical guidelines for hepatocellular carcinoma. 2015 , 7, 261-9		12
635	Latin American Association for the Study of the Liver (LAASL) Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. <i>Annals of Hepatology</i> , 2014 , 13, S4-S40	3.1	17

634	Hepatocellular carcinoma and cholangiocarcinoma: an update. 2014 , 8, 63-82	15
633	Effect of cantharidins in chemotherapy for hepatoma: a retrospective cohort study. 2014 , 42, 561-7	22
632	Factors predicting surgical resection in patients with intrahepatic cholangiocarcinoma and cirrhosis. 2014 , 27, 219-25	8
631	Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model. 2014 , 110, 2090-8	32
630	Current and future challenges in the surgical treatment of hepatocellular carcinoma: a review. 2014 , 99, 779-86	7
629	Processing and analysis of imbalanced liver cancer patient data by case-based reasoning. 2014 ,	
628	Stereotactic body radiotherapy: an effective local treatment modality for hepatocellular carcinoma. 2014 , 10, 2227-41	11
627	Low use of surveillance and early diagnosis of hepatocellular carcinoma in Norway--a population-based cohort study. 2014 , 38, 741-7	11
626	Merits of prophylactic sclerotherapy for esophageal varices concomitant unresectable hepatocellular carcinoma: prospective randomized study. 2014 , 26, 172-7	3
625	Risk factors for 1-year mortality in patients with intermediate-stage hepatocellular carcinoma treated solely with transcatheter arterial chemoembolization. 2014 , 1, 126-131	1
624	Serum transferrin as a predictor of prognosis for hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma. 2014 , 44, 481-90	5
623	Survival analysis of high-intensity focused ultrasound therapy vs. transarterial chemoembolization for unresectable hepatocellular carcinomas. 2014 , 34, e136-43	20
622	A discussion of serum albumin level in advanced-stage hepatocellular carcinoma: a medical oncologist's perspective. 2014 , 31, 282	25
621	Advances in non-surgical management of primary liver cancer. <i>World Journal of Gastroenterology</i> , 2014 , 20, 16630-8	5.6 38
620	Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry. 2014 , 48, 279-89	64
619	The use of proton therapy in the treatment of gastrointestinal cancers: liver. 2014 , 20, 371-7	15
618	Barcelona clinic liver cancer stage B hepatocellular carcinoma: transarterial chemoembolization or hepatic resection?. <i>Medicine (United States)</i> , 2014 , 93, e180	1.8 46
617	The Glasgow Prognostic Score is an independent prognostic predictor of hepatocellular carcinoma following radical resection. 2014 , 37, 192-7	10

616	Computed tomography during hepatic arteriography pattern may predict hepatocellular carcinoma recurrence following transarterial chemoembolization. 2014 , 44, E455-63		2
615	Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. 2014 , 146, 1691-700.e3		425
614	The inflammation-based scores to predict prognosis of patients with hepatocellular carcinoma after hepatectomy. 2014 , 31, 883		43
613	Staging of biliary tract and primary liver tumors. 2014 , 23, 313-22		7
612	TNM/Okuda/Barcelona/UNOS/CLIP International Multidisciplinary Classification of Hepatocellular Carcinoma: concepts, perspectives, and radiologic implications. 2014 , 39, 1070-87		27
611	Reassessing hepatocellular carcinoma staging in a changing patient population. 2014 , 86, 63-71		1
610	Bleeding after expandable nitinol stent placement in patients with esophageal and upper gastrointestinal obstruction: incidence, management, and predictors. 2014 , 55, 1069-75		7
609	Lactose targeting oxaliplatin prodrug loaded micelles for more effective chemotherapy of hepatocellular carcinoma. 2014 , 2, 2097-2106		19
608	Hepatocellular carcinoma. 2014 , 164, 450-5		17
607	Prognosis prediction and staging. 2014 , 28, 855-65		15
606	CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. 2014 , 273, 30-50		305
605	Hepatocellular carcinoma: clinicopathological profile and challenges of management in a resource-limited setting. 2014 , 12, 246		16
604	Influence of preoperative transcatheter arterial chemoembolization on gene expression in the HIF-1 α pathway in patients with hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014 , 140, 1507-15	4.9	26
603	Systematic review and meta-analysis of adjuvant i(131) lipiodol after excision of hepatocellular carcinoma. 2014 , 21, 2700-7		18
602	Surgical resection after down-staging of locally advanced hepatocellular carcinoma by localized concurrent chemoradiotherapy. 2014 , 21, 3646-53		41
601	Significance of an increase in the Child-Pugh score after radiotherapy in patients with unresectable hepatocellular carcinoma. <i>Radiation Oncology</i> , 2014 , 9, 101	4.2	19
600	Risk of secondary cancers from scattered radiation during intensity-modulated radiotherapies for hepatocellular carcinoma. <i>Radiation Oncology</i> , 2014 , 9, 109	4.2	20
599	Adjuvant Intraarterial Lipiodol or ^{131}I -Lipiodol After Curative Treatment of Hepatocellular Carcinoma: A Prospective Randomized Trial. 2014 , 55, 877-83		12

598	Association of abnormal plasma bilirubin with aggressive hepatocellular carcinoma phenotype. 2014 , 41, 252-8		28
597	Platelet-related phenotypic patterns in hepatocellular carcinoma patients. 2014 , 41, 415-21		24
596	The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and review. <i>Cancer</i> , 2014 , 120, 2824-38	6.4	179
595	Staging of hepatocellular carcinoma. 2014 , 4, S74-9		54
594	Treatment algorithms for managing hepatocellular carcinoma. 2014 , 4, S80-9		48
593	Comparative study of staging systems for hepatocellular carcinoma in 428 patients treated with radioembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2014 , 25, 1056-66	2.4	19
592	Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. 2014 ,		2
591	Proposal of Japan Red Cross score for sorafenib therapy in hepatocellular carcinoma. 2015 , 45, E130-40		12
590	Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B-positive patients with hepatocellular carcinoma. 2015 , 111, 862-7		17
589	Treatment Patterns and Outcomes in Patients With Hepatocellular Carcinoma Stratified by Stage-Guided Treatment Categories. 2015 , 13, 987-94		5
588	Lack of evidence that adherence to standard of care therapy improves survival in subjects with hepatocellular carcinoma in clinical practice. 2015 , 87, 1368-76		2
587	Predictors of hepatic decompensation after TACE for hepatocellular carcinoma. 2015 , 2, e000032		18
586	Validation of models in patients with hepatocellular carcinoma: comparison of Hong Kong Liver Cancer with Barcelona Clinic Liver Cancer staging system in a Chinese cohort. 2015 , 27, 1180-6		25
585	King's score as a novel prognostic model for patients with hepatitis B-associated hepatocellular carcinoma. 2015 , 27, 1337-46		8
584	Sarcopenia Impacts on Short- and Long-term Results of Hepatectomy for Hepatocellular Carcinoma. 2015 , 261, 1173-83		210
583	Glutathione for Hepatotoxicity in Patients with Liver Cirrhosis and Advanced Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy. 2015 , 2, 54-60		1
582	The Importance of Lamivudine Therapy in Liver Cirrhosis Patients Related HBV with Advanced Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy. 2015 , 2, 112-118		0
581	Evaluation of eight different clinical staging systems associated with overall survival of chinese patients with hepatocellular carcinoma. 2015 , 128, 316-21		11

580	Hepatocellular carcinoma: A comprehensive review. 2015 , 7, 2648-63		136
579	Staging systems for hepatocellular carcinoma: Current status and future perspectives. 2015 , 7, 406-24		84
578	Establishment and Validation of SSCLIP Scoring System to Estimate Survival in Hepatocellular Carcinoma Patients Who Received Curative Liver Resection. <i>PLoS ONE</i> , 2015 , 10, e0129000	3.7	10
577	Modifiable Prognostic Factors of Hepatocellular Carcinoma in Patients with Non-Surgical Treatment. <i>PLoS ONE</i> , 2015 , 10, e0144893	3.7	1
576	Management of hepatocellular carcinoma with portal vein thrombosis. <i>World Journal of Gastroenterology</i> , 2015 , 21, 3462-71	5.6	68
575	Brazilian society of hepatology recommendations for the diagnosis and treatment of hepatocellular carcinoma. 2015 , 52 Suppl 1, 2-14		10
574	Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2015 , 2, 131-42	5.3	11
573	Current and future treatments for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2015 , 21, 8478-91	5.6	112
572	Management before hepatectomy for hepatocellular carcinoma with cirrhosis. 2015 , 7, 2292-302		10
571	Anti-angiogenic drug delivery from hydrophilic resorbable embolization microspheres: an in vitro study with sunitinib and bevacizumab. 2015 , 484, 218-27		14
570	Combination of transarterial chemoembolisation (TACE) plus antivirals for the management of hepatitis B-related hepatocellular carcinoma: A systematic review of the literature. 2015 , 16, 40-5		3
569	The role of radiotherapy in the treatment of hepatocellular carcinoma with portal vein tumor thrombus. 2015 , 56, 325-31		18
568	Prognostic Role of Glasgow Prognostic Score in Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. <i>Medicine (United States)</i> , 2015 , 94, e2133	1.8	42
567	Clinical comparison of laparoscopic and open liver resection after propensity matching selection. 2015 , 158, 573-87		22
566	Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Impact of Early Response to 4 Weeks of Treatment. 2015 , 4, 228-40		34
565	Survival analysis of proposed BCLC-B subgroups in hepatocellular carcinoma patients. 2015 , 35, 591-600		50
564	Radiofrequency ablation combined with chemolipiodolization in a porcine liver: Comparison of the pharmacokinetic analysis with cisplatin powder and miriplatin. 2015 , 45, 589-94		
563	Development of 4-hexadecyl-4,7-diaza-1,10-decanedithiol (HDD) kit for the preparation of the liver cancer therapeutic agent Re-188-HDD/lipiodol. 2015 , 42, 317-22		5

562	Barcelona Clinic Liver Cancer staging system and survival of untreated hepatocellular carcinoma in a hepatitis B virus endemic area. 2015 , 30, 696-705		11
561	Prognostic nomogram for patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. 2015 , 63, 122-30		81
560	Local tumour progression after ultrasound-guided microwave ablation of liver malignancies: risk factors analysis of 2529 tumours. 2015 , 25, 1119-26		49
559	Chinese medicine herbal treatment based on syndrome differentiation improves the overall survival of patients with unresectable hepatocellular carcinoma. 2015 , 21, 49-57		11
558	Down-regulation of G protein-coupled receptor 137 by RNA interference inhibits cell growth of two hepatoma cell lines. 2015 , 39, 418-26		6
557	Treatment of Liver Cancer. 2015 , 5, a021535		144
556	Classification and staging of hepatocellular carcinoma: an aid to clinical decision-making. 2015 , 19, 277-94		16
555	Locoregional therapy of hepatocellular carcinoma. 2015 , 19, 401-20		22
554	FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas: Value to Patient Management and Patient Outcomes. 2015 , 10, 327-43		28
553	Prognostic value of (18)F-FDG PET/CT in liver transplantation for hepatocarcinoma. <i>World Journal of Gastroenterology</i> , 2015 , 21, 3049-54	5.6	22
552	Transplantation for Primary Hepatic Malignancy. 2015 , 189-204		0
551	Interreader and inter-test agreement in assessing treatment response following transarterial embolization for hepatocellular carcinoma. 2015 , 25, 2779-88		14
550	Was adjuvant immunotherapy really effective to reduce hepatocellular carcinoma recurrence?. 2015 , 149, 1639		
549	Tumor size is a major determinant of prognosis of resected stage I hepatocellular carcinoma. 2015 , 400, 725-34		20
548	Adjuvant immunotherapy for postoperative hepatocellular carcinoma. 2015 , 149, 1639-40		2
547	Management of hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015 , 141, 861-76	4.9	79
546	Prognostication systems as applied to primary and metastatic hepatic malignancies. 2015 , 24, 41-56		0
545	New advances in hepatocellular carcinoma. 2016 , 8, 421-38		102

544	Why Hepatocellular Carcinoma (hcc) Management and Control is Challenging in the Developing Countries? Problems vs. Strategies. 2016 , 01,	1
543	Radiotherapy and Sorafenib in the Management of Patients with Hepatocellular Carcinoma Have Led to Improved Survival: A Single Center Experience. 2016 , 7, 883-9	4
542	Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments. 2016 , 8, 703-15	21
541	A Liver Index and its Relationship to Indices of HCC Aggressiveness. 2016 , 5,	22
540	Hepatocellular Carcinoma in Pakistan: National Trends and Global Perspective. 2016 , 2016, 5942306	17
539	Simple models based on gamma-glutamyl transpeptidase and platelets for predicting survival in hepatitis B-associated hepatocellular carcinoma. 2016 , 9, 2099-109	17
538	Low metallothionein 1M expression association with poor hepatocellular carcinoma prognosis after curative resection. 2016 , 15,	8
537	Risk factors of postoperative ascites on hepatic resection for hepatocellular carcinoma. 2016 , 20, 153-158	8
536	Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. 2016 , 2, CD011313	19
535	Multifunctional Nanostructures for Tumor-Targeted Molecular Imaging and Photodynamic Therapy. 2016 , 5, 311-8	15
534	Oncological management of primary liver cancer in the era of minimal access surgery. 2016 , 185-199	
533	Application of the Immunoscore as prognostic tool for hepatocellular carcinoma. 2016 , 4, 71	10
532	A review of prognostic scores after liver resection in hepatocellular carcinoma: the MSKCC, SLICER and SSCLIP scores. 2017 , 47, 287-293	6
531	Overexpression of PCBP2 contributes to poor prognosis and enhanced cell growth in human hepatocellular carcinoma. 2016 , 36, 3456-3464	18
530	Hepatic resection versus transarterial chemoembolization for patients with Barcelona Clinic Liver Cancer intermediate stage Child-Pugh A hepatocellular carcinoma. 2016 , 12, 3813-3819	17
529	Nomograms for survival prediction in patients undergoing liver resection for hepatitis B virus related early stage hepatocellular carcinoma. 2016 , 62, 86-95	35
528	Determination of Resectability. 2016 , 96, 163-81	8
527	Hepatitis B and Hepatocellular Carcinoma. 2016 , 20, 703-720	23

526	Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. 2016 , 146, 511.e1-511.e22	1
525	Intermediate-stage hepatocellular carcinoma treated with hepatic resection: the NSP score as an aid to decision-making. 2016 , 115, 1039-1047	13
524	Long noncoding RNA CCHE1 indicates a poor prognosis of hepatocellular carcinoma and promotes carcinogenesis via activation of the ERK/MAPK pathway. 2016 , 83, 450-455	57
523	Medical applications of Cu, Zn, and S isotope effects. 2016 , 8, 1056-1070	50
522	Impact of Histological Factors of Hepatocellular Carcinoma on the Outcome of Liver Transplantation. 2016 , 48, 1968-77	12
521	A novel cell cycle blocker extracted from <i>Stellera chamaejasme</i> L. inhibits the proliferation of hepatocarcinoma cells. 2016 , 35, 3480-8	4
520	Cancer and liver cirrhosis: implications on prognosis and management. 2016 , 1, e000042	124
519	Molecular targets of Chinese herbs: a clinical study of hepatoma based on network pharmacology. 2016 , 6, 24944	52
518	Differences in Patient Characteristics and Midterm Outcome Between Asian and European Patients Treated with Radiofrequency Ablation for Hepatocellular Carcinoma. 2016 , 39, 1708-1715	1
517	The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients?. 2016 , 36, 1490-7	41
516	Cancer of the Liver Italian Program score helps identify potential candidates for transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage C. 2016 , 15, 152-7	5
515	Total tumor volume predicts survival following liver resection in patients with hepatocellular carcinoma. 2016 , 37, 9301-10	15
514	Transarterial Alcohol-Lipiodol Therapy in Patients with Hepatocellular Carcinoma Using Low Alcohol Concentrations. 2016 , 188, 676-83	
513	Which system is better to predict prognosis of patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization as initial therapy? Comparison between CLIP and JIS in a Japanese population. 2016 , 57, 1445-1452	1
512	Hepatocellular carcinoma: modern image-guided therapies. 2016 , 92, 165-71	6
511	Perspectives of physicians regarding screening patients at risk of hepatocellular carcinoma. 2016 , 4, 237-40	4
510	A Hepatocellular Carcinoma Aggressiveness Index and Its Relationship to Liver Enzyme Levels. 2016 , 90, 215-20	31
509	Sociodemographic impact on survival in unresectable hepatocellular carcinoma: a survival epidemiology and end results study. 2016 , 12, 183-98	8

508	Staging for hepatocellular carcinoma: An embarrassment of riches. 2016 , 64, 535-6		5
507	Hepatocellular carcinoma surgery outcomes in the developing world: A 20-year retrospective cohort study at the National Cancer Institute of Peru. <i>Heliyon</i> , 2016 , 2, e00052	3.6	15
506	[Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. 2016 , 146, 511.e1-511.e22		36
505	Operative Techniques in Liver Resection. 2016 ,		
504	Impact of current staging systems on treatment strategy for HBV-related hepatocellular carcinoma. 2016 , 379, 220-4		12
503	Incorporating albumin-bilirubin grade into the cancer of the liver Italian program system for hepatocellular carcinoma. 2017 , 32, 221-228		39
502	Immunosuppression strategies in liver transplantation patient; patients with hepatocellular carcinoma. 2017 , 9, 197-206		1
501	Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey. 2017 , 52, 1112-1121		18
500	Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis. 2017 , 3, CD011649		13
499	Nomogram prediction of individual prognosis of patients with hepatocellular carcinoma. <i>BMC Cancer</i> , 2017 , 17, 91	4.8	36
498	Prognostic significance of combined albumin-bilirubin and tumor-node-metastasis staging system in patients who underwent hepatic resection for hepatocellular carcinoma. 2017 , 47, 1289-1298		18
497	Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence. 2017 , 13, 984-992		13
496	Hepatocellular carcinoma in Danish patients: a single Copenhagen center experience. 2017 , 52, 768-772		1
495	Sequential adaptive changes in a c-Myc-driven model of hepatocellular carcinoma. 2017 , 292, 10068-10086		25
494	Impact of viral hepatitis aetiology on survival outcomes in hepatocellular carcinoma: A large multicentre cohort study. 2017 , 24, 982-989		13
493	Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply. 2017 , 8, e98		54
492	Prognostic Nomograms Stratify Survival of Patients with Hepatocellular Carcinoma Without Portal Vein Tumor Thrombosis After Curative Resection. 2017 , 22, 561-569		27
491	New macroscopic classification and back-flow thrombectomy for advanced hepatocellular carcinoma with portal vein tumor thrombus invading the contralateral second portal branch. 2017 , 47, 1094-1103		9

490	Validation of a Liver Index and Its Significance for HCC Aggressiveness. 2017 , 48, 262-266		3
489	Overview of Staging Systems for Hepatocellular Carcinoma and Implications for Interventional Radiology. 2017 , 34, 213-219		1
488	Hepatocellular carcinoma. 2017 , 1333-1338.e2		1
487	PLGA-based dual targeted nanoparticles enhance miRNA transfection efficiency in hepatic carcinoma. 2017 , 7, 46250		33
486	The Plasma and Serum Metabotyping of Hepatocellular Carcinoma in a Nigerian and Egyptian Cohort using Proton Nuclear Magnetic Resonance Spectroscopy. 2017 , 7, 83-92		3
485	Cancer-directed therapy and potential impact on survivals in nonresected hepatocellular carcinoma: SEER-Medicare population study. 2017 , 13, 2021-2033		4
484	Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria. 2017 , 162, 1250-1258		17
483	Proton beam therapy for hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2017 , 17, 911-924		19
482	Validity of eleven prognostic scores with respect to intra- and extrahepatic recurrence of hepatocellular carcinoma after liver transplantation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017 , 143, 2595-2605	4-9	3
481	Definitive radiation therapy for hepatocellular carcinoma with portal vein tumor thrombus. 2017 , 4, 39-45		8
480	Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function. 2017 , 6, 325-336		102
479	Gene expression profiling, pathway analysis and subtype classification reveal molecular heterogeneity in hepatocellular carcinoma and suggest subtype specific therapeutic targets. 2017 , 216-217, 37-51		26
478	Simplified HCC-ART score for highly sensitive detection of small-sized and early-stage hepatocellular carcinoma in the widely used Okuda, CLIP, and BCLC staging systems. 2017 , 22, 332-339		9
477	Hepatocellular Carcinoma (Ordinary Hepatocellular Carcinoma). 2017 , 27-64		
476	Early or Small Hepatocellular Carcinoma. 2017 , 195-214		
475	Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma: Validation in a Chinese cohort. 2017 , 47, 731-741		45
474	Screening of up- and downregulation of circRNAs in HBV-related hepatocellular carcinoma by microarray. 2018 , 15, 423-432		24
473	Early diagnostic evaluation of miR-122 and miR-224 as biomarkers for hepatocellular carcinoma. 2017 , 4, 215-221		50

472	Clinical effects and safety of intra-arterial infusion therapy of cisplatin suspension in lipiodol combined with 5-fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra-hepatic spread: A prospective cohort study. 2017 , 7, 1013-1020		21
471	Management of Hepatocellular Carcinoma in the Setting of Liver Cirrhosis. 2017 ,		
470	Advances in systemic therapy for hepatocellular carcinoma. 2017 , 1502-1513.e4		
469	Enhanced Radiation Therapy of Gold Nanoparticles in Liver Cancer. 2017 , 7, 232		16
468	Prognostic signatures from hepatocellular carcinoma biopsy. 2017 , 4, 65-68		
467	Screening for hepatocellular carcinoma: patient selection and perspectives. <i>Journal of Hepatocellular Carcinoma</i> , 2017 , 4, 71-79	5.3	20
466	From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world. <i>World Journal of Gastroenterology</i> , 2017 , 23, 5282-5294	5.6	158
465	Hepatocellular carcinoma: a clinicopathological study of 64 cases. 2017 , 27, 41		1
464	Stereotactic body radiation therapy (SBRT) for definitive treatment and as a bridge to liver transplantation in early stage inoperable Hepatocellular carcinoma. <i>Radiation Oncology</i> , 2017 , 12, 163	4.2	36
463	MicroRNAs and clinical implications in hepatocellular carcinoma. 2017 , 9, 1001-1007		33
462	Predictors of Micrometastases in Patients with Barcelona Clinic Liver Cancer Classification B Hepatocellular Carcinoma. 2017 , 58, 737-742		10
461	Extrahepatic metastasis risk of hepatocellular carcinoma based on α -fetoprotein and tumor staging parameters at cross-sectional imaging. 2017 , 9, 503-511		16
460	Shanghai Score: A Prognostic and Adjuvant Treatment-evaluating System Constructed for Chinese Patients with Hepatocellular Carcinoma after Curative Resection. 2017 , 130, 2650-2660		12
459	Combination of LINE-1 hypomethylation and RASSF1A promoter hypermethylation in serum DNA is a non-invasion prognostic biomarker for early recurrence of hepatocellular carcinoma after curative resection. 2017 , 64, 795-802		21
458	Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era. 2018 , 19, 26-32		6
457	Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment. 2018 , 7, 104-119		57
456	EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. 2018 , 69, 182-236		3196
455	Liver Cancers. 2018 , 100-116		

454	Transcatheter Arterial Chemoembolization With or Without Radiofrequency Ablation: Outcomes in Patients With Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma. 2018 , 210, 891-898	23
453	Staging for hepatocellular carcinoma in light of tumor heterogeneity: Time to change or update?. 2018 , 67, 2076-2078	3
452	Outcomes of surgery for hepatocellular carcinoma with tumor thrombus in the inferior vena cava or right atrium. 2018 , 48, 819-824	31
451	Precision Molecular Pathology of Liver Cancer. 2018 ,	1
450	Genomics Studies in Hepatocellular Carcinoma via Next-Generation Sequencing. 2018 , 49-68	1
449	Hepatic resection vs. transarterial chemoembolization for hepatocellular carcinoma beyond the Milan criteria with portal hypertension. 2018 , 50, 713-719	5
448	Comparison and validation of the prognostic value of preoperative systemic immune cells in hepatocellular carcinoma after curative hepatectomy. 2018 , 7, 1170-1182	10
447	SBRT for Hepatocellular Carcinoma: 8-Year Experience from a Regional Transplant Center. 2018 , 49, 463-469	17
446	Absorbed doses in humans from Re-Rituximab in the free form and bound to superparamagnetic iron oxide nanoparticles: Biodistribution study in mice. 2018 , 131, 96-102	6
445	Validation of inflammation-based prognostic models in patients with hepatitis B-associated hepatocellular carcinoma: a retrospective observational study. 2018 , 30, 60-70	18
444	Validation of the American Joint Committee on Cancer eighth edition staging system in patients undergoing hepatectomy for hepatocellular carcinoma: a US population-based study. 2018 , 222, 55-68	9
443	Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score. 2018 , 30, 44-53	7
442	An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib. 2018 , 20, 322-329	12
441	Tumor Recurrence in Hepatocellular Carcinoma Patients after Radiofrequency Ablation: Portal Hypertension as an Indicator of Recurrence of Hepatocellular Carcinoma. 2018 , 79, 264	
440	Five-CpG-based prognostic signature for predicting survival in hepatocellular carcinoma patients. 2018 , 15, 425-433	9
439	A new tumor-associated antigen prognostic scoring system for spontaneous ruptured hepatocellular carcinoma after partial hepatectomy. 2018 , 15, 415-424	2
438	Evaluation and Surgical Management of Hepatocellular Carcinoma. 2018 ,	1
437	Staging systems of hepatocellular carcinoma: A review. <i>Indian Journal of Gastroenterology</i> , 2018 , 37, 481-491	1.9 52

436	Expression of Plasma hsa-miR122 in HBV-Related Hepatocellular Carcinoma (HCC) in Vietnamese Patients. 2018 , 7, 92-99	5
435	Serum human endothelial cell-specific molecule-1 (endocan) and vascular endothelial growth factor in cirrhotic HCV patients with hepatocellular carcinoma as predictors of mortality. 2018 , 11, 431-438	8
434	15 Hepatocellular Carcinoma: Staging and Clinical Management. 2018 ,	
433	Radiotherapy for Hepatocellular Carcinoma. 2018 , 28, 277-287	16
432	A novel inflammation-based nomogram system to predict survival of patients with hepatocellular carcinoma. 2018 , 7, 5027-5035	18
431	Efficacy of Percutaneous Thermal Ablation Combined With Transarterial Embolization for Recurrent Hepatocellular Carcinoma After Hepatectomy and a Prognostic Nomogram to Predict Survival. 2018 , 17, 1533033818801362	5
430	Dysregulated serum metabolites in staging of hepatocellular carcinoma. 2018 , 61, 7-11	6
429	The Prognostic Ability of Major Hepatocellular Carcinoma Staging Systems Is Improved by Including a Treatment Variable. 2018 , 63, 2277-2284	1
428	Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database. 2018 , 7, 2816	11
427	Epidemiology and Etiologic Associations of Non-alcoholic Fatty Liver Disease and Associated HCC. 2018 , 1061, 3-18	15
426	IL-28B rs12979860 polymorphism affect the course of chronic hepatitis and the development of HCC in Egyptian patients with hepatitis C type 4. 2018 , 75, 157-162	11
425	Evaluation of survival of patients with hepatocellular carcinoma: A comparative analysis of prognostic systems. <i>PLoS ONE</i> , 2018 , 13, e0194922	3-7 11
424	Intention-to-treat analysis of liver transplantation, resection and thermal ablation for hepatocellular carcinoma in a single centre. 2018 , 20, 966-976	2
423	Nomogram predicting survival of hepatocellular carcinoma with portal vein tumour thrombus after curative resection. 2019 , 89, E20-E25	4
422	Platelet-Albumin Score as a Sensitive Measure for Surgical Risk Prediction and Survival Outcomes of Patients with Hepatocellular Carcinoma. 2019 , 23, 76-83	10
421	Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. 2019 , 39, 2214-2229	116
420	Hepatocellular Carcinoma. 2019 ,	1
419	External-beam radiation therapy versus surgery in the treatment of hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombi. 2019 , 15, 316-322	5

418	Hypofractionated radiotherapy as a salvage treatment for recurrent hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus: a multi-center analysis. <i>BMC Cancer</i> , 2019 , 19, 668	4.8	16
417	Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation. 2019 , 8, 5023-5032		20
416	Sulfhydryl functionalized graphene oxide for efficient preconcentration and photoablation of pathogenic bacteria. 2019 , 43, 917-925		6
415	Dynamic modeling and characteristic analysis of piezoelectric rudder actuator. 2019 , 90, 016102		1
414	Genetic Biomarkers For Hepatocellular Carcinoma In The Era Of Precision Medicine. <i>Journal of Hepatocellular Carcinoma</i> , 2019 , 6, 151-166	5.3	18
413	Radioembolization for the Treatment of Primary and Metastatic Liver Cancers. 2019 , 53, 367-373		10
412	Comparison of albumin-bilirubin grade, platelet-albumin-bilirubin grade and Child-Turcotte-Pugh class for prediction of survival in patients with large hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation. 2019 , 36, 841-853		10
411	Prognostic role of serial alpha-fetoprotein levels in hepatocellular carcinoma treated with locoregional therapy. 2019 , 54, 1132-1137		3
410	Radiomics in hepatocellular carcinoma: a quantitative review. 2019 , 13, 546-559		56
409	Clinical and morpho-molecular classifiers for prediction of hepatocellular carcinoma prognosis and recurrence after surgical resection. 2019 , 13, 715-725		4
408	Using natural language processing to extract clinically useful information from Chinese electronic medical records. 2019 , 124, 6-12		29
407	Clinical Relevance of Reductive Hepatectomy for Barcelona Clinic Liver Cancer Stages B and C Advanced Hepatocellular Carcinoma: A Single-Center Experience of 102 Patients. 2019 , 43, 2571-2578		6
406	Contribution of Hepatitis B Virus Infection to the Aggressiveness of Primary Liver Cancer: A Clinical Epidemiological Study in Eastern China. <i>Frontiers in Oncology</i> , 2019 , 9, 370	5.3	22
405	Status of inflammation in relation to health related quality of life in hepatocellular carcinoma patients. 2019 , 28, 2597-2607		3
404	NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging. 2019 , 34, 2179-2186		1
403	TACE, DEE-TACE, and Its Evolution in Metastatic Disease. 2019 , 03, 052-062		
402	Platelet-albumin-bilirubin grade: Risk stratification of liver failure, prognosis after resection for hepatocellular carcinoma. 2019 , 51, 1430-1437		14
401	Correlations of health-related quality of life with serum inflammatory indicators IL-8 and mBI in patients with hepatocellular carcinoma. 2019 , 11, 2719-2727		7

400	Endoscopic Ultrasound for the Diagnosis and Staging of Liver Tumors. 2019 , 29, 339-350		7
399	Hepatocellular carcinoma with extrahepatic metastasis: Are there still candidates for transarterial chemoembolization as an initial treatment?. <i>PLoS ONE</i> , 2019 , 14, e0213547	3.7	5
398	Bone Mineral Density as a Risk Factor for Patients Undergoing Surgery for Hepatocellular Carcinoma. 2019 , 43, 920-928		8
397	Utility of FIB4-T as a Prognostic Factor for Hepatocellular Carcinoma. <i>Cancers</i> , 2019 , 11,	6.6	2
396	An elevated neutrophil-to-lymphocyte ratio predicts a poor postoperative survival in primary hepatocellular carcinoma patients with a normal preoperative serum level of alpha-fetoprotein. 2019 , 49, 661-669		5
395	Hepatocellular Carcinoma: Diagnosis and Prognosis. 2019 , 693-702		0
394	Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients. 2019 , 8, 312-325		37
393	An Eastern Hepatobiliary Surgery Hospital Microvascular Invasion Scoring System in Predicting Prognosis of Patients with Hepatocellular Carcinoma and Microvascular Invasion After R0 Liver Resection: A Large-Scale, Multicenter Study. 2019 , 24, e1476-e1488		20
392	Immune checkpoint inhibitors for unresectable hepatocellular carcinoma. 2019 ,		78
391	BCLC-B Subclassification and the Hong Kong Liver Cancer System in Intermediate Hepatocellular Carcinoma: Identifying Candidates for Curative Therapy. 2019 , 42, 466-471		4
390	Effect of drug-loaded microbubbles combined with ultrasound on the apoptosis of cancer cells and the expression of Bax and Bcl-2 in a rabbit VX2 liver tumor model. 2019 , 39,		4
389	Hepatocellular carcinoma: resection with adjuvant hepatic artery infusion therapy vs resection alone. A systematic review and meta-analysis. 2019 , 119, 455-463		11
388	Child-Pugh Classification: Time to Abandon?. 2019 , 39, 96-103		22
387	The Munich-Transarterial Chemoembolisation Score Holds Superior Prognostic Capacities Compared to TACE-Tailored Modifications of 9 Established Staging Systems for Hepatocellular Carcinoma. 2019 , 100, 15-26		3
386	The Critically Ill Cirrhotic Patient. 2020 ,		
385	A combination of Ffetoprotein, midkine, thioredoxin and a metabolite for predicting hepatocellular carcinoma. <i>Annals of Hepatology</i> , 2020 , 19, 179-185	3.1	8
384	Liver and Bile Duct Cancer. 2020 , 1314-1341.e11		3
383	Use of a novel index, the A-index, and its associated nomogram to predict overall survival rates after resection of primary hepatocellular carcinoma. 2020 , 500, 34-41		3

382	Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. 2020 , 5, 167-228		120
381	May Neutrophil Gelatinase-Associated Lipocalin (NGAL) Level Predict Mortality in Patients with Hepatocellular Carcinoma (HCC)?. 2020 , 51, 932-938		3
380	Defining and predicting early recurrence after liver resection of hepatocellular carcinoma: a multi-institutional study. 2020 , 22, 677-689		16
379	Proton beam therapy for hepatocellular carcinoma associated with inferior vena cava tumor thrombus. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 711-720	4.9	8
378	Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma. 2020 , 9, 167-181		16
377	The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma. 2020 , 1874, 188451		17
376	Pretreatment peripheral neutrophils, lymphocytes and monocytes predict long-term survival in hepatocellular carcinoma. <i>BMC Cancer</i> , 2020 , 20, 937	4.8	6
375	Development and validation of a prognostic model based on the albumin-to-fibrinogen ratio (AFR) and gamma-glutamyl transpeptidase-to-platelet ratio (GPR) in hepatocellular carcinoma patients. 2020 , 511, 107-116		3
374	Correlating serum alpha-fetoprotein in hepatocellular carcinoma with response to Yttrium-90 transarterial radioembolization with glass microspheres (TheraSphere®) 2020 , 22, 1330-1338		4
373	Current perspectives on the tumor microenvironment in hepatocellular carcinoma. 2020 , 14, 947-957		12
372	Clinical Role of Newly Developed ALBI and mALBI Grades for Treatment of Hepatocellular Carcinoma. 2020 , 10, 7178		
371	Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: A Validation Study. <i>Journal of Hepatocellular Carcinoma</i> , 2020 , 7, 143-153	5.3	1
370	The prognostic value of aspartate aminotransferase-to-lymphocyte ratio index in early-stage hepatocellular carcinoma after hepatectomy: A propensity-score matched analysis. 2021 , 17, e238-e248		2
369	Prognostic effect of a novel long noncoding RNA signature and comparison with clinical staging systems for patients with hepatitis B virus-related hepatocellular carcinoma after hepatectomy. 2020 , 21, 650-663		3
368	Use of a Novel Thyroid-Stimulating Hormone Model for Predicting the Progression of Hepatocellular Carcinoma. 2020 , 13, 11421-11431		0
367	Tumor aggression among hepatitis-C related hepatocellular carcinoma patients: an observational study regarding the impact of anti-HCV therapy. 2020 , 15, 35		2
366	Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma and other liver diseases. <i>Annals of Translational Medicine</i> , 2020 , 8, 553	3.2	15
365	Prognostic model for identifying candidates for hepatectomy among patients with hepatocellular carcinoma and hepatic vein invasion. 2020 , 107, 865-877		6

364	Relationship between presarcopenia and event occurrence in patients with primary hepatocellular carcinoma. 2020 , 10, 10186		2
363	Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. <i>Annals of Hepatology</i> , 2020 , 19, 546-569	3.1	6
362	Nomograms to predict the long-time prognosis in patients with alpha-fetoprotein negative hepatocellular carcinoma following radical resection. 2020 , 9, 2791-2802		10
361	Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 1033-1050	4.9	8
360	Predictive performance of the mHAP-II score in a real-life western cohort with hepatocellular carcinoma following trans-arterial chemoembolisation with drug-eluting beads (DEB-TACE). 2020 , 30, 3782-3792		6
359	Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. 2020 , 1, CD011313		7
358	Milestones in the pathogenesis and management of primary liver cancer. 2020 , 72, 209-214		22
357	Targeting Autophagy Augments BBR-Mediated Cell Death in Human Hepatoma Cells Harboring Hepatitis C Virus RNA. 2020 , 9,		7
356	Increased Survival Benefit of Adjuvant Intra-arterial Infusion Chemotherapy in HCC Patients with Portal Vein Infiltration after Hepatectomy. 2020 , 44, 2770-2776		4
355	A New Scoring Method for Personalized Prognostic Prediction in Patients with Combined Hepatocellular and Cholangiocarcinoma After Surgery. 2021 , 25, 971-982		3
354	Can Hematological Inflammatory Parameters Predict Mortality in Hepatocellular Carcinoma?. 2021 , 52, 666-675		0
353	Monofocal hepatocellular carcinoma: How much does size matter?. 2021 , 41, 396-407		7
352	Prognostic nomograms and risk classifications of outcomes in very early-stage hepatocellular carcinoma patients after hepatectomy. 2021 , 47, 681-689		1
351	HCC-Mark: a simple non-invasive model based on routine parameters for predicting hepatitis C virus related hepatocellular carcinoma. 2021 , 78, 72-77		0
350	Prognostic evaluation of HCC patients undergoing surgical resection: an analysis of 8 different staging systems. 2021 , 406, 75-86		5
349	Quality and performance of validated prognostic models for survival after resection of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. 2021 , 23, 25-36		4
348	Particle Beam Radiotherapy. 2021 , 121-138		
347	Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib. 2021 , 12, e00286		7

- 346 Hepatocellular Carcinoma in Pakistan: An Update. **2021**, 387-396
- 345 Computational intelligence identifies alkaline phosphatase (ALP), alpha-fetoprotein (AFP), and hemoglobin levels as most predictive survival factors for hepatocellular carcinoma. **2021**, 27, 1460458220984205
- 344 Serum levels of gamma-glutamyl transpeptidase in relation to HCC human biology and prognosis. **2021**, 7,
- 343 Development and validation of an individualized prediction calculator of postoperative mortality within 6 months after surgical resection for hepatocellular carcinoma: an international multicenter study. **2021**, 15, 459-471 0
- 342 Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter. **2021**, 36, 54-61 5
- 341 Comparative Analysis of Presentation and Outcome After Liver Resection of Patients With Hepatocellular Carcinoma With and Without HIV. **2021**, 86, 361-368 1
- 340 Modified albumin-bilirubin grade to predict eligibility for second-line therapies at progression on sorafenib therapy in hepatocellular carcinoma patients. **2021**, 26, 922-932 2
- 339 Radiomics-based model using gadoxetic acid disodium-enhanced MR images: associations with recurrence-free survival of patients with hepatocellular carcinoma treated by surgical resection. **2021**, 46, 3845-3854 4
- 338 Artificial neural network model to predict post-hepatectomy early recurrence of hepatocellular carcinoma without macroscopic vascular invasion. *BMC Cancer*, **2021**, 21, 283 4.8 0
- 337 Prediction of Prognosis for cHCC-CC Patients After Surgery: Comparison of Tumor Marker Score Based on AFP, CEA, CA19-9, and Other Clinical Stages. **2021**, 28, 7647-7660 2
- 336 Selecting an Optimal Staging System for Intermediate-Stage Hepatocellular Carcinoma: Comparison of 9 Currently Used Prognostic Models. *Journal of Hepatocellular Carcinoma*, **2021**, 8, 253-261 5.3 2
- 335 Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications. *Cancers*, **2021**, 13, 6.6 7
- 334 Prognosis prediction or treatment allocation?. **2021**, 15, 852-854
- 333 Diagnostic and Prognostic Value of miR-16, miR-146a, miR-192 and miR-221 in Exosomes of Hepatocellular Carcinoma and Liver Cirrhosis Patients. *Cancers*, **2021**, 13, 6.6 7
- 332 Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. **2021**, 10, 181-223 38
- 331 Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis. **2021**, 2021, 6670367 3
- 330 The growth rate of hepatocellular carcinoma is different with different TNM stages at diagnosis. **2021**, 20, 330-336 1
- 329 State-of-the-art surgery for hepatocellular carcinoma. **2021**, 406, 2151-2162 2

328	Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study. 2021 , 53, 1011-1019		6
327	Correlation of liver enhancement in gadoxetic acid-enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial. 2021 , 1		1
326	Comparison of treatments for hepatocellular carcinoma patients with portal vein thrombosis: a systematic review and network meta-analysis. <i>Annals of Translational Medicine</i> , 2021 , 9, 1450	3.2	0
325	Prognostic nomogram predicting survival of patients with unresectable hepatocellular carcinoma after hepatic arterial infusion chemotherapy. 2021 , 142, 109890		1
324	Isotretinoin and Thalidomide Down-Regulate Gene Expression and Modify Proteins Associated with Cancer in Hepatic Cells. 2021 , 26,		1
323	Systematic review and meta-analysis of validated prognostic models for resected hepatocellular carcinoma patients. 2021 ,		3
322	Differences in the presentation and treatment of primary liver tumors at a hepatology center and an oncology center. 2021 ,		1
321	Reducing the heterogeneity in hepatocellular carcinoma. A cluster analysis based on clinical variables in patients treated at a quaternary care hospital. 2021 ,		3
320	Differences in the presentation and treatment of primary liver tumors at a hepatology center and an oncology center. 2021 , 86, 370-377		1
319	Reducing the heterogeneity in hepatocellular carcinoma. A cluster analysis based on clinical variables in patients treated at a quaternary care hospital. 2021 , 86, 356-362		
318	Biological Aspects of HCC. 2021 , 3-11		1
317	Stereotactic Body Radiation Therapy (SBRT) in Hepatocellular Carcinoma. 2021 , 20, 12-22		5
316	Albumin-to-alkaline phosphatase ratio as a predictor of tumor recurrence and prognosis in patients with early-stage hepatocellular carcinoma undergoing radiofrequency ablation as initial therapy. 2021 , 38, 1-10		5
315	Liver. 2010 , 191-199		4
314	Hepatocellular carcinoma. 1998 , 98, 83-109		1
313	Results of surgical resection for hepatocellular carcinoma. 2001 , 109, 59-75		7
312	Liver (Including Intrahepatic Bile Ducts). 2002 , 131-138		13
311	Staging of Hepatocellular Carcinoma. 2011 , 69-80		1

310	Hepatocellular Carcinoma: Etiology and Natural History. 2012 , 1-16	2
309	Staging of Hepatocellular Carcinoma. 2012 , 161-175	1
308	Hepatocellular Carcinoma Surveillance and Staging. 2019 , 27-51	2
307	Molecular Subtypes and Genomic Signatures of Hepatocellular Carcinoma for Prognostication and Therapeutic Decision-Making. 2019 , 109-123	1
306	Hepatocellular Carcinoma and Patient Assessment. 2015 , 21-32	1
305	Hepatocellular Carcinoma: Surgical Management and Evolving Therapies. 2016 , 168, 165-83	2
304	Liver Cancer. 2011 , 225-249	1
303	Liver. 2001 , 585-616	2
302	Rationale for Non-surgical Interventional Treatment of Hepatocellular Carcinoma. 1999 , 245-253	1
301	Chemoembolization of Liver Tumors. 1989 , 201-215	2
300	Hepatobiliäre Malignome. 1991 , 422-480	0
299	Die systemische Chemotherapie des Leberkarzinoms. 1991 , 31-46	1
298	Hepatocellular Carcinoma. 1995 , 88-93	5
297	Systemic chemotherapy for hepatocellular carcinoma. 1992 , 301-305	2
296	Prognostic factors in surgical patients with hepatocellular carcinoma. 1992 , 421-426	2
295	Small Hepatocellular Carcinoma. 1987 , 215-226	16
294	Chemotherapy of Primary Liver Cancer. 1987 , 321-326	6
293	Arterial Embolization in the Treatment of Hepatocellular Carcinoma. 1987 , 327-334	3

292	Prognosis of Hepatocellular Carcinoma. 1987 , 407-415		4
291	No synergistic activity of epirubicin and interferon- α 2b in the treatment of hepatocellular carcinoma. 1995 , 35, 334		1
290	Hepatocellular carcinoma patients with portal vein thrombosis treated with robotic radiosurgery: Interim results of a prospective study. <i>Indian Journal of Gastroenterology</i> , 2021 , 40, 389-401	1.9	2
289	Liver. 2011 , 857-980		3
288	Liver and Bile Duct Cancer. 2008 , 1569-1594		1
287	Transplantation for Primary Hepatic Malignancy. 2005 , 211-231		1
286	Epidemiology of Hepatocellular Carcinoma. 1987 , 16, 545-551		73
285	Screening Studies and Markers. 1987 , 16, 563-573		9
284	PRIMARY MALIGNANT NEOPLASMS IN THE ADULT. 1997 , 5, 289-318		22
283	A prospective randomized administration of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization. 1997 , 20, 202-8		15
282	A prospective phase II trial to evaluate the efficacy and toxicity of hepatic arterial infusion of ifosfamide in patients with inoperable localized hepatocellular carcinoma. 1997 , 20, 289-92		7
281	Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients. 1998 , 21, 386-91		122
280	Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. 1999 , 229, 216-22		451
279	An analysis of 412 cases of hepatocellular carcinoma at a Western center. 1999 , 229, 790-9; discussion 799-800		633
278	Superselective intra-arterial radiometabolic therapy with I-131 lipiodol in hepatocellular carcinoma. 1996 , 21, 221-6		20
277	MR appearance and spectral features of injected ethanol in the liver: implication for fast MR-guided percutaneous ethanol injection therapy. 1997 , 21, 82-8		10
276	Hepatocellular carcinoma presenting with paraneoplastic neurologic syndrome in a hepatitis B surface antigen-positive patient. 1998 , 26, 144-7		6
275	Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma. 1998 , 26, 200-3		49

274	Chemotherapy for hepatocellular carcinoma with portal hypertension due to tumor thrombus. 2000 , 31, 247-9		11
273	Surveillance for hepatocellular carcinoma in cirrhosis: is it cost-effective?. 2001 , 10, 111-5		13
272	Spontaneous regression of hepatocellular carcinoma: potential promise for the future. 2007 , 100, 223-4		8
271	Characteristics of Hepatocellular Carcinoma Aggressiveness Factors in Turkish Patients. 2018 , 94, 116-124		14
270	Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. 2016 , 13, e1002006		81
269	Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization. <i>PLoS ONE</i> , 2013 , 8, e68193	3-7	116
268	A new model to estimate prognosis in patients with hepatocellular carcinoma after Yttrium-90 radioembolization. <i>PLoS ONE</i> , 2013 , 8, e82225	3-7	19
267	Prognosis of unresectable hepatocellular carcinoma: comparison of seven staging systems (TNM, Okuda, BCLC, CLIP, CUPI, JIS, CIS) in a Chinese cohort. <i>PLoS ONE</i> , 2014 , 9, e88182	3-7	31
266	The Singapore Liver Cancer Recurrence (SLICER) Score for relapse prediction in patients with surgically resected hepatocellular carcinoma. <i>PLoS ONE</i> , 2015 , 10, e0118658	3-7	29
265	Identifying prognostic features by bottom-up approach and correlating to drug repositioning. <i>PLoS ONE</i> , 2015 , 10, e0118672	3-7	8
264	Impact of tumor burden on prognostic prediction for patients with terminal stage hepatocellular carcinoma: A nomogram study. <i>PLoS ONE</i> , 2017 , 12, e0188031	3-7	7
263	Proton Beam Therapy for Hepatocellular Carcinoma: A Review of the University of Tsukuba Experience. 2016 , 2, 570-578		8
262	Hepatocellular carcinoma with atrial tumor thrombus presenting as myxoma: Resection under cardiopulmonary bypass. 2020 , 24, 518-521		1
261	The best strategy for HCC patients at each BCLC stage: a network meta-analysis of observational studies. 2017 , 8, 20418-20427		23
260	Validation of different staging systems for hepatocellular carcinoma in a cohort of 249 patients undergoing radiotherapy. 2017 , 8, 46523-46531		3
259	Prognostic nomogram for hepatocellular carcinoma in adolescent and young adult patients after hepatectomy. 2017 , 8, 106393-106404		10
258	Applying of pretreatment extent of disease system in patients with hepatocellular carcinoma after curative partial hepatectomy. 2016 , 7, 30408-19		2
257	Liver transplantation for hepatocellular carcinoma with live donors or extended criteria donors: a propensity score-matched comparison. 2018 , 31, 722-727		1

256	The Prognostic Value of Preoperative Geriatric Nutritional Risk Index in Patients with Pancreatic Ductal Adenocarcinoma. 2020 , 12, 385-395		5
255	Talin-1 Gene Expression as a Tumor Marker in Hepatocellular Carcinoma Patients: A Pilot Study. 2020 , 10, 15-22		5
254	The mutational landscape of hepatocellular carcinoma. 2015 , 21, 220-9		72
253	[Clinical features and treatment outcome of advanced hepatocellular carcinoma with inferior vena caval invasion or atrial tumor thrombus]. 2007 , 13, 387-95		12
252	[Analysis of the clinical characteristics and prognostic factors of ruptured hepatocellular carcinoma]. 2009 , 15, 148-58		9
251	[Comparison of radiofrequency ablation and transarterial chemoembolization for the treatment of a single hepatocellular carcinoma smaller than 4 cm]. 2009 , 15, 474-85		4
250	Clinicopathologic significance of the expression of Snail in hepatocellular carcinoma. 2011 , 17, 12-8		16
249	Applicability of the BCLC staging system to patients with hepatocellular carcinoma in Korea: analysis at a single center with a liver transplant center. 2011 , 17, 113-9		22
248	Natural history of hepatitis-related hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2008 , 14, 1652-6	5.6	175
247	Hepatocellular carcinoma: defining the place of surgery in an era of organ shortage. <i>World Journal of Gastroenterology</i> , 2008 , 14, 4445-53	5.6	14
246	Surgical treatment of hepatocellular carcinoma: evidence-based outcomes. <i>World Journal of Gastroenterology</i> , 2008 , 14, 685-92	5.6	21
245	Salvage therapy for hepatocellular carcinoma with thalidomide. <i>World Journal of Gastroenterology</i> , 2004 , 10, 649-53	5.6	37
244	Impact of pre-operative transarterial embolization on the treatment of hepatocellular carcinoma with liver transplantation. <i>World Journal of Gastroenterology</i> , 2005 , 11, 1433-8	5.6	18
243	Survival outcome of lobar or segmental transcatheter arterial embolization with ethanol-lipiodol mixture in treating hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2005 , 11, 2792-5	5.6	14
242	Outcome of transarterial chemoembolization in patients with inoperable hepatocellular carcinoma eligible for radiofrequency ablation. <i>World Journal of Gastroenterology</i> , 2005 , 11, 4465-71	5.6	30
241	Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2006 , 12, 2563-8	5.6	86
240	Inhibition of hepatic tumor cell proliferation in vitro and tumor growth in vivo by taltobulin, a synthetic analogue of the tripeptide hemiasterlin. <i>World Journal of Gastroenterology</i> , 2006 , 12, 6771-8	5.6	5
239	Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2007 , 13, 280-4	5.6	21

238	Chinese medicinal compound delisheng has satisfactory anti-tumor activity, and is associated with up-regulation of endostatin in human hepatocellular carcinoma cell line HepG2 in three-dimensional culture. <i>World Journal of Gastroenterology</i> , 2007 , 13, 5432-9	5.6	14
237	CT volume measurement for prognostic evaluation of unresectable hepatocellular carcinoma after TACE. <i>World Journal of Gastroenterology</i> , 2010 , 16, 2038-45	5.6	13
236	Staging systems for predicting survival of patients with hepatocellular carcinoma after surgery. <i>World Journal of Gastroenterology</i> , 2010 , 16, 5257-62	5.6	14
235	Surgical treatment for liver cancer. <i>World Journal of Gastroenterology</i> , 2010 , 16, 927-33	5.6	36
234	Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis. <i>World Journal of Gastroenterology</i> , 2013 , 19, 4679-88	5.6	29
233	Proposal of new classification for postoperative patients with hepatocellular carcinoma based on tumor growth characteristics. <i>World Journal of Gastroenterology</i> , 2013 , 19, 5534-41	5.6	2
232	Hepatocellular carcinoma treated by conventional transarterial chemoembolization in field-practice: serum sodium predicts survival. <i>World Journal of Gastroenterology</i> , 2014 , 20, 8158-65	5.6	16
231	Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis. <i>World Journal of Gastroenterology</i> , 2015 , 21, 246-53	5.6	31
230	Comparison of hepatic resection and transarterial chemoembolization for solitary hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2015 , 21, 4635-43	5.6	7
229	Prognostic roles of preoperative α -fetoprotein and des- γ -carboxy prothrombin in hepatocellular carcinoma patients. <i>World Journal of Gastroenterology</i> , 2015 , 21, 4933-45	5.6	36
228	Comparison of percutaneous radiofrequency ablation and CyberKnife() for initial solitary hepatocellular carcinoma: A pilot study. <i>World Journal of Gastroenterology</i> , 2015 , 21, 13490-9	5.6	23
227	Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization. <i>World Journal of Gastroenterology</i> , 2016 , 22, 10406-10414	5.6	16
226	Prognostic value of serum microRNA-122 in hepatocellular carcinoma is dependent on coexisting clinical and laboratory factors. <i>World Journal of Gastroenterology</i> , 2020 , 26, 86-96	5.6	3
225	Review of 336 patients with hepatocellular carcinoma at Songklanagarind Hospital. <i>World Journal of Gastroenterology</i> , 2000 , 6, 339-343	5.6	39
224	Prediction of recurrence and prognosis in patients with hepatocellular carcinoma after resection by use of CLIP score. <i>World Journal of Gastroenterology</i> , 2002 , 8, 237-42	5.6	54
223	Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis. <i>World Journal of Gastroenterology</i> , 2003 , 9, 2666-70	5.6	45
222	Percutaneous cryoablation in combination with ethanol injection for unresectable hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2003 , 9, 2686-9	5.6	47
221	Transcatheter arterial embolization treatment in patients with hepatocellular carcinoma and risk of pulmonary metastasis. <i>World Journal of Gastroenterology</i> , 2003 , 9, 1208-11	5.6	15

220	Inhibition of S-phase kinase-associated protein 2-mediated p27 degradation suppresses tumorigenesis and the progression of hepatocellular carcinoma. 2015 , 11, 3934-40	7
219	Identification of miRNA and mRNA expression profiles by PCR microarray in hepatitis B virus-associated hepatocellular carcinoma. 2018 , 18, 5123-5132	4
218	Natural history and prognostic factors of primary hepatocellular carcinoma: study of 70 untreated patients. 1989 , 4, 136-41	8
217	Combined cis-platinum and alpha interferon therapy of advanced hepatocellular carcinoma. 1996 , 11, 58-68	15
216	Spontaneous regression of hepatocellular carcinoma--a case report. 2000 , 15, 147-50	9
215	Clear cell hepatocellular carcinoma with spontaneous regression of primary and metastatic lesions. 2005 , 20, 268-73	19
214	Pathologically Confirmed Spontaneous Partial Regression of Hepatocellular Carcinoma. 2014 , 86, 198	1
213	Impact of cytolysis following transarterial chemoembolization for hepatocellular carcinoma. 2013 , 4, 45-52	3
212	Computed tomography-guided iodine-125 brachytherapy for unresectable hepatocellular carcinoma. 2019 , 15, 1553-1560	7
211	Re-HEDP therapy in the therapy of painful bone metastases. 2018 , 17, 133-138	9
210	Bone metastasis from primary hepatocellular carcinoma: characteristics of soft tissue formation. 2007 , 39, 104-8	27
209	Hepatocellular carcinoma presenting as uterine metastasis. 2008 , 40, 141-4	5
208	Multicenter validation study of a prognostic index for portal vein tumor thrombosis in hepatocellular carcinoma. 2014 , 46, 348-57	11
207	The Prognostic Role of Mitotic Index in Hepatocellular Carcinoma Patients after Curative Hepatectomy. 2016 , 48, 180-9	9
206	Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib. 2018 , 50, 366-373	8
205	Multi-Detector-Row CT Diagnosis of Adrenal Incidentaloma in Patients with Hepatocellular Carcinoma. 2013 , 02, 34-40	1
204	Management of Hepatocellular Carcinoma: Updated Review. 2013 , 04, 536-545	9
203	Current status of radiofrequency ablation of hepatocellular carcinoma. 2010 , 2, 128-36	23

202	Advances and challenges in laparoscopic surgery in the management of hepatocellular carcinoma. 2017 , 9, 233-245	24
201	Hepatocellular carcinoma staging systems: Hong Kong liver cancer Barcelona clinic liver cancer in a Western population. 2019 , 11, 678-688	13
200	Hepatic flow is an intraoperative predictor of early allograft dysfunction in whole-graft deceased donor liver transplantation: An observational cohort study. 2019 , 11, 689-700	3
199	Circulating miR-21-5p level has limited prognostic value in patients with hepatocellular carcinoma and is influenced by renal function. 2020 , 12, 1031-1045	4
198	Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases. 2020 , 12, 533-557	3
197	Update in management of hepatocellular carcinoma in Eastern population. 2015 , 7, 1562-71	19
196	Treatment of hepatocellular carcinoma: Steps forward but still a long way to go. 2015 , 7, 566-74	38
195	Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. 2015 , 7, 738-52	43
194	The efficacy of powerful proton radiotherapy for hepatocellular carcinoma. 1998 , 7, 9-17	3
193	Current Concepts in Hepatocellular Carcinoma and Liver Transplantation: A Review and 2014 Update. 2015 , 5, 19-25	3
192	Treatment of hepatocellular carcinoma with portal vein thrombosis by sorafenib combined with hepatic arterial infusion chemotherapy. 2010 , 4, 423-7	12
191	The optimal selection of radiotherapy treatment for hepatocellular carcinoma. 2012 , 6, 139-48	19
190	Management of Hepatocellular Carcinoma: Current Status and Future Directions. 2015 , 9, 437-48	41
189	Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines. 2012 , 32, 174-99	19
188	Hepatocellular carcinoma: 100 most influential manuscripts: A bibliometric analysis. 2019 , 9, 1	4
187	International validation of the Chinese university prognostic index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study. 2014 , 33, 481-91	18
186	Diagnostic Value of Serum Level of Soluble Tumor Necrosis Factor Receptor II in Egyptian Patients With Chronic Hepatitis C Virus Infection and Hepatocellular Carcinoma. 2014 , 14, e19346	4
185	Clinicopathological characteristics of hepatocellular carcinoma in Turkey. 2012 , 13, 2985-90	13

- 184 Epidemiology and survival of hepatocellular carcinoma in north-east Peninsular Malaysia. **2013**, 14, 6955-9 25
- 183 Treating hepatocellular carcinoma with Y-bearing microspheres: a review. **2016**, 6, 19 14
- 182 Decompensated cirrhosis is the commonest presentation for NAFLD patients undergoing liver transplant assessment. **2020**, 20, 313-318 4
- 181 Relationships Between Indices of Tumor Aggressiveness in Hepatocellular Carcinoma. **2021**, 52, 1340 1
- 180 Percutaneous Microwave Coagulation Therapy for Hepatocellular Carcinoma. **2000**, 17-22
- 179 Hepatocellular Carcinoma. **2000**, 392-475
- 178 Surgical Treatment of Hepatocellular Carcinoma. **2000**, 56-63
- 177 Maligne Tumoren der Leber und Gallenwege. **2001**, 357-376 1
- 176 Liver Resection in Advanced Hepatocellular Carcinoma. **2002**, 11-19
- 175 Cancer of the Liver, Biliary Tree, and Pancreas. **2002**, 478-505
- 174 Internal Radiation Therapy through the Hepatic Artery. **2002**, 323-344
- 173 Primäre Tumoren der Leber. **2003**, 746-785
- 172 Primäre Lebertumoren. **2003**, 99-129
- 171 Hepatobiliary Cancer, Pancreatic Cancer, and Neuroendocrine Cancers of the Gastrointestinal Tract. **2003**, 461-487
- 170 Liver Cancer. **2004**, 203-211
- 169 Hepatozelluläres Karzinom. **2004**, 941-971
- 168 Combination Chemotherapy for Advanced Hepatocellular Carcinoma. **2004**, 251-257
- 167 Chemoembolization, Infusion, and Embolization. **2004**, 179-224

- 166 Staging system for hepatocellular carcinoma. **2005**, 46, 53-63 1
- 165 Hepatocellular Carcinoma. **2006**, 1109-1131
- 164 Lokoregionelle Therapie von primären Lebertumoren. **2006**, 937-957
- 163 Hepatozelluläres Karzinom (HCC). **2006**, 4045-4070
- 162 Efficacy of radiation therapy for advanced hepatocellular carcinoma with vascular and/or bile duct involvement. **2006**, 47, 283-289 2
- 161 Liver Tumors. **2006**, 502-514 1
- 160 Embolization of Liver Tumors. **2007**, 1218-1245
- 159 Literatur. **2007**, 83-88
- 158 Malignome des Gastrointestinaltrakts. **2007**, 573-690
- 157 Preoperative and Postoperative Nutrition in Hepatobiliary Surgery. **2007**, 375-385
- 156 Chemotherapy of Liver Tumors. **2007**, 1298-1311
- 155 Hepatocellular Carcinoma. **2007**, 1152-1158
- 154 Modelos para definir receptores de alto riesgo y el momento del trasplante. **2008**, 30-43
- 153 90Y Microspheres for Other Liver Metastases. **2008**, 125-134
- 152 Liver. **2008**, 943-961
- 151 Prognostic prediction in hepatocellular carcinoma: from art to science. **2008**, 42, 221-3 1
- 150 Pathologic Aspects of Hepatocellular Tumors. **2009**, 183-233
- 149 Radiation Therapy for Hepatocellular Carcinoma. **2009**, 615-640

- 148 A case of stage IVa hepatocellular carcinoma with lymph node metastasis successfully treated by multidisciplinary therapy. **2009**, 50, 571-577
- 147 Staging. **2009**, 94-103
- 146 Liver Transplantation as Treatment for HCC. **2009**, 146-156
- 145 Transarterielle Chemoembolisation (TACE). **2010**, 350-355
- 144 Chirurgische Therapie primärer maligner Lebertumoren. **2010**, 595-637
- 143 Chemotherapie bei primären Lebertumoren. **2010**, 368-374
- 142 Cancer of the Liver, Bile Duct, and Gallbladder. **2010**, 820-841
- 141 Liver. **2010**, 237-245
- 140 Hypofractionated Radiotherapy for Small-sized Hepatocellular Carcinoma as Salvage Therapy: Sustained Local Control and Safety. **2010**, 28, 85 1
- 139 Malignant Tumors. **2010**, 1305-1350
- 138 Treatment outcome of hepatocellular carcinoma patients with high-risk vascular invasion: a retrospective analysis. **2010**, 4, 491-496
- 137 Preoperative Imaging of Liver Cancers: Hepatocellular Carcinoma. **2011**, 51-59
- 136 Therapeutic Effect of Transcatheter Arterial Embolization for Hypervascular Hepatocellular Carcinoma: Web-based Multicenter Analysis. **2011**, 64, 557
- 135 Surgical Options in Liver Cancers. 990-1005
- 134 Rival Scoring Systems: Do they Offer more?. 81-90
- 133 Comparative Performances of Staging Systems for Hepatocellular Cancer: Early HCC Considerations. 73-80
- 132 Advances in systemic therapy for hepatocellular carcinoma. **2012**, 1444-1452.e3
- 131 Preoperative and postoperative nutrition in hepatobiliary surgery. **2012**, 391-400.e3

- 130 Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Canada. **2013**, 169-178
- 129 Radiation Therapy in the Treatment of Primary Liver Cancers. **2013**, 373-381
- 128 Elite portuguese soccer players Use of psychological techniques: where, when and why. **2013**, 8, 847-860 1
- 127 90Yttrium Microsphere Radioembolization for Liver Malignancies: A Technical Overview. **2013**, 47, 61-64
- 126 Semantic Rule-Based Determination of Cancer Stages from Free-Text Radiology Reports. **2013**, 37-49
- 125 Liver and Bile Duct Cancer. **2014**, 1373-1396.e8 1
- 124 Primary cancer of the liver: considerations about resection. **1988**, 179-187
- 123 Hepatic Diseases in the Elderly. **1990**, 19, 459-472 5
- 122 Indikation und Begrenzung der Notfalltherapie bei Patienten mit hepatozellulärem Karzinom: Eine retrospektive Studie. **1991**, 277-280
- 121 Veränderungen der Leberfunktion nach Chemoembolisation bei Patienten mit Leberzirrhose und hepatozellulärem Karzinom. **1991**, 87-95
- 120 Prävalenz des hepatozellulären Karzinoms bei Patienten mit fortgeschrittener Leberzirrhose. **1992**, 22-24 1
- 119 Tumors of the Liver and Biliary Tract. **1992**, 1019-1056 1
- 118 CHEMOTHERAPY IN THE MANAGEMENT OF MALIGNANT GASTROINTESTINAL DISEASE. **1992**, 21, 695-714
- 117 Selective Perfusion of Chemotherapeutic Agents. **1993**, 79-108
- 116 Periodische Chemoembolisation hepatozellulärer Karzinome. **1993**, 231-235
- 115 Grenzen chirurgischen Handelns beim Lebercarcinom. **1993**, 451-455
- 114 Surgical Treatment of Malignant Liver Lesions. **1993**, 44-61
- 113 Chirurgische Behandlungsmöglichkeiten maligner Leber- und Gallengangstumore. **1993**, 113-118

- 112 Fokale Leberläsionen. **1993**, 93-150
- 111 Study of Trace Elements in Blood of Cancer Patients by Proton-Induced X-Ray Emission (PIXE) Analysis. **1994**, 351-355
- 110 Hepatozelluläres Karzinom. **1995**, 536-546 1
- 109 Primäre Lebertumoren und Lebermetastasen. **1995**, 193-212
- 108 Pharmacokinetics of intravenous adriamycin for anhepatic chemotherapy during liver transplantation. **1996**, 9 Suppl 1, S105-8
- 107 Hepatozelluläres Karzinom. **1997**, 782-796
- 106 Hepatozelluläres Karzinom. **1998**, 639-646
- 105 Ultrasound and Doppler Ultrasound of Hepatocellular Carcinoma. **1999**, 47-70
- 104 Rare and Secondary Tumors of the Pancreas. **1999**, 295-310 1
- 103 Hepatocellular Carcinoma.
- 102 Okuda staging system.
- 101 Liver. 241-262
- 100 Surgical Treatment of Hepatocellular Carcinoma Accompanied with Portal Vein Tumor Thrombus. **2016**, 133-151
- 99 Novel Prognostic Biomarkers for HCC Progression in Egyptian Patients. **2015**, 3,
- 98 Staging of Hepatocellular Carcinoma, Hepatoblastoma, and Cholangiocarcinomas. **2016**, 1-19
- 97 Hepatocellular Carcinoma (Ordinary Hepatocellular Carcinoma). **2016**, 1-38
- 96 Early or Small Hepatocellular Carcinoma. **2016**, 1-20
- 95 Radiation Therapy for Hepatocellular Carcinoma. **2016**, 531-546

- 94 Current HCC Staging Systems: Their Uses and Limitations. **2016**, 425-442 3
- 93 Staging of Hepatocellular Carcinoma, Hepatoblastoma, and Cholangiocarcinomas. **2017**, 3501-3516
- 92 Malignancy and Primary Sclerosing Cholangitis: Cholangiocarcinoma, Hepatocellular Carcinoma, and Gallbladder Carcinoma. **2017**, 13-27 2
- 91 Primary Liver Cancer: Background and Clinical Evidence. **2017**, 103-117
- 90 Liver. 241-262
- 89 Hepatocellular Carcinoma. **2018**, 668-692.e9 1
- 88 Surgical Approach in Hepatocellular Carcinoma: Resection Versus Transplantation. **2018**, 45-55
- 87 Concomitant Chemoradiation Using Gemcitabine in Locally Advanced Hepatocellular Carcinoma. **2018**, 09, 1027-1038
- 86 Transarterial chemoembolization as a substitute to radiofrequency ablation for treating Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma. **2018**, 9, 21560-21568 5
- 85 Evaluation of Iodine-125 Interstitial Brachytherapy Using Micro-Positron Emission Tomography/Computed Tomography with 18F-Fluorodeoxyglucose in Hepatocellular Carcinoma HepG2 Xenografts. **2019**, 25, 371-380 3
- 84 Usefulness of Balloon-type Hemostatic Device After Transarterial Chemoembolization. **2019**, 42, 181-186
- 83 The Management of Hepatocellular Carcinoma. **2020**, 237-271 0
- 82 Study on the Accuracy of Vessel Measurement According to Table Object Distance Changes. **2019**, 42, 435-440
- 81 Development and validation of a risk score for predicting mortality after resection of primary hepatocellular carcinoma. **2020**, 12, 11878-11892
- 80 The Epidemiological, Clinical, Biological and Morphological Characteristics of Primitive Liver Cancers in Bangui. **2020**, 10, 97-105
- 79 Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. **2020**, 26, S1-S40 4
- 78 Liver Cancer. **2020**, 341-368
- 77 Chapter 33: Therapeutic Applications of Radioactive Agents. **2020**,

76	Proposal and Validation of a Novel Scoring System for Hepatocellular Carcinomas Beyond Curability Borders. 2021 ,		0
75	Liver. 2003 , 235-250		
74	Cancer of the Liver and Bile Ducts. 2006 , 752-770		
73	Benigne und maligne Neoplasien der Leber. 2005 , 837-844		
72	Chirurgische Therapie primärer maligner Lebertumoren. 2006 , 539-574		1
71	Radiation Therapy for Hepatocellular Carcinoma. 2005 , 265-284		
70	Hepatozelluläres Karzinom. 734-739		
69	Benigne und maligne Neoplasien der Leber. 2007 , 921-929		
68	Surgical Management of Hepatocellular Carcinoma. 1987 , 16, 613-626		4
67	Viruses and human cancer. <i>Yale Journal of Biology and Medicine</i> , 2006 , 79, 115-22	2.4	53
66	Current management of advanced hepatocellular carcinoma. <i>Gastrointestinal Cancer Research: GCR</i> , 2008 , 2, 64-70		18
65	Decoding human liver cancer signatures. <i>Gastrointestinal Cancer Research: GCR</i> , 2008 , 2, S31-4		
64	Accomplishments in 2007 in the management of hepatobiliary cancers. <i>Gastrointestinal Cancer Research: GCR</i> , 2008 , 2, S25-31		5
63	Treatment of hepatocellular carcinoma: considerations regarding etiology and molecular biology. <i>Gastrointestinal Cancer Research: GCR</i> , 2007 , 1, S85-9		
62	A Phase II Study of Long-Acting Octreotide in Patients With Advanced Hepatocellular Carcinoma and CLIP Score of 3 or Higher. <i>Gastrointestinal Cancer Research: GCR</i> , 2009 , 3, 45-8		5
61	Epidemiology and survival of patients with hepatocellular carcinoma in Southern Germany. <i>International Journal of Clinical and Experimental Medicine</i> , 2010 , 3, 169-79		15
60	Updates in the management of hepatocellular carcinoma. <i>Gastroenterology and Hepatology</i> , 2011 , 7, 16-24	0.7	37
59	Anti-angiogenesis in hepatocellular carcinoma treatment: current evidence and future perspectives. <i>World Journal of Gastroenterology</i> , 2011 , 17, 3075-81	5.6	18

58	Evaluation of transarterial chemoembolization combined with percutaneous ethanol ablation for large hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2011 , 17, 3145-50	5.6	5
57	Liver transplantation for hepatocellular carcinoma: the ochsner experience. <i>Ochsner Journal</i> , 2002 , 4, 215-20	1.5	0
56	Current management of hepatocellular carcinoma. <i>Gastroenterology and Hepatology</i> , 2014 , 10, 153-61	0.7	70
55	Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma. <i>Gastroenterology and Hepatology</i> , 2013 , 9, 1-24	0.7	5
54	Effect of ischemia reperfusion on rabbit VX2 cells in a hepatocellular carcinoma model. <i>International Journal of Clinical and Experimental Pathology</i> , 2015 , 8, 497-503	1.4	1
53	A novel treatment strategy in hepatocellular carcinoma by down-regulation of histone deacetylase 1 expression using a shRNA lentiviral system. <i>International Journal of Clinical and Experimental Medicine</i> , 2015 , 8, 17721-9		5
52	Low expression of GNAI3 predicts poor prognosis in patients with HCC. <i>International Journal of Clinical and Experimental Medicine</i> , 2015 , 8, 21482-6		8
51	To determine the prognostic value of the albumin-bilirubin grade (ALBI) in patients underwent transarterial chemoembolization for unresectable hepatocellular carcinoma. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2019 , 12, 110-115	1.2	3
50	Predictive scores for hepatocellular carcinoma: a race with no winners?. <i>Annals of Translational Medicine</i> , 2020 , 8, 1211	3.2	
49	Strategies to improve sorafenib efficacy during image-guided treatment of hepatocellular carcinoma.. <i>Annals of Translational Medicine</i> , 2021 , 9, 1745	3.2	
48	Improved performance and consistency of deep learning 3D liver segmentation with heterogeneous cancer stages in magnetic resonance imaging. <i>PLoS ONE</i> , 2021 , 16, e0260630	3.7	0
47	Potential of PALBI-T score as a prognostic model for hepatocellular carcinoma in alcoholic liver disease.. <i>JGH Open</i> , 2022 , 6, 36-43	1.8	
46	Predictive scores for hepatocellular carcinoma: a race with no winners?. <i>Annals of Translational Medicine</i> , 2020 , 8, 1211-1211	3.2	
45	Clinical effects and safety of different transarterial chemoembolization methods for bridging and palliative treatments in hepatocellular carcinoma.. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022 , 1	4.9	1
44	A K-nearest Neighbor Model to Predict Early Recurrence of Hepatocellular Carcinoma After Resection. <i>Journal of Clinical and Translational Hepatology</i> , 2022 , 000, 000-000	5.2	1
43	Nomograms Incorporating the CNLC Staging System Predict the Outcome of Hepatocellular Carcinoma After Curative Resection.. <i>Frontiers in Oncology</i> , 2021 , 11, 755920	5.3	0
42	Tumour Staging for Hepatocellular Carcinoma. 2022 , 145-153		
41	Evaluation of staging systems to predict prognosis in hepatocellular carcinoma patients treated with radioembolization.. <i>Heliyon</i> , 2022 , 8, e08770	3.6	

40	Nomogram for prediction of long-term survival with hepatocellular carcinoma based on NK cell counts.. <i>Annals of Hepatology</i> , 2022 , 27, 100672	3.1	0
39	EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds.. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022 , 49, 1682	8.8	3
38	Survival Analysis Using ALBI Grade for Patients Treated with DEE-TACE for Hepatocellular Carcinoma.. <i>Journal of Vascular and Interventional Radiology</i> , 2022 ,	2.4	1
37	Updates on the staging and treatment of hepatocellular carcinoma. 2022 , 307-319		
36	Profile of patients with hepatocellular carcinoma: An experience from a tertiary care center in India.. <i>Indian Journal of Gastroenterology</i> , 2022 , 1	1.9	1
35	Patient stratification in hepatocellular carcinoma: impact on choice of therapy.. <i>Expert Review of Anticancer Therapy</i> , 2022 ,	3.5	1
34	Dosimetry of bone seeking beta emitters for bone pain palliation metastases.. <i>Seminars in Nuclear Medicine</i> , 2021 ,	5.4	1
33	Development and validation of a therapy-independent hepatocellular carcinoma survival prediction score. <i>Liver Cancer International</i> ,	0.8	1
32	Delivery of anti-cancer drugs using microbubble-assisted ultrasound in digestive oncology: From preclinical to clinical studies.. <i>Expert Opinion on Drug Delivery</i> , 2022 ,	8	1
31	Favorable response to multimodal treatment in hepatocellular carcinoma with inferior vena cava and right atrial tumor thrombus and left adrenal gland metastasis: A case report and literature review. <i>Medicine (United States)</i> , 2021 , 100, e27987	1.8	2
30	Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation.. <i>Cancers</i> , 2022 , 14,	6.6	2
29	Safety and Long-Term Survival Outcome in Patients With Unresectable Barcelona Clinic Liver Cancer (BCLC) Stages C and D Advanced Hepatocellular Carcinoma Treated With 40 Gh Drug-Eluting Bead Transcatheter Arterial Chemoembolization.. <i>Cureus</i> , 2022 , 14, e24047	1.2	0
28	Data_Sheet_1.docx. 2019 ,		
27	Practical utility of liver segmentation methods in clinical surgeries and interventions. <i>BMC Medical Imaging</i> , 2022 , 22,	2.9	0
26	Tumor Response and Nomogram-Based Prognostic Stratification for Hepatocellular Carcinoma After Drug-Eluting Beads Transarterial Chemoembolization. <i>Journal of Hepatocellular Carcinoma</i> , Volume 9, 537-551	5.3	0
25	Prognostic models for outcome prediction in patients with advanced hepatocellular carcinoma treated by systemic therapy: a systematic review and critical appraisal. <i>BMC Cancer</i> , 2022 , 22,	4.8	0
24	Intraarterial Therapies for the Management of Hepatocellular Carcinoma. <i>Cancers</i> , 2022 , 14, 3351	6.6	1
23	Assessment of dose perturbations for metal stent in photon and proton radiotherapy plans for hepatocellular carcinoma. <i>Radiation Oncology</i> , 2022 , 17,	4.2	

22	Liver Cancer: Hepatocellular and Fibrolamellar Carcinoma. 2023 , 109-132	
21	Comparison of the long-term outcomes of patients with hepatocellular carcinoma within the Milan criteria treated by ablation, resection, or transplantation.	0
20	Preoperative Diagnosis of Dual-Phenotype Hepatocellular Carcinoma Using Enhanced MRI Radiomics Models.	0
19	Magnetic Resonance Imaging of Diseases of the Liver and Biliary System. 1991 , 29, 1259-1284	2
18	Systemic Treatments and Related Side Effects in Liver Tumors. 2022 , 259-270	0
17	Modified preoperative score to predict disease-free survival for hepatocellular carcinoma patients with surgical resections. 14, 1778-1789	0
16	Changes in the Epidemiology of Hepatocellular Carcinoma in Asia. 2022 , 14, 4473	2
15	Prospective validation of the Eastern Staging in predicting survival after surgical resection for patients with hepatocellular carcinoma: a multicenter study from China. 2022 ,	0
14	Outcome after Resection for Hepatocellular Carcinoma in Noncirrhotic Liver: A Single Centre Study. 2022 , 11, 5802	1
13	Primary Neoplasms of the Liver. 1-16	0
12	Use of Yttrium-90 TheraSphere for the Treatment of Unresectable Hepatocellular Carcinoma. 2004 , 70, 947-953	1
11	An Integrated Liver Function, Systemic Inflammation, and Tumor Characteristic Score Predicts Prognosis in Hepatocellular Carcinoma After Curative Resection.	0
10	Multimodality annotated hepatocellular carcinoma data set including pre- and post-TACE with imaging segmentation. 2023 , 10,	0
9	Short- and Long-Term Outcomes of Indocyanine Green Fluorescence Navigation-Versus Conventional-Laparoscopic Hepatectomy for Hepatocellular Carcinoma: A Propensity Score-Matched, Retrospective, Cohort Study.	0
8	Development and Validation of Prognostic Nomograms for Hepatocellular Carcinoma After Hepatectomy Based on Inflammatory Markers. Volume 9, 1403-1413	0
7	Hepatocellular Carcinoma: Current Therapeutic Algorithm for Localized and Advanced Disease. 2022 , 2022, 1-14	0
6	Perspectives in Biochemical Staging of Hepatocellular Carcinoma Over the Current Microscopical Methodology. 2023 , 1-21	0
5	Favorable Prognostic Factors for Survival Outcomes of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis After Hepatectomy.	0

- 4 The appropriate method of hepatectomy for hepatocellular carcinoma within University of California San Francisco (UCSF) criteria through neural network analysis. **2023**, ○
- 3 Management of Hepatocellular Carcinoma. **2023**, 158, 410 ○
- 2 Diagnosis and management of hepatocellular carcinoma. **2007**, 13, 1 ○
- 1 Surgical Treatment of Hepatocellular Carcinoma: Multicenter Competing-risk Analysis of Tumor-related Death Following Liver Resection and Transplantation Under an Intention-to-treat Perspective. Publish Ahead of Print, ○